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Abstract
BACKGROUND: With population ageing, prevention of frailty is increasingly important.
However, significant gaps in the evidence base exist. Accordingly, the purpose of this
thesis was to: (1) identify the current measures of frailty undertaking an overview; (2)
validate the ‘phenotype of frailty’ using data from the Whitehall II study; and (3) examine
the relation of cardiovascular disease (CVD) and diabetes risk factors with future frailty
risk.
METHODS AND RESULTS: For objective 1, a literature review identified 27 original
articles describing 27 different frailty measurements. Of them, the most tested and
frequently used measure was the ‘phenotype of frailty’ which comprises five components:
weight loss, exhaustion, physical activity, walking speed, and grip strength.
For objectives 2 and 3, I used data from the Whitehall II study, an occupationally-based
cohort of 10,308 British men and women aged 35-55 years followed-up since 1985. Of
the participants aged 55 to 79 years in 2007-2009 (n=5,169), 2.8% were frail and 38.6%
pre-frail.
Using survival analyses, in sex- and age-adjusted model, compared with the non-frail
group, the frail group was 2.40 (95% confidence interval (CI): 1.83, 3.14) times more
likely to be hospitalised for any cause during the mean follow-up of 15.2 months, while
for the pre-frail group the risk was 1.20 (95%CI: 1.06, 1.35) greater.
Logistic regression models were used to examine the performance of risk algorithms for
CVD and diabetes assessed in 1997-1999 in predicting frailty in 2007-2009. CVD and
diabetes risk scores were significantly associated with frailty: odds ratios per 1-standard
deviation increment (disadvantage) in CVD scores ranged from 1.17 (95%CI: 1.10, 1.25)
to 1.20 (95%CI: 1.13, 1.28) and in diabetes scores ranged from 1.05 (95%CI: 0.98, 1.14)
to 1.27 (95%CI: 1.17, 1.37) depending on the risk score used.
CONCLUSIONS: Both frailty and pre-frailty are associated with increased risk of
hospitalisation. Better prevention of cardiovascular and diabetes risk factors in midlife is
likely to reduce frailty at older ages.
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1 Introduction
1.1 Frailty as a public health concern
During the 20th century, life expectancy has increased by 30 years or more in developed
countries.1 It continues to increase at the rate of five or more hours per day.2 As a result,
populations of these countries are ageing.1,2 Resource-poor countries are also
experiencing similar demographic shifts.3 In the UK, over the last 25 years, the
percentage of the population aged 65 or over increased from 15% in 1984 to 16% in 2009
representing 1.7 million people. By 2034, it is predicted that 23% of the population is
expected to be aged 65 or over compared to 18% under 16 years.4 This success in growth
of longevity raises obvious challenges related to an increased burden of diseases.
Ageing is strongly related to a range of diseases such as selected cancers, coronary heart
disease, and Alzheimer’s disease,2 but also conditions such as frailty which, in principle,
is distinct from diagnosed diseases or disability.2,5 The term ‘frailty’ has been used for
many years in everyday and academic language. It is simple in its meaning, yet it has
been used in a variety of ways to describe both individuals and a condition that applies to
people. There has been a growing research interest in this condition as evidenced by the
increasing number of publications utilising the term (Figure 1.1).
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Figure 1.1. Number of publications including the term ‘frailty’ from 1953 to 2010
(Medline, n=2,071)
1.2 Defining frailty
Efforts to define frailty are relatively new. It appeared as a Medical Subject Heading
(MeSH) in Medline, ‘frail elderly’, appeared in 1991. According to MeSH, frail elderly is
defined as ‘older adults or aged individuals who are lacking in general strength and are
unusually susceptible to disease or to other infirmity’.6 At a clinical level, frailty may
refer to a ‘state of high vulnerability for adverse health outcomes, including disability,
dependency, falls, need for long-term care, and mortality’.7 This definition is similar to
the MeSH. There are several other definitions, typically variations of these, listed by
Gobbens and colleagues (Table 1.1).8
In order to find a consensus on a conceptual definition of frailty, experts in the field of
frailty have been consulted.8 During the course of 2 meetings, 14 respondents were asked
Chapter 1
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by Gobbens and colleagues which of the 11 definitions given in Table 1.1 placed most
emphasis on the integral functioning of older people. The definition given the highest
score by the committee was that of Schuurmans and colleagues:9 ‘frailty is a loss of
resources in several domains of functioning, which leads to a declining reserve capacity
for dealing with stressors’. Putting these semantics aside, the main consequence of such
vulnerability is an increased risk of multiple adverse health-related outcomes.10,11
From these conceptual definitions, frailty is distinguished from other concepts such as
ageing, comorbidity, and disability (see following section). Although these terms overlap,
it is now established that these are distinct clinical entities.7,10-14
Chapter 1
- 19 -
Table 1.1. Conceptual definitions of frailty ranked according to scoresa assigned by
experts8
Definition Investigators Score
Frailty is a loss of resources in several domains of
functioning, which leads to a declining reserve capacity
for dealing with stressors.
Schuurmans et al, 20049 142
A syndrome involving grouping of problems and losses of
capacities in multiple domains, which make the individual
vulnerable to environmental challenge.
Strawbridge et al, 199815 123
A syndrome of multisystem reduction in reserve capacity
as a result of which an older person’s function may be
severely compromised by minor environmental stresses,
giving rise to the condition of ‘unstable disability’.
Campbell et al, 199713 107
A biologic syndrome of decreased reserve and resistance
to stressors, resulting from cumulative declines across
multiple physiologic systems, causing vulnerability to
adverse outcomes.
Fried et al, 200116 104
A combination of biological, physiological, social, and
environmental changes that occur with advancing age and
increase vulnerability to changes in the surroundings and
to stress.
Nourhashemi et al, 200117 104
A vulnerability state resulting from a precarious balance
between the assets maintaining health and the deficits
threatening it.
Rockwood et al, 199418 87
A state of reduced physiological reserve associated with
increased susceptibility to disability.
Buchner and Wagner, 199219 74
A combination of aging, disease, and other factors that
make some people vulnerable.
Rockwood et al, 199920 67
Complex and cumulative expression of altered
homeostatic responses to multiple stresses resulting in
metabolic imbalance.
Hamerman, 199921 60
Frailty is diminished ability to carry out important
practical and social activities of daily living.
Brown et al, 199522 49
A state of being neither ‘too independent’ nor ‘too
impaired’ that puts the person at risk for adverse health
outcomes.
Winograd et al, 198823 40
a Overall, 14 experts were asked to assigned 11 points to the definition that is close to that expected and 1
point to the least suited. The scores ranged between 14 and 154.
Permission to reproduce this table has been granted by Elsevier.
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Frailty and ageing
Many characteristics of frailty also apply to the ageing process in general. Although
frailty is closely related to ageing, the concept of frailty is suggested to help in
understanding the heterogeneity of functional decline observed with chronological
ageing.10 Bergman and colleagues found that chronological age alone was only an
approximate indicator of a person’s vulnerability to adverse outcomes. This implies that
although ageing predisposes to frailty, not all elderly are frail, suggesting a heterogeneity
in ageing.10,11 The heterogeneity of functional decline, which is the result of the
interaction between genes and environment, is observed through lifetime, at all levels: (1)
at molecular level: decrease in the capacity for deoxyribonucleic acid (DNA) repair,
telomere (repetitive DNA sequences at the ends of chromosomes) length decreased with
age, accumulation of mitochondrial DNA damage, impairment of protein turnover;24 (2)
at cellular level: deterioration in cell function;24 (3) at organ level: decrease in cognitive,25
cardiac26, pulmonary,27 hepatic,28 and kidney functions,29 hormonal alterations (cortisol)30
or deficiencies (dehydroepiandrosterone, testosterone, sex hormone-binding globulin,
insulin growth factor-1);31,32 (4) at vascular level: coronary atherosclerosis develops at
early age and can be symptomatic at middle or older age;33 (5) at inflammation level:
presence of low level of inflammation;34-38 (6) at immunological level:39 decrease or
abnormality in the immune response responsible for chronic cytomegalovirus (CMV)
infection,40,41 autoimmunity,42 and decreased response to vaccination;43 (7) at muscle
level: sarcopenia;44 (8) at bone level: osteoporosis.45-51 Other characteristics observed
among older adults are: low nutrition intake,52,53 polymedication,54 pain,55,56 and sleep
disturbances.57-59
Thus, the distinction between frailty and ageing is relevant. For example, in clinical
decision-making for aggressive treatment of a cancer, frail individuals, irrespective of
age, are less likely to tolerate some toxic treatments than their non-frail counterparts.12,14
Figure 1.2 illustrates that the frailty syndrome is sometimes described as a continuum
from normal ageing but with a poorer physical performance. It also shows the possibility
of frail persons to reach the performance of non-frail individuals after primary and
secondary interventions (Figures 1.2 and 1.3). The term ‘primary’ and ‘secondary’ frailty
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have been used to refer to frailty in the absence or presence of chronic diseases. This
distinction supports the bidirectional association between frailty and diseases. Older
adults without a clinical disease can be frail because of undiagnosed conditions due to
atypical, silent, or subclinical presentation (primary frailty).60 In addition, among elderly
persons with a chronic condition, the burden generated by these diseases (pain, fatigue,
complications of disease or treatment) can lead to frailty (secondary frailty).
Figure 1.2. Comparison of evolution of physical performance among participants
with normal ageing and among frail participants61
Image redacted for copyright reasons. Please see the original source or print copy of this
thesis.
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Figure 1.3. Pathways to frailty62
Permission to reproduce this figure has been granted by Elsevier.
As Figures 1.2 and 1.3 suggest, there is strong evidence from observational63,64 and
randomised controlled trials65-68 that frailty may be prevented5,18,63,64,69,70 and perhaps
even reversed with appropriate intervention. Existing interventions intend to limit some
function declines due to age-related conditions. These interventions are: (1) physical
exercise programs: muscles in older adults are adaptable to resistance exercise as it
increases muscle protein synthesis rates,71 Tai Chi-like exercise can decrease risk of fall
and physical performance in pre-frail participants;65 (2) hormonal therapy:
dehydroepiandrosterone (DHEA) and testosterone were shown to improve lower
extremity strength and performance and to improve body composition by increasing lean
mass and decreasing fat mass in frail participants;66-68 and (3) vitamin D: by increasing
bone density and quality and muscle strength, vitamin D supplementation reduces the risk
of fall72 and fractures48 in persons 65 years of age or older. There are strong assumptions
that vitamin D has pleiotropic effects in particular on cardiovascular disease (CVD),
immune system, and cancer.72
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Frailty and comorbidity
Comorbidity is defined as the concurrent presence of two or more medically diagnosed
diseases in the same individual, with the diagnosis of each contributing disease based on
established, widely recognised criteria.7
With ageing, the presence of comorbidity increases as individual chronic diseases rise
with age. In the United States, 87.6% of adults aged ≥ 65 years old were reported to have
at least one chronic condition and 69.2% of them more than two conditions.73 In the
Newcastle 85+ study conducted among those aged 85 years old or more, all participants
had at least one chronic condition.74 CVD was the highest prevalent disease with 57.5%
of hypertension, 31.4% of ischemic heart disease, and 31.4% of cerebrovascular disease.
Second prevalent disease was osteoarthritis (51.8%). Diabetes mellitus was also frequent
with 13.1%. CVD and diabetes were shown to be highly prevalent in frail individuals.60,75-
77
The association between frailty and chronic disease has been theorised by Bouchon and
named ‘1 + 2 + 3’ (Figure 1.4).78 According to this theory, for a given organ, a chronic
disease (state 2) accelerates its physiological decline (state 1). An acute event (state 3)
can further accelerate it. States 2 and 3 can be reversible with an appropriate intervention.
However, the reserve function is lost when organ function passes through the failure
threshold, leading to loss of homeostatic capability to withstand stressors and resulting
vulnerabilities.
Chapter 1
- 24 -
Figure 1.4. Combined effect of physiological ageing, chronic disease, and acute event
on reserve function (‘1+2+3’ theory)78
Image redacted for copyright reasons. Please see the original source or print copy of this
thesis.
Frailty and disability
Disability is defined as difficulty or dependency in carrying out activities essential to
independent living, including essential roles, tasks needed for self-care and living
independently in a home, and desired activities important to one’s quality of life.7
Disability in self-care tasks is measured using the Basic Activities of Daily Living
(BADL) instrument,79 and in tasks of household management using the Instrumental
Activities of Daily Living (IADL) instrument.80
In research on frailty, disability is usually considered as an adverse health outcome
caused by frailty. However, disability can also be a predictor of frailty.
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Although overlapping with comorbidity and disability, frailty is distinct from them.7
Frailty and comorbidity predict disability. Disability can exacerbate frailty and
comorbidity. Comorbidity may contribute to the development of frailty. These
interrelationships explain why these three entities co-occur (Figure 1.3).
It is important to distinguish these entities as each of them confers specific interventions.
In the management of frail individuals, interventions can include the treatment of the
underlying conditions, weakness, and undernutrition. These interventions may minimise
risk for falls, disability, hospitalisation, and mortality.
1.3 Measurement of frailty
This paragraph reviews how the concept of frailty has been operationalised. Most general
reviews or editorials on frailty have implicitly presented the measure called ‘phenotype of
frailty’ developed by Fried and colleagues16 as reference,10,47,81-90 and a few others91 that
of Mitnitski and colleagues named ‘frailty index’.92 Description of the operationalisation
of these instruments is presented in Chapter 2. However, in recently published reviews on
frailty measures61,93-95 where authors have identified more than 20 alternative measures of
frailty, the recommendations on the instrument – ‘gold standard’ – to use to identify frail
elderly are not clear.
Aims of this thesis
My coverage of conceptual and operational definitions, together with the epidemiological
evidence, support frailty as an emerging public health issue. In the elderly, there is
growing evidence that frailty predicts various adverse health outcomes such as
disability,75,96 institutionalisation,75 falls,97 fractures,97 hospitalisation,98 and
mortality.75,97,99 However, significant gaps in knowledge exist. First, there is a lack of
consensus regarding the measurement of frailty, with existing tools largely having been
poorly validated. Second, there is insufficient understanding of frailty predictors, so
hindering efforts at prevention. There is some evidence suggesting that individual CVD
and diabetes risk factors are also related to frailty but whether established risk engines for
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CVD and diabetes, often used in primary care, also have predictive utility for frailty
remains unclear.
To address important limitations in frailty research, this thesis has 3 aims:
i. using systematic review, identify current measures of frailty;
ii. using the British Whitehall II cohort study validate the most commonly used
measure;
iii. again using the British Whitehall II cohort study, examine the predictive capacity
of CVD and diabetes risk factors and the corresponding diseases risk algorithms
for frailty.
Findings from the systematic review on frailty measures are provided in Chapter 2 to
respond to the objective (i). Description of the Whitehall II study, its design and data used
in this thesis is reported in Chapter 3. Validity and reliability of a selected frailty measure
are examined in Chapters 4, 5, and 6 (objective (ii)). Utility of existing CVD and diabetes
risk algorithms is evaluated in Chapters 7 and 8 (objective (iii)). Finally, Chapter 9
presents the summary of the main findings, implications of this present work, and
suggestion of direction for future research.
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2 Systematic review of frailty measures
2.1 Introduction
To date, there is no acknowledged gold standard measurement of frailty. Researchers
have shown that age-associated declines in physical capability – reflecting age-related
sarcopenia44 – assessed by grip strength, walking speed, chair rising, and standing balance
times are associated with adverse health outcomes such as falls, disability, and
mortality.100-103 These markers of frailty used separately do not constitute frailty but
presence of multiple markers does.13,104,105
A number of reviews have highlighted that there are several ways of measuring
frailty.61,93-95 However, there is a lack of assessment of each instrument and few evidence-
based recommendations on which instrument to use in research on frailty. Therefore, the
purpose of this literature review was to identify all existing frailty measurements and to
assess their performance in terms of reliability, validity, and utility.106
2.2 Objectives
The specific objectives addressed in this Chapter are:
i. to provide a comprehensive catalogue of existing frailty measures
ii. to review evidence on the validity and reliability of these measures
iii. to quantify the popularity of each frailty measure by investigators other than the
originators
2.3 Methods
Search strategy
Two approaches were used in the search strategy. First, the electronic database
MEDLINE (1948 to May 2011) was used through the OvidSP interface for all articles
including the keyword ‘frailty’ (using the term ‘frail’ yielded an unmanageably large
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literature with little relevance to the present objectives). This strategy allowed identifying
articles where this keyword appeared at least once in the title, abstract, or subject heading.
Second, the reference sections of the retrieved articles were scrutinised for additional
relevant papers. This overview followed the guidelines for the Meta-analysis of
Observational Studies in Epidemiology (MOOSE).107
Selection criteria
Studies with participants aged 50 years and older at baseline examination which clearly
stated that their measure allowed identification of frail individuals were included. Further
inclusion criteria were: (1) articles written in English, French, or Spanish; and (2) articles
describing the reliability and validity of a frailty instrument.
Assessment of the reliability and validity of frailty measures
The reliability and validity were assessed using suggested guidelines.104,106 Reliability,
which determines if a scale measures an entity (here frailty) in a reproducible way, has
several elements: internal consistency (the average of the correlations among all items in
the measure), intra-rater reliability (the agreement between observations made by the
same rater on two different occasions), inter-rater reliability (the agreement between
different raters), and test-retest reliability (the agreement between observations on the
participants on two occasions separated by an interval of time). Validity – whether the
scale in question measures what it purports to measure – was first assessed by content
validity. That is, items aimed at measuring frailty should not measure other entities, such
as disability or comorbidity. While it is recognised that although the concept of frailty
overlaps with that of comorbidity and disability, they are different entities.13,16 Another
measure, criterion validity refers to how well the instrument predicts an outcome. When
frailty and the outcome data are collected simultaneously, the criterion validity is referred
to as the concurrent validity. When the outcome data are prospectively collected, it is
called predictive validity. Finally, construct validity refers to the extent to which an
instrument measures the theoretical concept it is supposed to measure.106
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Use of frailty measurements by researchers
To evaluate the level of utilisation of a given frailty instrument by researchers, among the
selected articles, the number of publications which had been authored by researchers
other than the originators in the periods ≤ 2000, 2001-2005, and ≥ 2006 was counted. In
addition to this, the Scopus citation database108 of peer-reviewed literature was used to
analyze the number of citations to original research articles, excluding those cited by the
creators of a given frailty instrument, for each frailty scales up to October 2011.
2.4 Results
The initial keyword search using ‘frailty’ identified 2,166 articles, of which 1,509 were
excluded based on the content of the title and the abstract (Figure 2.1). A further 209
papers were excluded because they were reviews rather than empirical papers. Of the
remaining 448 articles, 2715,16,20,92,109-131 described the construction or psychometric
properties of measures of frailty, and were included in this review. Among them, five
instruments initially created to assess disability,132 vulnerability,133 and physical
capabilities or performances134-136 were used subsequently to assess frailty.110,112,113,119,122
For these 5 and 22 other instruments, reliability, validity, and use were studied as a
measure of frailty. A further 150 articles either applying or testing the validity of 27
frailty measurements were also included in this synthesis.
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Figure 2.1. Phases of the literature search
Classifications: self-report, objective, and mixed frailty measures
All 27 identified frailty measures were grouped into three categories of administration
(Table 2.1): subjective (self-reported items only), objective (inclusion of only directly
measured components), or subjective and objective combined. Eleven of the 27
instruments included only subjective components which were either reported by a
participant in nine out of 11 cases,15,20,92,109,113,115,120,122,129 or reported by a clinician or a
researcher.118,126 Of the 27 frailty instruments, only five included directly measured
components.110,112,119,123,124 Finally, the remaining 11 instruments included both self-
reported and measured components.16,111,114,116,117,121,125,127,128,130,131
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Table 2.1. Frailty instruments utilised in individual studies
Frailty instrument Name Original paper
Self-reported
Strawbridge et al, 199815 1994 frailty measure
Dayhoff et al, 1998115
Rockwood et al, 199920 CSHA rules based definition
Steverink et al, 2001129 Groningen frailty indicator
Mitnitski et al, 200292 Frailty index
Gerdhem et al, 2003118 Subjective frailty score
Rockwood et al, 2005126 Canadian Study of Health and Aging
(CSHA) clinical frailty scale
Cacciatore et al, 2005113 Frailty staging system Based from Lachs et al, 1990, USA132
Amici et al, 2008109 Marigliano-Cacciafesta polypathological
scale
Kanauchi et al, 2008122 Vulnerable elders survey-13 Based on Morris et al, 1984, USA137
and Saliba et al, 2001, USA133
Gobbens et al, 2010120 Tilburg frailty indicator
Measured
Brown et al, 2000112 Modified physical performance test Based on Reuben & Siu, 1990,
USA136 and Guralnik et al, 1995,
USA135
Gill et al, 2002119 Based on Gill et al, 1995, USA134
Klein et al, 2003123 Frailty index
Bandinelli, 2006110 Short physical performance battery Based on Guralnik et al, 1995,
USA135
Opasich et al, 2010124
Self-reported and measured
Speechley & Tinetti, 1991128
Fried et al, 200116 Phenotype of frailty
Binder et al, 2002111 Physical frailty
Studenski et al, 2004130 Clinical global impression of change in
physical frailty
Puts et al, 2005125 Static/dynamic frailty index
Carriere et al, 2005114 Score-risk correspondence for
dependency
Rolfson et al, 2006127 Edmonton frail scale
Ensrud et al, 2008116 Study of osteoporotic fractures index
Hyde et al, 2010121 FRAIL scale
Freiheit et al, 2010117 Brief frailty index
Sundermann et al, 2011131 Comprehensive assessment of frailty
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General description of frailty measurements
Of the 27 frailty assessments, 19 were developed in population-based samples,
15,16,20,92,110-116,118-121,123,125,126,128 7 among hospitalised patients,117,122,124,127,129-131 and 1
without specification.109 Half of the frailty instruments (n=14) were created by research
groups in the USA,15,16,110-113,115,116,119,122,123,128,130,131 five in Canada,20,92,117,126,127 three in
the Netherlands,120,125,129 two in Italy,109,124 and one each in Australia,121 France,114 and
Sweden;118 none from the UK. Five of the 27 frailty instruments were adapted from those
developed initially to assess functional status,132 vulnerability,133 or physical
performances.134-136 These were used to measure frailty for the first time by Cacciatore
and colleagues,113 Kanauchi and colleagues,122 Brown and colleagues,112 Gill and
colleagues,119 and Bandinelli and colleagues,110 respectively. Furthermore, some recently
tested tools assessing frailty, such as static/dynamic frailty index,125 study of osteoporotic
fractures index,116 FRAIL scale,121 and comprehensive assessment of frailty131, were
based on the Fried’s frailty scale16 and/or the Mitnitski’s frailty index.92
All identified frailty measures were composed of at least two items, except that of
Gerdhem and colleagues118 where a general assessment of health is made within a 15-
second observation by the investigator. Of the subjective and mixed frailty measures,
most contained disability and/or comorbidity components. Instruments without disability
or comorbidity information were: the 1994 frailty measure,15 subjective frailty score,118
Tilburg frailty indicator,120 all objective measures (modified physical performance test,112
physical frailty score,119 Klein’s frailty index,123 short physical performance battery,110
and Opasich’s frailty scale),124 Speechley & Tinetti’s frailty scale,128 Fried’s frailty
scale,16 score-risk correspondence for dependency,114 study of osteoporotic fractures
index,116 and brief frailty index.117 Further descriptions of characteristics of population
and type of components included in each instrument are also provided in Appendix 1.
Assessment of the reliability and validity of frailty measures
Appendix 2 presents reliability and validity data taken from the original articles and other
related articles on the frailty measures. Three approaches were used for reliability
assessment: internal consistency, inter-rater, and test-retest reliability. Concurrent and
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predictive validity were mainly assessed using outcomes such as mortality,
institutionalisation, activities of daily living (ADL) disability, hospitalisation, and quality
of life. Only 7 out of 27 instruments (26%) were found to have had both reliability and
validity ascertained.118,120,123,126,127,129,130
Although the Canadian Study of Health and Aging (CSHA) clinical frailty scale126 and
the Edmonton frail scale127 had good reliability (Kappa coefficient ≥ 0.7, Appendix 2),
they also included items on disability and/or comorbidity. Nineteen instruments had either
their reliability or validity assessed. Among them, 4 instruments were tested for validity
once only in the original sample/cohort of participants,20,113,121,131 and the phenotype of
frailty by Fried and colleagues16 and the frailty index by Mitnitski and colleagues92 had
their concurrent or predictive validity assessed in more than 3 samples/cohorts (17 and 13
samples/cohorts, respectively). As the frailty index92 includes items on disability or
comorbidity, it does not only measure frailty, reducing the specificity of this measure.
One instrument out of 27, the short physical performance battery, previously used to
assess physical functioning,135 had neither reliability nor validity information in
measuring frailty.110
Use of frailty instruments
Table 2.2 presents the number of publications in which a frailty measure had been used
by investigators other than those who created it. In 69% of publications, a frailty scale
developed by Fried and colleagues16 was utilised, 12% used the frailty index developed
by Mitnitski and colleagues,92 4% the Edmonton frail scale,127 and ≤ 2% used the
remaining instruments. This analysis also shows that half the frailty instruments (n=14)
have not been employed at all by other researchers. 109-111,113-115,117,118,121,123-125,130,131
Figure 2.2 displays the number of original research articles based on the Scopus citation
database, which referenced one of the 27 frailty instruments: the 3 most cited papers were
that of Fried and colleagues16 (n=676), Speechley and colleagues128 (n=167), and Gill and
colleagues119 (n=150). The citation rank for Mitnitski and colleagues’ paper92 was ninth
(n=52).
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Table 2.2. Use of subjective, objective and mixed frailty instruments by type and
publication year
Number of publications (%)a by year
Frailty instrument Before 2000
N=0
2001-2005
N=8
2006 or later
N=142
All
N=150
Subjective
Strawbridge et al, 1998:
1994 Frailty Measure
0 1 (12.5) 1 (0.7) 2 (1.3)
Dayhoff et al, 1998 0 0 0 0
Rockwood et al, 1999:
CSHA rules based definition
0 0 0 0
Steverink et al, 2001:
Groningen Frailty Indicator
NA 0 3 (2.1) 3 (2.0)
Mitnitski et al, 2002:
Frailty index
NA 2 (25.0) 16 (11.2) 18 (12.0)
Gerdhem et al, 2003:
Subjective Frailty Score
NA 0 0 0
Rockwood et al, 2005:
CSHA Clinical Frailty Scale
NA 0 3 (2.1) 3 (2.0)
Cacciatore et al, 2005:
Frailty Staging System
NA 0 0 0
Amici et al, 2008:
MCPS
NA NA 0 0
Kanauchi et al, 2008:
Vulnerable Elderly Survey-13
NA NA 3 (2.1) 3 (2.0)
Gobbens et al, 2010:
Tilburg Frailty Indicator
NA NA 1 (0.7) 1 (0.7)
Objective
Brown et al, 2000:
Modified Physical Performance Test
NA 1 (12.5) 1 (0.7) 2 (1.3)
Gill et al, 2002:
Physical Frailty Score
NA 0 2 (1.4) 2 (1.3)
Klein et al, 2003:
Frailty index
NA 0 0 0
Bandinelli, 2006:
Short Physical Performance Battery
NA NA 0 0
Opasich et al, 2010 NA NA 0 0
Mixed
Speechley & Tinetti, 1991 0 3 (37.5) 0 3 (2.0)
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Fried et al, 2001:
Phenotype of frailty
NA 1 (12.5) 103 (72.5) 104 (69.3)
Binder et al, 2002:
Physical frailty
NA 0 0 0
Studenski et al, 2004:
CGIC-PF
NA 0 0 0
Puts et al, 2005:
Static/Dynamic frailty index
NA 0 0 0
Carriere et al, 2005:
Score-Risk Correspondence for dependency
NA 0 0 0
Rolfson et al, 2006:
Edmonton Frail Scale
NA NA 6 (4.2) 6 (4.0)
Ensrud et al, 2008:
Study of Osteoporotic Fractures index
NA NA 3 (2.1) 3 (2.0)
Hyde et al, 2010 :
FRAIL scale
NA NA 0 0
Freiheit et al, 2010:
Brief Frailty Index
NA NA 0 0
Sundermann et al, 2011:
Comprehensive Assessment of Frailty
NA NA 0 0
CSHA: Canadian Study of Health and Aging; MCPS: Marigliano-Cacciafesta Polypathological Scale;
CGIC-PF: Clinical Global Impression of Change in Physical Frailty
a Number of publications / total number of publications during the period x 100
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Figure 2.2. Number of original research articles citing individual frailty instruments
according to the Scopus Citation Database, October 2011
Phenotype of frailty
Of 150 articles in which authors have used at least one of the 27 frailty instruments
described (Figure 2.1), 69 % used the phenotype of frailty. Thus, 104 articles are
evaluated in order to study the trend in the use of the phenotype of frailty and the domains
of research where it has been employed.
Among articles where the phenotype of frailty was used, I arbitrary selected 7
studies58,96,138-142 to provide some examples of its adaptation in other studies than the
Cardiovascular Health Study (CHS) where the phenotype of frailty has been originally
created.16 Characteristics of these studies are given in Table 2.3.
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Table 2.3. Characteristics of studies using the phenotype of frailty
Author Study Sex Nb participants
(age in years)
Alvarado et al, 2008138 Salud Bienestar y Envejecimiento
(SABE) project (multicentric cross-
sectional study)
Both sexes 10,661 (≥ 60)
Avila-Funes et al, 200896 Three-City Study (cohort) Both sexes 6,078 (≥ 65)
Boyd et al, 2005139 Women’s Health Aging Study-I (cohort) Women only 749 (≥ 65)
Ensrud et al, 200958 Osteoporotic Fractures in Men Study
(MrOS) (cohort)
Men only 3,133 (≥ 65)
Hubbard et al, 2010140 English Longitudinal Study of Ageing
(cohort)
Both sexes 3,055 (≥ 65)
LaCroix et al, 2008141 Women’s Health Initiative Observational
Study (cohort)
Women only 25,378 (≥ 65)
Masel et al, 2010142 Hispanic Established Populations for
Epidemiologic Study of the Elderly
(cohort)
Both sexes 1,013 (≥ 74)
Concept of frailty according to Fried and colleagues
A total of five criteria (weight loss, grip strength, exhaustion, walking speed, and physical
activity) are grouped to constitute the phenotype of frailty following a conceptual model
representing frailty associated with declining energetics and reserve of multiple systems
resulting in negative energy balance, sarcopenia, and decrease of strength and of tolerance
for exertion (Figure 2.3). According to this model, frailty is characterised by following
core clinical presentations: shrinking, weakness, poor endurance, slowness, and low
activity (Figure 2.3 and Table 2.4, Section A).
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Figure 2.3. Cycle of frailty16
Permission to reproduce this figure has been granted by Oxford University Press.
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Table 2.4. Definition of the phenotype of frailty16
A. Characteristics of frailty B. CHS measure (n=5,317)
original validation cohort
%
Poor endurance, exhaustion Self-report of either of:
1) felt that everything I did was an effort
in the last week, or
2) could not get going in the last week
21.3
Low physical activity (PA) Short version of the Minnesota Leisure
Time Activity questionnaire (lowest
20% Kcals of PA/week):
Men: Those with Kcal of PA/week<383
Women: Those with Kcal of
PA/week<270
24.1
Slowness Usual walking time/15 feet (4.57 m):
slowest 20% (by sex, height)
Men: Height ≤ 173 cm: ≥ 7sec or
height > 173 cm: ≥ 6 sec
Women: Height ≤ 159 cm: ≥ 7sec or
height > 159 cm: ≥ 6 sec
38.0
Weakness Grip strength (kg): lowest 20% (by sex
and BMI)
Men: BMI ≤ 24: ≤ 29 or
BMI ≤ 24.1-26: ≤ 30 or
BMI ≤ 26.1-28: ≤ 30 or
BMI > 28: ≤ 32
Women: BMI ≤ 23: ≤ 17 or
BMI ≤ 23.1-26: ≤ 17.3 or
BMI ≤ 26.1-29: ≤ 18 or
BMI > 29: ≤ 21
26.2
Shrinking: weight loss (unintentional),
sarcopenia (loss of muscle mass)
Either of:
1) Lost >10 pounds unintentionally in
the last year (self-report)
2) Lost ≥5% of previous year’s body
weight
7.3
C. Definition of phenotype of frailty
Not frail/robust if 0 criteria 46.4
Pre-frail if 1 or 2 criteria present 46.7
Frail if ≥ 3 criteria present 6.9
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Original operationalisation of the phenotype of frailty
Table 2.4 describes frailty characteristics – poor endurance/exhaustion, low activity,
slowness, weakness, and shrinking – and shows how they were assessed in CHS (Section
B). These 5 components are described as follows:
Exhaustion or poor endurance has been defined from two items drawn from the Center
for Epidemiologic Studies Depression (CES-D) scale:143 ‘I felt that everything I did was
an effort in the last week’ and ‘I could not get going in the last week’. If participants
answered ‘occasionally or moderate amount of the time (3-4 days)’ or ‘most or all of the
time (5-7 days)’ to either of these items, they were categorised as being exhausted.
Low physical activity: the level of physical activity was assessed in kilocalories expended
per week based on each participant’s report collected using the short version of the
Minnesota Leisure Time Physical Activity Questionnaire.144 The lowest quintile was used
to identify participants with low physical activity.
Slow walking speed was based on usual walking speed over a distance of a 15 feet (4.6
meters) walking test that incorporate physical stature as a proxy for stride length stratified
by sex. The lowest quintile was used to identify participants with slowed walking speed.
Low grip strength: Grip strength was measured in kg using the Smedley hand grip
dynamometer with the dominant hand. Thresholds are stratified by gender and BMI. The
lowest quintile was used to identify participants with low grip strength.
Weight loss: the shrinking phenomenon, which is considered as a result of unintentional
weight loss and sarcopenia by Fried and colleagues, is present if a participant reports to
have lost more than 10 pounds in weight in the prior year or if he/she has lost ≥ 5% of
previous year’s weight.
Classification of frailty: a total frailty score was calculated by allocating a value of 1 to
each of the above criteria if present, resulting in a range of 0 to 5. Participants with at
least three characteristics out of five are classified as ‘frail’, those with one or two
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characteristics as ‘pre-frail’, and those with none of these characteristics as ‘non-frail’
(Section C in Table 2.4).
Trend in the use of the phenotype of frailty
Figure 2.4 shows the number per year of articles authored by researchers other than the
originators of the phenotype of frailty since its creation in 2001. The increase was
exponential reflecting high level of its utilisation among researchers.
Figure 2.4. Number of publications using the phenotype of frailty
Different versions of the phenotype of frailty
This section presents how the components included in the phenotype of frailty have been
defined in studies other than the CHS.
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Exhaustion: examples of definition of exhaustion criterion in the literature are listed in
Table 2.5. Different questionnaires are used to define this criterion: Geriatric Depression
Scale, CES-D, visual analog scale of energy, and Rand-36 Vitality Scale.
Table 2.5. Examples of definitions of frailty for exhaustion
Author Indication of exhaustion
Alvarado et al, 2008 2 questions on the Geriatric Depression Scale:145
‘Do you have lots of energy?’ (yes/no) and ‘have
you dropped many of your activities or
interests?’ (yes/no)
A negative response to the first question and/or a
positive response to the second were considered
indications of exhaustion
Avila-Funes et al, 2008 As in the CHS
Boyd et al, 2005 Any of a score of 3 or less on a visual analog
scale of energy from 0 (no energy) to 10 (most
energy you have ever had):
‘Felt unusually tired in last month most or all of
the time’
‘Felt unusually weak in the past month most or
all of the time’
Ensrud et al, 2009 Negative response to the question from the
Geriatric Depression Scale:145
‘Do you feel full of energy?’
Hubbard et al, 2010 Self-report of ‘could not get going’ on the CES-
D scale
LaCroix et al, 2008 4 items of the Rand-36 Vitality Scale (range 0–
100):
‘Did you feel…worn out?; tired?; full of pep?;
have a lot of energy?’
Masel et al, 2010 As in the CHS
Low physical activity: examples of definitions of low physical activity criterion in the
literature are listed in Table 2.6. This criterion is based on individual questions or
structured questionnaires such as the Physical Activity Scale for the Elderly and those
peculiar to studies such as the English Longitudinal Study of Ageing and the Women’s
Health Initiative Observational Study.
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Table 2.6. Examples of definitions of frailty for low physical activity
Author Indication of low physical activity
Alvarado et al, 2008 When participants answering ‘no’ to the
question:
‘In the last twelve months, have you exercised
regularly or participated in vigorous physical
activity such as playing a sport, dancing or doing
heavy housework 3 or more times a week?’
Avila-Funes et al, 2008 Individuals who reported not doing daily leisure
activities such as walking or gardening and/or
not doing some sport activity per week
Boyd et al, 2005 ≤ 90 kilocalories/week on activity scale of six
items, including:
Walking for exercise, moderately strenuous
household chores, moderately strenuous outdoor
chores, dancing, bowling, participating in a
regular exercise
Ensrud et al, 2009 Lowest quintile of Physical Activity Scale for
the Elderly score
Hubbard et al, 2010 Lowest quintile of physical activity defined
using the English Longitudinal Study of Ageing
questionnaire
LaCroix et al, 2008 Lowest quintile of physical activity defined
using the Women’s Health Initiative
Observational Study
Masel et al, 2010 Lowest quintile of Physical Activity Scale for
the Elderly score
Slow walking time: examples of definitions of slow walking time criterion in the literature
are listed in Table 2.7. This criterion is mostly based on measured walking time for a
given distance. The cut-off point is usually stratified by sex and height.
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Table 2.7. Examples of definitions of frailty for slow walking time
Author Indication of slow walking time
Alvarado et al, 2008 Participants were considered to have lower body
functional limitations if they experienced
difficulty walking 100 yards and/or climbing
one flight of stairs
Avila-Funes et al, 2008 Slowest quintile of on a timed 6-meter walking
test, adjusting for gender and height
Boyd et al, 2005 Slow when the timed walk over 4 m:
≤0.65 m/sec for height ≤159 cm
≤0.76 m/sec for height >159 cm
Ensrud et al, 2009 Slowest quintile of walking time stratified
according to median height on a 6-m course
Hubbard et al, 2010 Slowest quintile of walking time on a 8-feet
course
LaCroix et al, 2008 Lowest quartile of the Rand-36 physical
function scale
Masel et al, 2010 Slowest quintile of walking time adjusted for sex
and height
Low grip strength: examples of definitions of low grip strength criterion in the literature
are listed in Table 2.8. This criterion is mainly assessed using a hand dynamometer. The
cut-off point was usually stratified by sex and BMI.
Table 2.8. Examples of definitions of frailty for low grip strength
Author Indication of low grip strength
Alvarado et al, 2008 As in the CHS
Avila-Funes et al, 2008 Participants answering ‘yes’ to the question:
‘Do you have difficulty rising from a chair?’
Boyd et al, 2005 As in the CHS
Ensrud et al, 2009 Lowest quintile in grip strength stratified by
BMI quartile
Hubbard et al, 2010 Lowest quintile in grip strength
LaCroix et al, 2008 Lowest quartile of the Rand-36 physical
function scale
Masel et al, 2010 Lowest quartile in grip strength adjusted for sex
and BMI
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Weight loss: examples of definitions of weight loss criterion in the literature are listed in
Table 2.9. This component is heterogeneously defined.
Table 2.9. Examples of definitions of frailty for weight loss
Author Indication of weight loss
Alvarado et al, 2008 Self-reported unintentional weight loss of 3 kg
(10 pounds) during the previous 3 months
Avila-Funes et al, 2008 Self-reported recent and unintentional weight
loss of ≥3 kg or BMI ≤ 21 kg/m2
Boyd et al, 2005 (Self-report of weight at age 60 years – weight at
baseline exam)/ weight at age 60 years ≥10%
Ensrud et al, 2009 (Weight at baseline – weight at sleep exam)/
weight at baseline ≥5% in combination with a
self-reported intentional loss. Mean years
between baseline and sleep exam of 3.4 years
Hubbard et al, 2010 (Weight at enrolment (1998, 1999, 2002) –
weight in 2004)/ weight at enrolment ≥5%
LaCroix et al, 2008 (Weight at baseline – weight at 3-year clinic
visits)/ weight at baseline >5% in combination
with a self-reported intentional loss.
Masel et al, 2010 Having 10 pounds or more of unintended weight
loss in the prior year
Application of the phenotype of frailty in research
The Fried and colleagues’ instrument has been used in different disciplines focused on
ageing, highlighting an increasing interest of this measure among research community.
Epidemiology: the phenotype of frailty has been shown to predict adverse health
outcomes such as disability, hospitalisation, and mortality. Makary and colleagues found
that among surgery patients, it also predicted postoperative complications, length of stay,
and discharge position.146 Another longitudinal study showed that frail older individuals
had a higher risk for venous thromboembolism.147 Cross-sectional and longitudinal
studies showed that the phenotype of frailty is closely associated with cognitive
decline.148-150 Other studies found that it was associated with socio-demographic
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indicators such as being female,151 having a low income,138,152 and being a non-European
American.153 Some researchers have observed a cross-sectional U-shaped relationship
between BMI and the phenotype of frailty definition, corresponding to the U-shaped
association between BMI and mortality.140,154 Sleep disturbances have been reported to be
cross-sectionally associated with frailty.57-59
Pharmaco-epidemiology: the associations between use of statins and angiotensin-
converting enzyme inhibitors and incidence of frailty have been studied in the Women’s
Health Initiative Observational Study (WHI-OS).141,155 The three-year incidence of frailty
was similar in current drug users at baseline and nonusers.
Nutrition research: low daily energy, protein, vitamins D and E, and omega-3 fatty acids
intakes52,156 and low serum level of vitamins A, B, D, and E were shown to be associated
with the phenotype of frailty.46,51,157-163 All these associations have been studied with
cross-sectional design except that of Semba and colleagues (longitudinal).162
Genetics: some mitochondrial single-nucleotide polymorphism (SNP) variations were
shown to be related to the phenotype of frailty.164 On the contrary, apolipoprotein E- and
ciliary neurotrophic factor polymorphisms were not shown to be related to the frailty
status.165,166
Physiology or physical functioning research: the phenotype of frailty was cross-
sectionally associated with: high oxidative stress or imbalance,167,168 low muscle mass,169
reduced postural control systems,170 impaired cardiac autonomic control,171,172 and
decreased pulmonary function.173-175
Studies of specific diseases: high prevalence of frailty has shown to be associated with
Parkinson’s disease,176 chronic renal insufficiency,177,178 chronic human
immunodeficiency virus (HIV)179 and cytomegalovirus (CMV) infections.40 It has been
suggested that the associations between these infections and frailty may be mediated by
the immune and inflammation system status. The prevalence of frailty has been reported
lower among HIV-positive patients with intact immune system compared with those with
impaired immune system.180,181 Among CMV-positive patients, those with high level of
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interleukine 6 (IL-6) had a high prevalence of frailty than those with low level of IL-6.40
A longitudinal association has been observed between the level of baseline CMV
antibody concentration and the three-year incidence of frailty.41
Immunology: a specific T cell subset has been shown to be cross-sectionally associated
with frailty status.182 Another cross-sectional study showed that independent of thyroid
function status, older women seropositive for thyroglobulin and thyroid peroxidase
antibodies were less likely to be frail than seronegative women.42
Inflammation studies: Cross-sectional associations showed that the level of C-reactive
protein (CRP), IL-6, tumour necrosis factor-alpha (TNF-α), and white blood cell counts
were higher among frail participants than among non-frail participants.34-38
Endocrinology: the phenotype of frailty was reported to be cross-sectionally associated
with high level and blunted diurnal variation of cortisol.183 A cross-sectional study found
that low level of DHEA was observed among frail male and female participants.184 Low
level of bioavailable testosterone and high level of sex hormone-binding globulin were
found to be associated with frailty in two cross-sectional studies.31,32
In addition, the phenotype of frailty is now widely used in randomised controlled trials as
inclusion criteria66-68,185-189 to select pre-frail and frail participants aiming at testing
effects of intervention (physical exercise versus none, multidisciplinary intervention
versus usual care, testosterone versus none, DHEA versus none) on physical functional
performance, muscle mass, quality of life, incidence of frailty, mobility, hospitalisation,
institutionalisation, and on cardiovascular risk factors.65,68,185,187-190
2.5 Discussion
Synopsis of main findings
This overview aimed to provide a comprehensive catalogue of frailty measures, reviewing
evidence on their validity and reliability, and quantifying the use of each measure by
investigators other than the originators. Of all, 27 frailty scales were identified and used
in 150 studies to date. A series of observations can be made.
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First, although frailty, disability, and comorbidity are closely inter-related, some
researchers suggest that they have distinct characteristics.7,10 Integrating disability or
comorbidity items into a frailty scale may therefore be debatable. However, half the
frailty instruments (n=14) include either disability or comorbidity
components.20,92,109,111,113,115,121,122,125-127,129-131
Second, at least five measures110,112,113,119,122 of frailty were originally created to measure
vulnerability, functional status, and physical performances, suggesting a lack of
terminological rigour.
Third, four recent scales116,121,125,131 are based on existing measures, in particular the Fried
scale.
Finally, confusion between frailty scales can be generated because sometimes a specific
instrument is named differently in different studies (the Fried scale16 being labelled as
Fried frailty index159 on occasion). Elsewhere, several instruments are identically named
but have different item content: for instance, the term ‘frailty index’ was used by different
researchers.92,117,123 This was also the case with ‘frail scale’.61,127
Assessment of the reliability and validity of frailty measures
The Standards for Educational and Psychological Testing,191 a guideline which describes
the best practice in the development of complex measures such as frailty, recommends the
reporting of the basic principles of test construction such as reliability and validity.
However, this information was available only for a few instruments. Two measures,
CSHA clinical frailty scale20 and Edmonton frail scale,127 had acceptable reliability and
good concurrent and predictive validity, although content validity was weak due to the
inclusion of items capturing disability and/or comorbidity. Two instruments were widely
tested for their validity but not reliability: the frailty index92 and the phenotype of
frailty.16 Reliability and validity are the most important indicators when selecting one
measure over another. However, even among 7 frailty measurements with such
information,118,120,123,126,127,129,130 none of them appear to be recognised as a ‘gold
standard’.
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Comparison between measures
In several studies, investigators have examined the inter-relationships between different
measures of frailty. Thus, the phenotype of frailty has been compared with the frailty
index192-194 and the study of osteoporotic fracture index98,116 using different methods:
correlation analyses,194 comparison of strength of cross-sectional192 and prospective
associations,98,193 and use of the c-index statistic.116 The phenotype of frailty is
moderately well correlated with the frailty index,194 and shows a stronger association with
age, sex, and ethnicity192 but a weaker association with mortality.193 The phenotype of
frailty and the study of osteoporotic fracture index have a similar strength of association
with falls, disability, hospitalisation98 and death.116 As Streiner and Norman106
highlighted, it was sometimes difficult to disentangle whether an assessment belongs to
concurrent validity or construct validity. Therefore, certain classifications in either
category might be arguable.
Use of the frailty instruments
In this Chapter, I have assessed the use of a frailty instrument by counting the number of
publications that had adopted the instrument other than the original creators. The frailty
scale developed by Fried and colleagues16 has been most extensively tested for its validity
and is the most widely used instrument in frailty research (Table 2.2). Randomised
controlled trials have also used the scale to screen elderly participants,66-68,185-189 or as an
outcome of interventions.65,188,190 The Fried’s scale is widely used, allowing comparisons
to be made between studies.
In addition to this manual counting procedure to estimate the use of the frailty
instruments, I computed the number of citations to the original research articles
(excluding those cited by the creators of a given frailty instrument) for the 27 papers
describing the frailty instruments. Even though the rank of citations was different for
some of the frailty instruments than that of the manual counting, the paper on the Fried’s
scale was still the most highly cited. Although the number of citations can be easily
accessed, this electronic database search cannot replace the manual counting method as
the papers citing the original articles do not necessarily use the tool in question.
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Phenotype of frailty
Although not recognised as a ‘gold standard’ in the identification of frail elderly, the
phenotype of frailty is, by far, the mostly used measure. Additionally, recent randomised
controlled trials have used it to select elderly participants. Wide use of the phenotype of
frailty by other researchers allows new results can be compared with the existing ones.
The popularity of use of the phenotype of frailty might, in part, be due to the fact that its
criteria are more clearly defined relative to other instruments and it does not include items
on comorbidity and disability
Strengths and limitations
Among previously published reviews61,93-95,195 on frailty measures, only one93 assessed
them in terms of reliability and validity. Compared with the De Vries and colleagues’
paper,93 this review has some strengths. First, to evaluate reliability and validity of a
given instrument, data from other studies have been extracted, reflecting the level of
external validation of this instrument. Second, to date, no article has been published on
the extent to which frailty measures have been used by other researchers. The
quantification of their use might reflect the level of preference of researchers for a given
frailty measurement in the absence of a consensually recognised tool. Moreover, I
identified 18 other frailty instruments,20,109-113,115,117-121,123,124,126-128,131 five of them created
in 2010 or after.
A limitation of this review may lie in the use of a unique keyword ‘frailty’ to identify
relevant publications on frailty measurements. One may find such a strategy restrictive,
leading to miss some screening tools helping to identify, for instance, ‘frail’ elderly.
However, most frailty instruments included in the reviews on frailty measures93,95 were
also identified in my review, highlighting that the probability of missing an instrument
may have been possible but very low.
Another limitation related to the assessment of use of the 27 identified instruments is that
it penalises the more recently published frailty instruments. However, the Fried scale is
not the oldest measure in the field and several more recent frailty instruments are either
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derived or similar to that measure, suggesting that qualities other than duration of
availability explain the popularity of this instrument.
Regarding the phenotype of frailty, the main criticisms are that (1) it only takes into
account physical aspects;91 (2) it does not capture the dynamic nature of frailty because it
is not a continuous scoring system or an ordinal scoring system; and (3) it does not
include social dimension.93 These drawbacks may be softened as an ordinal scoring
system is possible to construct from the criteria of the phenotype of frailty as Buchman
and colleagues did using a scale from 0 to 5.196 Furthermore, there are a few studies
which studied the association between the phenotype of frailty with socio-economic
factors.138,152
Research on the phenotype of frailty can be criticised for heterogeneity in defining the
components included in the measure. This variation in terms of the component definitions
and cut-offs is partly because most studies on frailty are based on secondary analyses of
already existing data collected for other purposes. The most consistent measurement has
been the grip strength and the least consistent the weight loss component. This may limit
the comparability of results between studies.
Conclusions
This review provides a comprehensive overview of existing frailty measurements.
Twenty-seven measures of frailty were identified but none of them was recognised as a
gold standard. Difficulty in accepting one measure as a reference relates to the fact that
the existence of frailty as a clinical entity is quite new and the definition of frailty is still
debatable. Therefore, it is difficult to create a composite measure that would meet all
criteria. Furthermore, none of the measures were supported by high-quality evidence on
validity and reliability.
Components to include in the frailty instruments need to be further discussed to reach a
consensus, in particular on whether to include disability and/or diseases data. Several
existing frailty measurements, such as the frailty scale developed by Fried and colleagues
need to be further tested to reach consensus regarding the gold standard.
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Researchers have shown that single frailty markers such as grip strength, walking speed,
chair rising, and standing balance times are associated with adverse health outcomes such
as falls, disability, and mortality.100-103 Therefore, it was suggested that a single
measurement may be sufficient instead of using a multi-component measure to identify a
frail elderly.10 However, evidence to substantiate this argument is scarce. In Chapter 6 of
this thesis, I examined whether risk association with frailty measure is greater with
combination of components than that of any single component with data from the
Whitehall II study.
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3 Description of the Whitehall II cohort study
3.1 Introduction
This Chapter provides the description of the Whitehall II study – its design and data – and
the operationalisation of the phenotype of frailty based on existing data.
Ethical approval for the Whitehall II study was obtained from the University College
London Medical School Committee on the ethics of human research (London, UK).
3.2 Objectives
The specific objectives addressed in this Chapter are:
i. to describe the Whitehall II study design, participants, and data
ii. to describe the construction of the phenotype of frailty
3.3 Study design and participants
The Whitehall II study is an ongoing longitudinal study of 10,308 (67% men) London-
based British civil servants aged 35-55 years in 1985.197 While the initial goal of
Whitehall II was to investigate the causes of social inequalities in disease, the study has
evolved into one of the determinants and health consequences of ageing. The baseline
examination (phase 1) took place during 1985-1988 and involved a clinical examination
and self-administered questionnaire. Subsequent phases of data collection have alternated
between postal questionnaire alone [phases 2 (1988-1990), 4 (1995-1996), 6 (2001), 8
(2006), and 10 (2011)], and postal questionnaire accompanied by a clinical examination
[phases 3 (1991-1993), 5 (1997-1999), 7 (2002-2004), and 9 (2007-2009)] (Figure 3.1).
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Figure 3.1. Eleven phases of Whitehall II data collection
3.4 Data specific to this thesis
To achieve the objectives of this thesis, analyses were performed using data from phases
5 to 9 and registries (Figure 3.2).
Data collected during phases
Components necessary to construct the phenotype of frailty were measured for the first
time at phase 9.
To achieve the objective (ii) of my thesis consisted in validating the phenotype of frailty
in the Whitehall II study, data from phase 9 were considered as ‘baseline’.
In the literature, CVD and diabetes risk scores were estimated to predict the 10-year risk
of CVD and diabetes, respectively. Thus, regarding the objective (iii) of my thesis
consisted in examining the predictive capacity of CVD and diabetes risk factors and the
corresponding diseases risk algorithms for frailty, I utilised CVD and diabetes risk factors
measured at phase 5 in order to respect 10 years of difference between the baseline and
the end of follow-up (phase 9).
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Figure 3.2. Design specific to this thesis
Data from registries
Mortality registry
Mortality was used as an outcome in the study of the predictive validity of the phenotype
of frailty in Section 4.5. A total of 10,297 respondents (99.9%) were successfully traced
for mortality through the national mortality register kept by the National Health Service
(NHS) Central Register using the NHS identification number assigned to each British
citizen. In the present analysis, mortality follow-up began at the measurement of the
phenotype of frailty (2007–2009, phase 9) and ended on January 31, 2010.
Hospitalisation registry
Hospitalisation was used as an outcome in studies of the validity of the phenotype of
frailty (Chapters 4 and 6). Hospitalisation information was provided by the NHS
Information Centre for health and social care.198 The latter is responsible for managing a
data warehouse called Hospital Episode Statistics (HES). The HES dataset has a record-
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level form (several observations per patient) and contains details of all admissions to
NHS hospitals in England.
Using anonymised patient identifiers, the NHS Information Centre provided us with a
tailor-made HES dataset including all admissions of participants of the Whitehall II study
from April 1989 to January 2010. It contains 31,881 records and 71 variables, in
particular episode start date which allowed to select HES records of participants after
taking part in the phase 9 examination. For the purposes of analyses, only information on
the first hospital admission after participating in phase 9 has been chosen. After merging
the subsample of HES dataset with that of the Whitehall II study, participants recorded in
the HES dataset were classified as an ‘incident case of hospitalisation’, and those who
were not registered in HES as a ‘non-case of hospitalisation’. Because the HES data were
available for England only at the time of this work, participants living outside of England
at phase 9 were excluded.
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4 Validity of the phenotype of frailty in the Whitehall II study
4.1 Introduction
In this Chapter, three types of validity of the phenotype of frailty were studied: content,
concurrent and predictive validity.
4.2 Objectives
The specific objectives to be addressed in this Chapter are:
i. to examine the content validity of the phenotype of frailty
ii. to test the concurrent validity of the phenotype of frailty by examining first
univariate associations between frailty and covariates which have been shown to
be associated with frailty in the literature and second the relationship between
frailty, comorbidity and disability
iii. to test the predictive validity of the phenotype of frailty by examining whether the
association between frailty and subsequent hospitalisation was independent from
comorbidity, disability, and other covariates.
4.3 Content validity
Content validity pertains to the degree to which the phenotype of frailty fully measures
the concept of frailty.
As seen in Section 1.2, the conceptual definition of frailty according to Fried and
colleagues is ‘biologic syndrome of decreased reserve and resistance to stressors,
resulting from cumulative declines across multiple physiologic systems, causing
vulnerability to adverse outcomes’. The authors operationalised this concept adding five
components: exhaustion, low physical activity, low walking speed, low grip strength, and
weight loss (Chapter 2). The concept of frailty defined by Fried and colleagues and its
operationalisation appear to be consistent as numerous studies have shown that the
phenotype of frailty is well associated with biological phenomena (Section 2.4).
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4.4 Concurrent validity
4.4.1 Materials and methods
Study population
Among 6,761 respondents at phase 9, 1,395 had missing data on frailty components. In
order to have the same study population in Sections 4.4 and 4.5, 197 participants were
further excluded as their hospitalisation data from the HES were not available for those
living outside of England at the time of this work.
Predictor of interest
Individual components were categorised similarly to Fried and colleagues, as described in
Section 2.4, in order to make comparable the prevalence of frailty in the Whitehall II
study with that of CHS. However, as described below, some harmonisation was necessary
as all components of frailty were not assessed in the Whitehall II study using protocols
recommended by Fried and colleagues:
Exhaustion: this component was operationalised as in CHS based on two items drawn
from the CES-D scale:143 ‘I felt that everything I did was an effort in the last week’ and ‘I
could not get going in the last week’. If participants answered ‘occasionally or moderate
amount of the time (3-4 days)’ or ‘most or all of the time (5-7 days)’ to either of these
items, they were categorised as being exhausted.
Physical activity: participants reported habitual physical activity from a 20-item
questionnaire on frequency and duration of participation in ‘mildly energetic’ (e.g.,
weeding, general housework, bicycle repair), ‘moderately energetic’ (e.g., dancing,
cycling, leisurely swimming), and ‘vigorous’ (e.g., running, hard swimming, playing
squash) physical activity.199 Frequency and duration of each activity were combined to
compute hours per week of physical activity. A compendium of activity energy costs was
then used to assign each of the 20 physical activities assessed a metabolic equivalent
(MET).200 MET values reflected the intensity of each physical activity, 1 MET being
approximately equal to the energy cost of lying quietly. Amount of time spent in activities
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with MET values ranging from 3 to 6 was summed to allow calculation of total number of
hours per week of moderate physical activity. Similarly, amount of time spent in activities
with MET values of 6 or above (e.g., sports) was summed to allow calculation of total
hours per week of vigorous physical activity. Using the existing derived variables on
physical activity expressed in number of MET per week, a kcal energy expenditure was
calculated using a formula from the Compendium of physical activity: Energy
expenditure (kcals/week) = MET/week*weight.200 This formula was then applied for each
participant. Low levels of physical activity were denoted by an expenditure of < 383
kcal/week in men and < 270 in women.
Walking time/8-foot: this component is based on usual walking speed over a distance of 8
feet (2.4 meters). Three trials were performed and the maximum of the three scores was
used for scoring purposes. Established thresholds to denote risk are based on results for a
15 feet (4.6 meters) walking test that incorporate physical stature as a proxy for stride
length. Cut-offs for frailty for walking speed were calculated in order to keep the same
magnitude (walking speed cut-off in the Whitehall II study = (8*walking speed cut-off in
CHS)/15). Thus, participants were categorised as having slow walking speed when time
to walk 8 feet was ≥ 3.73 seconds (for men (women) ≤ 173 (< 159) cm tall or ≥ 3.20
seconds (for taller men and women).
Grip strength: it was assessed with the participant’s dominant/preferred hand using the
Smedley’s hand grip dynamometer, and measured in kilograms. A trained interviewer
administered the test, and three trials were performed. The maximum of the three scores
was used for scoring purposes. Frailty for grip strength was stratified by sex and BMI,
using exact cut-offs given by Fried and colleagues. For men, low grip strength was
denoted as: ≤ 29 kg (BMI ≤ 24 kg/m2), ≤ 30 (BMI 24.1-28), and ≤ 32 (BMI > 28). For
women, low grip strength was: ≤ 17 kg (BMI ≤ 23 kg/m2), ≤ 17.3 (BMI 23.1-26), ≤ 18
(BMI 26.1-29), and ≤ 21 (BMI > 29).
Weight loss: no data were available to assess unintentional weight loss in the last year.
Therefore, this component was based on data on weight change between phases 7 and 9.
In the Whitehall II study, weight has been measured using a bioimpedance scale. Five-
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year relative weight loss was calculated as: K = (weight at phase 7-weight at phase 9)/
weight at phase 7. If the value K was higher than 10% then the weight loss criterion for
frailty definition was considered positive (and otherwise negative). The decision to use a
higher cut-off than in CHS was based on the following reasons: (1) the period during
which the change in weight was measured was longer; (2) weight loss is regarded as
ineluctable with ageing even with recommended caloric intake,201 and (3) in the Women’s
Health Aging Study-I, in which Fried is a principal investigator, researchers used a cut-
off of 10% (Table 2.9).
Classification of frailty status: as in CHS, a total frailty score was calculated by allocating
a value of 1 to each of the above component if presents, and 0, if absent, resulting in a
range of 0 to 5. Participants were classified as ‘frail’ if they had at least three of the five
frailty components, as ‘pre-frail’ if they had 1-2, and as ‘non-frail’ if they had none of
these components.16
Appendix 3 presents the criteria used to define frailty in the Whitehall II study in
comparison with CHS criteria and the percentage for each component of frailty. The
match is reasonably good given the different age range of the cohorts.
Outcomes
Comorbidity: participants were asked if they had any longstanding illness, diseases or
medical conditions for which they had sought treatment in the last 12 months. The list of
diseases has been coded using the International Classification of Diseases version 10
(ICD-10).202 Comorbidity was defined as self-reported two or more conditions.16
Disability: the World Health Organisation (WHO) defines disabilities as an ‘umbrella
term, covering impairments, activity limitations, and participation restrictions’.203
Disability was usually estimated using two measurements: basic and instrumental
activities of daily living (BADL and IADL) developed by Katz and colleagues and
Lawton and Brody, respectively.79,80
Chapter 4
- 64 -
Items included in these instruments slightly differed in the Whitehall II study compared to
the original instruments. Therefore, the versions of BADL and IADL in the Whitehall II
study were qualified as ‘modified’. Appendix 4 shows these differences.
For both BADL and IADL, participants were asked if they had any difficulties with the
listed everyday activities. For each domain of disability, if participants indicated that they
had difficulties in one or more activities, they were considered as having BADL or IADL
disability.79,80
Covariates
The selection of covariates was mostly based on Fried and colleagues’ work.204 They had
been shown to be predictive of mortality in the CHS cohort:
Socio-demographic variables comprised the following: sex; age; self-reported ethnicity
(White, non-White); education (none, lower secondary, A-levels, university or higher);
the socio-economic position (SEP) variable used in this thesis was derived from the
British occupational based social class:205 the category ‘high’ or ‘administrator’ groups
classes I and II, the category ‘intermediate’ or ‘executive officer’ classes IIIN, IIIM, IV,
V, and the category ‘low’ or ‘office support staff’ class VI);206 total household income in
₤/year (< 15,000, 15,000-< 25,000, 25,000-< 50,000, ≥ 50,000) from any source including
wages or salary from work, savings or investments, rent or property, pensions, benefits
and/or maintenance;207 marital status (married/cohabitating, other); and number of close
relatives and good friends.
Behavioural variables included the following: smoking status (none, stopped smoking
before phase 1, stopped smoking during the follow-up between phases 1 and 9, current
smoker); daily consumption of fruit and vegetables (yes, no); daily alcohol consumption
in units per week; and physical activity (moderate and vigorous) in hours per week.
Further details on the definition of the physical activity in the Whitehall II study are
described above in this Chapter.
Clinical examination variables were body mass index (BMI) was calculated as weight in
kilograms divided by height in meters squared and categorised using the WHO
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classification:208 < 25, 25-29.99, and ≥ 30 kg/m2 (weight was measured to the nearest 0.1
kg on digital Soehnle electronic scales (Leifheit AS, Nassau, Germany) with the study
participant in their underwear. Height was measured in bare feet to the nearest 1 mm
using a stadiometer with the participant standing erect with head in the Frankfurt plane);
systolic and diastolic blood pressure in millimetres of mercury; and mini-mental state
examination (MMSE) to assess global cognitive function.
Medical variables included the following information: presence of diabetes mellitus,
defined as reported doctor-diagnosed diabetes mellitus or use of diabetes medication;
presence of CVD; previous history of hospitalisation, determined using the HES data;
and, number of medications.
Statistical analyses
Description of variables
Each variable was described according to its characteristics: arithmetic means and
standard deviations (SD) if quantitative variables had a normal distribution, medians and
inter-quartile ranges (IQRs) if quantitative variables had not a normal distribution, or
frequencies and proportions for qualitative variables.
Univariate analysis
Chi-square, Fisher’s exact, Wilcoxon-Mann-Whitney, Cochrane-Armitage trend, and
Student’s t-tests were used accordingly. Agreement between frailty, comorbidity, and
disability was assessed with Cohen’s Kappa statistic.
Venn diagram
This diagram was drawn to visualise all possible relations between frailty, comorbidity,
and disability.
Multivariable analysis
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To determine the concurrent validity of the phenotype of frailty, separate logistic
regression models209 were performed to estimate the strength of association between
frailty (frail, pre-frail and non-frail) and comorbidity (yes, no), and BADL/IADL (yes,
no), and adjusting for sex and age. This model estimates odds ratios (ORs) and their 95%
confidence interval (CI) expressing the strength of the association between an exposure
and an outcome.
In logistic regression no assumptions are made about the distributions of the dependent
variables. However, two points need to be considered: (1) covariates should not be highly
correlated with one another because this can produce inaccurate estimates or the analysis
may fail to converge, and (2) sufficient numbers in both categories of the outcome
variable are required. Thus, the more covariates, the larger the sample size required.
Descriptive analyses and logistic regression models were performed using SAS version
9.1.
4.4.2 Results
Description of study population and missing data
Of 10,308 study members participating in phase 1, 5,169 were included in the present
analysis. Compared with participants alive at phase 9 but excluded (owing to unknown
vital status, non participation, missing data on the frailty scale, and living outside of
England) (n=4,153), people in the analytic sample (n=5,169) were on average 0.7 years
younger, less likely to be female (27.5% versus 39.7%) and of low socio-economic status
(3.9% versus 12.4%).
Table 4.1 describes the characteristics of study population. The median age at phase 9
was 65.8 years and 72.6% were men.
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Table 4.1. Characteristics of the 5,169 study participants
N
% / mean (SD) or
median (IQR)
Sex
Men 3750 72.6
Women 1419 27.4
Age (years) in median (IQR) 5169 65.8 (60.9; 70.8)
Ethnicity
White 4779 92.5
Non-White 390 7.5
Education
No or lower secondary 2133 42.9
A levels 1334 26.8
University or higher 1509 30.3
Missing 193 -
Socio-economic position
Low 515 10.0
Intermediate 2214 42.8
High 2440 47.2
Income ₤/year
< 15,000 562 11.2
15,000-< 25,000 1097 21.8
25,000-< 50,000 2108 41.9
≥ 50,000 1265 25.1
Missing 137 -
Marital status
Married/cohabiting 3870 76.0
Other 1223 24.0
Missing 76 -
Number of relatives and friends in median (IQR) 5079 6 (4; 10)
Smoking status
Never 2688 52.5
Stopped before phase 1 1543 30.1
Stopped during follow-up 536 10.5
Current 356 6.9
Missing 46 -
Daily consumption of fruit and vegetables
No 1127 21.8
Yes 4038 78.2
Missing 4 -
Daily alcohol consumption level (WHO)
None 933 18.2
Not risky 3252 63.6
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Risky 930 18.2
Missing 54 -
Alcohol consumption (units/week) in median (IQR) 5115 7 (2; 15)
Physical activity (hours/week) in categories
< 2.5 2208 42.9
≥ 2.5 2940 57.1
Missing 21 -
Physical activity (hours/week) in median (IQR) 5148 3.0 (1.1; 5.6)
BMI (kg/m2) in categories
Normal (< 25) 1984 38.4
Overweight ([25-30[) 2214 42.8
Obese (≥ 30) 971 18.8
BMI (kg/m2) in mean (SD) 5169 26.7 (4.4)
Systolic blood pressure status
Hypotension/normal 2009 38.9
Prehypertension 2281 44.2
Hypertension 870 16.9
Missing 9 -
Systolic blood pressure (mmHg) in mean (SD) 5160 125.2 (16.1)
Diastolic blood pressure status
Hypotension/normal 4220 81.8
Prehypertension 758 14.7
Hypertension 182 3.5
Missing 9 -
Diastolic blood pressure (mmHg) in mean (SD) 5160 70.9 (10.1)
MMSE score < 24
No 5088 99.4
Yes 30 0.6
Missing 51 -
MMSE score in median (IQR) 5118 29 (28; 29)
Diabetes status
No 3632 70.3
Yes 1537 29.7
Previous history of hospitalisation
No 2073 40.1
Yes 3096 59.9
Number of medications in median (IQR) 5169 2 (1; 4)
Phenotype of frailty
Non-frail 3029 58.6
Pre-frail 1993 38.6
Frail 147 2.8
Modified basic ADL ≥1
No 4713 91.4
Yes 442 8.6
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Missing 14 -
Modified instrumental ADL ≥1
No 4490 87.1
Yes 665 12.9
Missing 14 -
Presence of comorbidity
No 3382 65.4
Yes 1787 34.6
Hospitalisation after phase 9
No 4019 77.8
Yes 1150 22.2
Death after phase 9
No 5131 99.3
Yes 34 0.7
Unknown 4 -
Association between frailty, disability and comorbidity
According to the phenotype of frailty, 2.8% (n=147) of participants were classified as
frail, 38.6% as pre-frail, and 58.6% as non-frail. Overall, 8.6% were considered as BADL
disabled and 34.6% had comorbidity (Table 4.1). Kappa coefficients was 0.04 (95% CI:
0.03, 0.06) between frailty and comorbidity, 0.17 (95% CI: 0.13, 0.21) between frailty
and basic ADL, and 0.11 (95% CI: 0.09, 0.13).
Venn diagram
Overall, 61.1% of participants had none of these conditions. For 38.9% (n=2,003) of
those who had at least one of these conditions, a Venn diagram was drawn to represent
the extent of overlap of frailty with disability and comorbidity (Figure 4.1). Among those
who were frail, 25.3% had neither disability nor comorbidity, 13.0% had disability,
33.6% had comorbidity, and 28.1% had both disability and comorbidity.
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Figure 4.1. Association between frailty, disability and comorbidity
Univariate analysis
Tables in Appendices 5, 6, and 7 display results of univariate associations between
participants’ characteristics (socio-demographic, behavioural, clinical examination, and
medical) and frailty, comorbidity, and BADL disability, respectively. Table in Appendix
8 summarises results from these appendices. These tables show that globally the three
conditions – frailty, disability, and comorbidity – were associated with same covariates.
Those who were frail, disabled or had comorbidity, compared to those without these
conditions, were more likely to be women, older, non-White, in a lower socio-economic
position, not married or not in partnership, ex-smokers (stopped smoking during the
follow-up); have a low daily consumption of fruit and vegetables, low consumption of
alcohol, low physical activity, high BMI, diabetes (for frailty and disability), a history of
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a previous hospitalisation, and been treated with a higher number of drugs. Low MMSE
score, indicating poor cognitive function, was more strongly associated with frailty than
with other conditions.
Multivariable analysis
Appendix 9 displays the association between frailty and modified basic and instrumental
ADL and comorbidity. Sex- and age-adjusted results show that, in comparison with the
non-frail group, the pre-frail and frail groups were 2.2 to 13.9 times more likely to be
disabled and 1.4 to 3.2 times more likely to have comorbidity.
4.4.3 Discussion
The prevalence of frailty in the Whitehall II study, according to the phenotype of frailty
was 2.8%. This is low compared to that found in the CHS (6.9%),16 in the Hertfordshire
Cohort Study (6.3%),210 in the English Longitudinal Study of Ageing (approximately
8%).140 The low prevalence of frailty in the Whitehall II cohort may be mainly explained
by the younger age (range 55 to 79 years) of participants compared to that of other studies
(≥ 64 years) and the fact that Whitehall II is an occupational cohort. Selection on the basis
of being fit enough to work is likely to mean that this cohort was healthier at baseline
than the general population. Furthermore, the harmonisation of measurements to match
those in previous studies may have been imperfect leading to imprecise determination of
frailty prevalence.
Consistent with the literature,138,152,153,211 in the Whitehall II study, socio-demographic
variables were associated with frailty. Although frailty was highly correlated with
comorbidity and disability, over 25% of frail participants were without
comorbidity/disability. This provides some support for the hypothesis that frailty captures
other characteristics unrelated to these conditions.
Criterion validation (e.g., concurrent validation examined here) is the correlation of a
scale with some other measure of the trait or disorder under study, ideally, a gold standard
which has been used and accepted in the field. Whereas construct validity is used when
such a gold standard does not exist; in this case, we relate the new measure – frailty– to a
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similar construct. Although their theoretical definitions are clear, their applications appear
to be confusing. For example, Fried and colleagues16 and Gobbens and colleagues120
tested the concurrent validity of their frailty instruments against adverse health outcomes
such as disability and comorbidity. In this thesis, I have followed these examples, which
may be questionable. This confusion is also reported in the literature.106
4.5 Predictive validity
4.5.1 Materials and methods
Study population
Analytic sample used in this Chapter was the same as in Section 4.4.
Predictor of interest
Frailty status (frail, pre-frail, and non-frail) is defined in Section 4.4.1.
Outcomes
Definitions of mortality (yes, no) and hospitalisation (yes, no) were provided in Section
3.4.
Covariates
The following variables had been used as covariates: sex, age, ethnicity, educational
level, socio-economic position, income/year, number of relatives and friends, alcohol
status, physical activity, BMI, systolic blood pressure, diastolic blood pressure, MMSE,
diabetes status, previous history of hospitalisation, and number of medications. They were
described in Section 4.4.1.
Statistical analyses
Univariate analysis
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As mortality and hospitalisation are time-to-event data, Kaplan-Meier method212 and log-
rank test213 were used to determine the difference in survival curves between frailty and
mortality and hospitalisation. Time-to-event data comprised following characteristics: (1)
case status: death (yes, no), hospitalisation (yes, no); (2) start date: date of phase 9
examination; (3) end date for cases: date of death or date of hospitalisation, for non-cases:
January 31, 2010; and (4) duration of follow-up was calculated in months as end date
minus start date.
Multivariable analysis
Multivariable survival analyses were performed using the Cox proportional hazards
model.214 Violations of proportional hazards assumptions were explored. This model
estimates hazard ratios (HRs) and their 95% CIs expressing the strength of the association
between an exposure and a time to event data.
Predictive validity of frailty for mortality was examined after adjustment for sex and age
only because of a low number of deaths (n=34).
For hospitalisation, three potential predictors were studied: frailty, disability, and
comorbidity performing three following models: model 1: sex and age adjusted; model 2:
frailty, comorbidity, and disability were each adjusted for covariates that were associated
with hospitalisation with a p-value of 0.20 or less; and, model 3 included frailty,
comorbidity, and disability together with the covariates in model 2. Potential interaction
terms – frailty*sex, frailty*age, frailty*disability, and frailty*comorbidity – in
hospitalisation had p-values > 0.05 negating any necessity to stratify the analyses by sex,
age, disability, or comorbidity. The proportional hazards assumption for the Cox model
was verified for the phenotype of frailty graphically (1) observing Kaplan-Meier curves
(parallel curves were expected) (see below) and (2) log(-log(survival)) versus log of
survival time graph (parallel lines were expected) (Appendix 10). This assumption was
also tested including in the model a time-dependent covariate frailty*log(follow-up). As
the time-dependent variable was not significant (p-value=0.12), this supported the
assumption of proportional hazard.
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Kaplan-Meier method, log-rank test, and Cox proportional hazards models were
performed using SAS version 9.1.
4.5.2 Results
Mortality
After phase 9 examination until January 31, 2010, with a median follow-up of 17.5
months (SD=6.1), 34 (0.7%) participants died (Table 4.1). Unadjusted survival curves
showed that frail participants were more likely to die within less than 1 year after phase 9
examination compared to those who were pre-frail or non-frail (Figure 4.2) but this
difference did not the statistical significance (log-rank test, p=0.13). After adjusting for
sex and age, those who were frail were 4.6 times more likely to die than non-frail
participants (Table 4.2).
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Figure 4.2. Kaplan-Meier curves showing probability of death according to frailty
status
Table 4.2. HRs (95% CIs) for mortality according to the frailty status with a
maximum follow-up time of 30 months
Mortality
n(event)=34
HR 95% CI p-value
Sex and age adjusted
Frailty
Non-frail
(n=3028)
1 -- --
Pre-frail
(n=1990)
1.39 0.68-2.86 0.37
Frail
(n=147)
4.64 1.51-14.26 0.007
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Hospitalisation
After phase 9 examination until January 31, 2010, 22.2% had been hospitalised at least
once (Table 4.1), with a median follow-up of 15.2 months (SD=7.1). Kaplan-Meier
curves showed that frail or pre-frail participants were more likely to be hospitalised than
non-frail participants after phase 9 examination (Figure 4.3).
Figure 4.3. Kaplan-Meier curves showing probability of hospitalisation according to
frailty status
In univariate analysis, variables associated with hospitalisation with p-values ≤ 0.20 were:
sex, age, ethnicity, educational level, socio-economic position, income/year, number of
relatives and friends, alcohol consumption, daily consumption of fruit and vegetables,
physical activity, BMI, systolic blood pressure, diastolic blood pressure, MMSE, diabetes
status, previous history of hospitalisation, and number of medications (Appendix 11).
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In age- and sex-adjusted analyses, with the non-frail group as the referent, the frail group
had an elevated HR for hospitalisation of 2.40 (95% CI: 1.83, 3.14) while for the pre-frail
group it was 1.20 (95% CI: 1.06, 1.35).
High risk of hospitalisation among frail participants persisted after multivariable
adjustment (model 2), even after entering in the model comorbidity and disability data
(model 3, see Figure 4.4 and Appendix 12).
Figure 4.4. HRs (95% CIs) for hospitalisation according to frailty, comorbidity, and
disability status, with a maximum follow-up time of 30 months
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4.5.3 Discussion
The findings on concurrent and predictive validity suggest that the phenotype of frailty is
a reasonably valid instrument. Results from the concurrent validity showed that frailty
was strongly associated with disability, assessed using the modified basic and
instrumental ADL, and moderately associated with comorbidity, with respective sex and
age-adjusted ORs of 10.3, 13.3 and 2.8. Kiely and colleagues98 in the MOBILIZE Boston
study compared cross-sectional association between disability and frailty measured using
the criteria from the study of osteoporotic fractures (SOF)116 with that of CHS.16 In a fully
adjusted model, they showed that frail participants were 5.4 and 7.7 times more likely to
be disabled according to the instrumental ADL definition, in SOF and CHS studies,
respectively.
In prospective analyses, the phenotype of frailty was found to predict hospitalisation and
the strength of prediction (RR=1.33) was similar to that of basic ADL disability
(RR=1.33) and comorbidity (RR=1.25) in a mutually adjusted model. The strength of the
prediction was also similar to that found in several other studies: in CHS, it was 1.29;16
and in the Three-City Study, the corresponding OR was 1.36.96 In the MOBILIZE Boston
study, a stronger association was reported (RR=3.54)98 whereas in the Women’s Health
and Aging Studies no association between frailty and hospital admissions was observed
(RR=0.67; 95% CI: 0.33; 1.35).75 In longitudinal studies on frailty, ADL disability is
regarded as an adverse outcome of frailty,16,96,139,215 but researchers seldom distinguish
between measurements of frailty, disability and comorbidity.61 Compared with other
studies, the strength of this present work is to be able to adjust for disability and
comorbidity in the prediction of hospitalisation by the phenotype of frailty.
These findings provide some justification for the use of this instrument in further analyses
in this thesis.
Chapter 4
- 79 -
Chapter 5
- 80 -
5 Reliability of the phenotype of frailty in the Whitehall II study
5.1 Introduction
Reliability is defined in Chapter 2. Briefly, reliability refers to the consistency of a
measure. A measure is reliable if it gives consistent results under consistent conditions.
There are several types of reliability.106 Two types of reliability can be assessed in the
Whitehall II study: internal consistency and test-retest reliability. Internal consistency
reliability assesses how a set of items are closely related as a group. Test-retest reliability
assesses the degree to which test scores are consistent from one test administration to the
next.
5.2 Objective
The specific objective addressed in this Chapter is to assess internal consistency and test-
retest reliability of the phenotype of frailty in the Whitehall II study.
5.3 Materials and methods
Internal consistency reliability
Study population
Analytic sample used in this Section was described in Chapter 4 (n=5,169).
Statistical analysis
Internal consistency is assessed with Cronbach’s alpha. This coefficient represents the
average inter-item correlation. As the average increases, Cronbach’s alpha increases as
well. A reliability coefficient of 0.70 or higher is considered ‘acceptable’.216 The
standardised Cronbach’s alpha was calculated by the software SAS 9.1.
Test-retest reliability
Study population
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After the clinic visit at phase 9, two percent of participants, selected at random from the
clinic appointments schedule, were asked to have repeated examinations within 30 days
of the visit. Of the 5,169 participants examined in Chapter 4, data from the repeated
examinations were available for 182 of them.
Statistical analysis
Because completion of a health survey questionnaire was not requested during the second
visit, it was not possible to assess fully the reliability of the phenotype of frailty measure.
Thus, its reliability has been approximately evaluated with the following three
components – walking speed, grip strength, and weight – measured during the repeated
examination. Components measured during the first visit were called ‘test’ and during the
second visit ‘re-test’. The agreement between test and re-test measures was examined
using the Bland-Altman plot.217 This plot is a graphical method to compare two repeated
measures. This is a scatter plot of mean of measurements and the differences plotted on
the vertical axis which shows the amount of disagreement between 2 measures.
Horizontal lines are drawn at the mean difference, and at the limits of agreement, which
are defined as the mean difference plus and minus 1.96 times the SD of the differences.
The presentation of the 95% limits of agreement is for visual judgment of how well two
methods of measurement agree.
5.4 Results
Cronbach’s alpha
The standardised Cronbach’s alpha coefficient was 0.28. This coefficient is low compared
with the threshold of an acceptable scale (0.7).
Bland-Altman plot
The distribution of walking speed, grip strength, and weight of test and retest measures
was normal (Appendix 13). Agreement between the test and retest values of these
components was evaluated by the Bland-Altman approach and shown in Figure 5.1. For
these three components, more than 95% of the differences between the test-retest
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measures were approximately within the limits of agreement. Number of values outside
of the 95% limits was expected to be 9 or less (182 participants * 0.05) and this was the
case. In addition, the variability was approximately random and uniform along the range
of values.
Figure 5.1. Bland-Altman plots
5.5 Discussion
Internal consistency of the phenotype of frailty was low when compared to psychometric
scales measuring a unidimensional concept. The low level of internal consistency was not
surprising given that the phenotype of frailty is expected to include multiple items which
are heterogeneous, reflecting the complexity of frailty phenomenon.218 Therefore, a weak
internal consistency found in this study should not be regarded as an indication of poor
reliability. In fact, the estimation of the internal consistency reliability here was not
necessary.
Regarding the test and re-test reliability, as the 95% of differences between test and re-
test measures were included within the limits of agreement, walking speed, grip strength,
and weight components have been reliably measured.
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6 Phenotype of frailty: composite versus single measurements in the
Whitehall II study
6.1 Introduction
While it is assumed that the measurement of frailty needs to include multiple components,
these may overlap. Using fewer components would be more time- and cost-efficient.
Although studies using the phenotype of frailty have generally shown that the greater the
number of frailty components used the higher the risk of a given adverse health
outcome,16,75,96,116,193,219 it remains unclear whether all components of the scale contribute
to associations with health outcomes or whether some of them are redundant.
6.2 Objectives
Specific objectives addressed in this Chapter were:
i. to test whether the association between the phenotype of frailty and hospitalisation
was greater than that of any single component of measure or the additive risk
associated with combination of components
ii. to compare the prediction accuracy of multi-component measures of frailty for
total hospitalisations with a single-component measure
6.3 Materials and methods
Study population
For the current analyses, the flow of participants through the study is the same as depicted
in Chapter 4 (n=5,169).
Exposure and outcome
Exposure variables were the phenotype of frailty and its five individual components
described in Section 4.4.1. The outcome variable of interest was hospitalisation.
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Statistical analysis
Univariate analysis examining association between participants’ characteristics and the
phenotype of frailty and its individual components and hospitalisation was performed
using Wilcoxon-Mann-Whitney and Chi-square tests and Cochrane-Armitage trend.
Following strategies were adapted for the analyses to respond to the objectives of this
Chapter.
First, having ascertained that the proportional hazards assumptions had not been violated,
HRs and accompanying 95% CIs for the associations of frailty (and its individual
components) with all hospitalisations combined were computed using Cox proportional
hazard regression models.214
In order to explore whether a single component was responsible for generating the
association between the overall frailty scale and the risk of hospitalisation, the cumulative
effect of frailty markers in the prediction of hospitalisation was studied by creating a
frailty score ranging from 0 (no frailty) to 5. Then, the effect of number and combinations
of frailty components on the risk of hospitalisation in two separate models was examined.
A subgroup analysis was conducted among study participants who were negative for a
given frailty component to estimate cumulative effects (0 to 4) of other frailty
components in the prediction of adverse health outcomes. In all analyses, the reference
group was that with no apparent frailty.
To evaluate the predictive power for each individual component and the full frailty scale,
Harrell’s C concordance statistic was calculated,220 an equivalent to the area under the
curve (AUC) statistic for receiver-operating characteristic (ROC) in survival model. It
estimates the concordance between the predicted failure order of a pair of subjects and the
observed order. Analytic sample was split into ‘derivation’ and ‘validation’ datasets of
equal size after stratification by age and sex. Then age- and sex- adjusted models were
fitted in the derivation dataset and the performance of the models was evaluated in the
validation dataset.221
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Descriptive analyses and Cox proportional hazards models were performed using SAS
version 9.1. Calculations of Harrell’s C concordance statistic were performed using Stata
version 10.
6.4 Results
Study participants and missing data
In Table 6.1, baseline characteristics of study members according to hospitalisation were
reported. Of the 5,169 participants, 22.3% had at least one hospitalisation episode during
the follow-up (range 0.03 to 28.13 months; mean=15.17). In comparison with non-
hospitalised participants, hospitalised participants were more likely to be older, positive
for each frailty components, and classified as frail or pre-frail.
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Table 6.1. Baseline characteristics of the 5,169 study participants according to
hospitalisation during follow-up
Hospitalisation
n (%)
P-valuea
No Yes
N 4019 1150
Age in years (mean (SD)) 65.4 (5.8) 67.2 (6.0) <0.0001
Women 1104 (27.5) 315 (27.4) 0.96
Frailty components
Exhaustion 402 (10.0) 152 (13.2) 0.002
Low physical activity 875 (21.8) 301 (26.2) 0.002
Slow walking speed 340 (8.5) 163 (14.2) <0.0001
Low grip strength 373 (9.3) 139 (12.1) 0.005
Weight loss 135 (3.4) 54 (4.7) 0.03
Frailty status <0.0001
Non-frail 2415 (60.1) 614 (53.4)
Pre-frail 1517 (37.8) 476 (41.4)
Frail 87 (2.1) 60 (5.2)
a P-value for heterogeneity except for frailty status where P-value is for trend
Association between single components of frailty and future risk of hospitalisation
Table 6.2 shows the association between individual frailty components and the risk of
hospitalisation. All five components were related to hospitalisation, with the age- and sex-
adjusted HRs ranging from 1.18 (95% CI: 0.98, 1.41) for grip strength to 1.60 (95% CI:
1.35, 1.90) for walking speed. Some attenuation was apparent following adjustment for
other components but the rank order of the strength of association remained unchanged.
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Table 6.2. HRs (95% CIs) for the association of individual frailty components with
hospitalisation (n=5,169)
Hospitalisation
N (%)
No Yes
HR [95% CI]
Sex- and age- adjusted
HR [95% CI]
Fully-adjusteda
Exhaustion
No 3617 (90.0) 998 (86.8) 1 (ref) 1
Yes 402 (10.0) 152 (13.2) 1.38 [1.17, 1.64] 1.30 [1.10, 1.55]
Low physical activity
No 3144 (78.2) 849 (73.8) 1 1
Yes 875 (21.8) 301 (26.2) 1.26 [1.10, 1.44] 1.19 [1.04, 1.36]
Slow walking speed
No 3679 (91.5) 987 (85.8) 1 1
Yes 340 (8.5) 163 (14.2) 1.60 [1.35, 1.90] 1.52 [1.28, 1.80]
Low grip strength
No 3646 (90.7) 1011 (87.9) 1 1
Yes 373 (9.3) 139 (12.1) 1.18 [0.98, 1.41] 1.07 [0.89, 1.28]
Weight loss
No 3884 (96.6) 1096 (95.3) 1 1
Yes 135 (3.4) 54 (4.7) 1.41 [1.07, 1.86] 1.34 [1.02, 1.77]
a Adjustment for sex, age, exhaustion, physical activity, walking speed, grip strength, and weight loss
Cumulative effect of frailty markers and the risk of hospitalisation
Figure 6.1 shows a dose-response relationship between the risk of hospitalisation and the
number frailty components: the HRs for hospitalisation ranged from 1.10 (95% CI: 0.96,
1.26) (any single frailty component) to 2.41 (95% CI: 1.84, 3.16) (3-5 frailty
components). Figure 6.1 also displays HRs and their 95% CIs for hospitalisation
according to different combinations of indicators included in the frailty scale when the
scores were less than 3. Among study members with one frailty component only, the
strength and the rank of association of each separate frailty component was largely
similar to those reported in Table 6.2 where this estimation was carried out among the
study participants with a frailty score of one or more. When examining the possible
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combinations of 2 items from the frailty scale, there were very few study members with
weight loss; therefore, three combinations were not represented. Two (low physical
activity and slow walking speed; exhaustion and low physical activity) of a possible 10
combinations of those with 2 frailty indicators had very similar and strong associations
(HRs ranging from 1.80 to 1.83) with hospitalisation.
Figure 6.1. HRs (95% CIs) for the association of combinations of frailty components
with subsequent hospitalisation
a Results from 2 models: one with different combinations included in the model (diamonds); the other one
with number of frailty components included in the model (squares). All analyses were adjusted for age at
baseline and sex. The reference group was those with no frailty component.
b Three combinations were not reported owing to too few hospitalizations: weight loss & slow walking
speed (n=0), weight loss & exhaustion (n=2), and weight loss & low grip strength (n=3).
c Owing to low numbers, participants with 3 to 5 frailty components were collapsed.
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Table 6.3 presents the results of the association between the number of frailty components
with the risk for hospitalisation stratified by the presence of individual frailty
components. Within each stratum, a dose-response association between the frailty score
and the risk for hospitalisation was still observed.
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Table 6.3. HRs (95% CIs) for the association of number of frailty components with
hospitalisation, stratified by individual components
PA: physical activity; WS: walking speed; GS: grip strength.
N
hosp
N non-
hosp HR [95% CI]
N
hosp
N non-
hosp HR [95% CI]
Exhaustion
=No
998 3617 Exhaustion
=Yes
152 402
0 614 2415 1 [Ref] 0 56 215 1 [Ref]
1 281 970 1.11 [0.96, 1.28] 1 60 136 1.62 [1.12, 2.33]
2 79 196 1.40 [1.10, 1.77] 2 24 39 2.30 [1.41, 3.74]
3-4 24 36 2.09 [1.39, 3.16] 3-4 12 12 3.72 [1.97, 7.01]
P for trend 0.0001 P for trend <0.0001
Low PA
=No
849 3144 Low PA
=Yes
301 875
0 614 2415 1 [Ref] 0 147 567 1 [Ref]
1 190 618 1.14 [0.96, 1.34] 1 101 231 1.52 [1.17, 1.96]
2 38 101 1.40 [1.01, 1.96] 2 41 64 2.25 [1.58, 3.21]
3-4 7 10 2.22 [1.05, 4.69] 3-4 12 13 3.61 [2.00, 6.55]
P for trend 0.005 P for trend <0.0001
Slow WS
=No
987 3679 Slow WS
=Yes
163 340
0 614 2415 1 [Ref] 0 61 146 1 [Ref]
1 276 1039 1.05 [0.91, 1.21] 1 54 124 1.13 [0.78, 1.63]
2 85 208 1.47 [1.17, 1.85] 2 36 57 1.52 [1.00, 2.30]
3-4 12 17 2.58 [1.46, 4.57] 3-4 12 13 2.46 [1.32, 4.58]
P for trend 0.0004 P for trend 0.004
Low GS
=No
1011 3646 Low GS
=Yes
139 373
0 614 2415 1 [Ref] 0 46 187 1 [Ref]
1 291 998 1.15 [1.00, 1.32] 1 50 128 1.58 [1.06, 2.36]
2 89 204 1.61 [1.29, 2.02] 2 33 49 2.56 [1.63, 4.01]
3-4 17 29 2.48 [1.52, 4.03] 3-4 10 9 4.93 [2.47, 9.84]
P for trend <0.0001 P for trend <0.0001
Weight loss
=No
1096 3884 Weight loss
=Yes
54 135
0 614 2415 1 [Ref] 0 27 70 1 [Ref]
1 310 1115 1.08 [0.94, 1.23] 1 13 45 0.69 [0.35, 1.35]
2 126 287 1.59 [1.31, 1.92] 2 10 13 2.09 [0.99, 4.39]
3-4 46 67 2.33 [1.72, 3.16] 3-4 4 7 1.54 [0.53, 4.49]
P for trend <0.0001 P for trend 0.19
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Predictive power of single- and multi-component measures for hospitalisation
Harrell’s C concordance statistic for individual frailty components and the full frailty
scale varied very little: 0.57 (95% CI: 0.55, 0.60) for grip strength and 0.58 (95% CI:
0.56, 0.61) for exhaustion and the full frailty scale. The difference of Harrell’s
concordance indices between pairs of individual components and the full scale was not
statistically significant at conventional levels (all p-values > 0.06; Table 6.4).
Table 6.4. Performance of models in the prediction for hospitalisation including
individual components and the phenotype of frailty
Model Harrell’s c statistic [95% CI] P-valuea
M1: Age, sex 0.574 [0.549, 0.600] 0.196
M2: M1 + exhaustion (yes/no) 0.583 [0.558, 0.607] 0.401
M3: M1 + low physical activity (yes/no) 0.579 [0.554, 0.605] 0.903
M4: M1 + slow walking speed (yes/no) 0.578 [0.553, 0.604] 0.841
M5: M1 + low grip strength (yes/no) 0.573 [0.548, 0.598] 0.056
M6: M1 + weight loss (yes/no) 0.575 [0.549, 0.600] 0.236
M7: M1 + Fried frailty scale (3-5 versus 0-2) 0.579 [0.554, 0.604] Ref
a P-value comparing the predictive values of M1 to M6 with M7.
6.5 Discussion
The main objective of this study was to examine whether the five components included in
the phenotype of frailty scale were equally related to the risk of hospitalisation or whether
one single component, or a combination, had the same utility as the full scale.
Although the dose-response relationship between the number of frailty components and
the risk of adverse health outcomes16,75,96,116,193,219 has been previously described, the
present results add some novel findings to this literature. First, all five frailty components
– exhaustion, low physical activity, slow walking speed, low grip strength, and weight
loss – were found to be independently associated with hospitalisation with none of them
being redundant. Thus, these analyses support the hypothesis that several components are
required to measure frailty.16,104 These results are also consistent with those from a
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previous study149 where the authors found that slow walking speed was the strongest, and
low grip strength the weakest predictor of hospitalisation.
Second, the predictive performance of the individual frailty components was tested and
compared with that of the full frailty scale. Harrell’s C concordance statistic varied
between 0.57 and 0.58 (0.50 indicates that the prediction does not differ from chance),
suggesting that neither the components nor the full scale were adequate prediction tools
for hospitalisation in the clinical settings.
Third, the absence of difference in predictive performance between individual
components and the full scale suggest that measuring only one component of frailty might
enable an equally precise prediction of hospitalisation as the full scale, although other
analyses conducted in this study did not support this conclusion. Importantly, findings in
this Chapter showed that within the group of individuals with a frailty component, those
who additionally had other frailty components were up to 4.9 times more likely to
experience hospitalisation at follow-up compared with those with no additional frailty
components. Thus, the frailty measure seems to stratify risk even within the group of
individuals with an individual frailty component.
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7 Predictive validity of CVD risk algorithms for frailty in the
Whitehall II study
7.1 Introduction
There is increasing evidence to suggest that CVD risk factors measured in midlife predict,
in addition to CVD endpoints, a wide range of old-age health outcomes. These include
cognitive decline and dementia,222,223 late-life depression,224-226 disability,227 and
cancer.228-231 Although few large-scale prospective studies have examined the association
between CVD risk factors and frailty, such a link is plausible for at least two reasons.
First, several studies have shown a cross-sectional association between CVD and
frailty.75,77 In one cross-sectional study, subclinical CVD diagnosed using non-invasive
testing (carotid ultrasound, ankle-arm index, electrocardiography, echocardiography, and
cerebral magnetic resonance imaging) was related to frailty after excluding clinically
diagnosed CVD.60 Second, several individual risk factors included in multi-factorial
prediction algorithms of CVD, such as the Framingham score, have been associated with
frailty status: high blood pressure,232 diabetes,76,232 low HDL cholesterol level,233,234 and
cigarette smoking.15 In this Chapter, I hypothesised that CVD risk scores would be
associated with subsequent frailty. If supported, such an observation would have
considerable utility for frailty in clinical practice where such CVD risk scores are
routinely administered.
7.2 Objective
The specific objective addressed in this Chapter was to test whether CVD risk scores used
to assess 10-year risk of CVD would be associated with subsequent frailty in people
without diagnosed CVD at baseline.
In this Chapter, four CVD risk algorithms were investigated: the American Framingham
CVD,235 CHD,236 and stroke237 risk scores, and the European SCORE (Systematic
Coronary Risk Evaluation).238
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7.3 Materials and methods
Study population
CVD risk factors measured at phase 5 were utilised to assess the risk of developing frailty
at phase 9 when frailty components were first measured.
Outcome of interest
Outcome was the phenotype of frailty as described in Section 4.4.1.
CVD risk factors at baseline
Individual CVD risk factors included in the CVD risk scores were measured as follows:
Total cholesterol was determined by an enzymatic procedure using the automated CHOD-
PAP method.
Serum HDL-cholesterol concentrations were measured from the supernatant after
precipitation of non-HDL-cholesterol with phosphotungstate.
Systolic blood pressure was measured twice with the Hawksley random zero
sphygmomanometer in the sitting position after five minutes’ rest. The average of the two
readings was used in the present analyses.
Participants reported the medications used in the previous 14 days; responses were coded
using the British National Formulary codes.239 Antihypertensive therapy was based on the
use of the following drugs: diuretics, beta-blockers, angiotensin-converting enzyme
inhibitors, calcium channel blockers, and other antihypertensive drugs.
Current smoking (yes, no) was ascertained by self-report.
Prevalent diabetes mellitus was defined based on reported doctor-diagnosed diabetes
mellitus or use of diabetes medication, or when participants had a baseline fasting plasma
glucose level greater than 126 mg/dL (> 7.0 mmol/L).240
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Presence of atrial fibrillation and left ventricular hypertrophy was determined on the
electrocardiograms (ECG) using the Minnesota Code:241 atrial fibrillation is coded as 8-3-
1 and left ventricular hypertrophy as 3-1-0.
CVD risk scores at baseline
Four CVD risk score algorithms – the Framingham CVD,235 CHD,236 stroke237 prediction
models, and SCORE238 – were estimated according to the literature. The table in
Appendix 14 summarises all components included in the models.
The distribution of the probability of CVD of these algorithms is shown in Appendix 15.
Cardiovascular disease
CVD were classified as non-fatal CHD and stroke, and non-fatal CVD.
Non-fatal CHD events: CHD diagnoses included ischemic heart diseases (international
classification of diseases version 9 (ICD-9) codes 410–414 or ICD-10 codes I20–
I25)202,242 which included non-fatal myocardial infarction (MI), angina pectoris, and other
forms of ischemic heart disease. Information on non-fatal MI and angina was obtained
from several sources. From 1989 onwards the British NHS Hospital Episode Statistics
(HES)198 database has provided reports of participants’ diagnoses on discharge and
procedure codes for all NHS hospitals in England and Wales. Participants also self-report
CHD events in the Whitehall II health survey questionnaires. These are then validated
using the study resting electrocardiograms, the HES database, and by contacting general
practitioners for confirmation when no other external source exists.
Non-fatal stroke events: non-fatal stroke included first subarachnoid hemorrhage,
intracerebral hemorrhage, cerebral infarction, and not specified stroke (ICD-10 codes
I60–I64), and transient cerebral ischemic attacks (ICD-10 codes G45). The cases were
ascertained from participants’ general practitioners, information extracted from hospital
medical records by study nurses, or data from the NHS HES database obtained after
linking the participants’ unique NHS identification numbers to this national database.
Self-reported stroke cases without clinical verification were excluded.
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Non-fatal CVD events: this group includes both non-fatal CHD and stroke cases.
Statistical analyses
Complete data analysis
Each CVD risk factor was described according to the frailty status (frail, pre-frail, and
non-frail) depending on its characteristics: arithmetic means and SDs if quantitative
variables had a normal distribution, medians and IQRs if quantitative variables had not a
normal distribution, or frequencies and proportions for qualitative variables.
The following statistical hypothesis tests were performed for univariate analysis:
Student’s t-test (if normal distribution) or Mann-Whitney test (if non normal distribution)
for quantitative variables, Chi-square test for categorical variables, Cochrane-Armitage
trend test for ordered categorical variables.
The associations between these risk factors and frailty were summarised using binary
logistic regression analyses with frailty status dichotomised (frail and pre-frail versus
non-frail) owing to the low number of frail participants (n=108, 2.8%). As the mean risk
scores among men were systematically higher than that among women (p-values for all
four scores < 0.0001), these risk scores were transformed into standard scores (mean=0,
SD=1) in men and women separately. The ORs of being frail or pre-frail was estimated
per one SD increase (higher score greater CVD risk) in the risk scores over the 10-year
follow-up. As sex did not modify the relation of the standardised risk scores with frailty at
follow-up (all p-values for sex interaction > 0.07), men and women were combined in the
analysis.
Following analyses were performed to reach the objective of this Chapter.
In examining the associations between individual risk factors and later frailty, sex-
adjusted models were performed and then adjusted for the other risk factors to explore the
independent effect of individual CVD risk factors with frailty. Binary logistic regression
models were then used to examine the impact of a 1-SD increment in the risk scores on
frailty at follow-up.
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Association between the CVD risk scores and incident cardiovascular events (CVD,
CHD, and strokes) were examined to compare the strength of their associations to that
with frailty.
Association between the CVD risk scores and frailty after excluding incident CVD cases
was estimated to examine whether the association between the risk scores and frailty was
mediated by underlying CVD.243
Finally, to explore the extent to which the relationship between the risk scores and frailty
was driven by specific CVD risk factors included in the scores, analyses on the risk scores
– frailty associations were adjusted individually for each of their risk factors. A greater
attenuation in the association after adjustment indicates a greater contribution of that
specific risk factor.
Missing data analysis
Analyses above were based on complete data (n=3,895). This cohort represents 52.5% of
study members for participants eligible at phase 5 and alive at the end of follow-up
(n=7,412). Because the association between the risk scores and frailty could be biased by
missing data, I imputed data for missing frailty/pre-frailty status and individual CVD risk
factors included in the risk scores. This consists of imputing missing values that is
replacing missing values with other values. There are several techniques:
a. Common imputation techniques
Two common approaches for dealing with missing data are:
- mean substitution where missing data values are replaced with the sample mean,
and,
- conditional mean imputation where the mean from cases that are similar to the
cases with missing values is utilised.
These methods have an important drawback: the imputed values are completely
determined by a model applied to the observed data. This tends to decrease variance and
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can deform relationships among variables. Another approach consists in imputing
multiple times to include some variation into the imputed values. This is possible as they
are drawn from a distribution.244 This technique is called ‘multiple imputation’.
b. Multiple imputation
Multiple imputation provides a ‘complete’ dataset, to which standard complete-data
analysis can be applied. It is a method for valid inference from partially observed data
using properties derived from the Bayesian method. The main advantage of this approach
is, it can be applied whether data are missing at random (MAR, the probability of data
being missing does not depend on the unobserved data, conditional on the observed data)
or missing not at random (MNAR, the probability of data being missing does depend on
the unobserved data, conditional on the observed data).244,245
There are different multiple imputation models depending on the missing data pattern.
Missing data pattern can be either monotone or arbitrary (Figure 7.1).
When the missing data pattern is monotone, Markov Chain Monte Carlo (MCMC)
method is used.
When missing data pattern is arbitrary, following methods are applied:
- multivariable normal approach. Imputed values are drawn from a multivariable
normal distribution of all the variables in the imputation model. Therefore, this
model is not well suited for categorical variables.
- imputation by chained equations (ICE) approach. This approach generates
imputations by performing a series of univariate regression models rather than a
single large multivariable normal model. Therefore, this model is well suited for
categorical variables.
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Figure 7.1. Missing data pattern
Monotone Arbitrary
V1 V2 V3 V4 V5 V1 V2 V3 V4 V5
X X X X X X X . X X
X X X X X . X X . .
X X X X X . X . X
X X X X X . . .
X X . X X X .
X X X . X .
Missing data pattern in the dataset used in this Chapter was presented in Appendix 16. As
it was arbitrary, the ICE approach has been used.
c. ICE approach
i. Theoretical explanation
ICE method generates imputations based on a series of regressions models, one for each
variable with missing values. Let’s consider x1, x2, …, xk variables with missing data.
Imputation values are performed as follows:244
Step 1: all variables with missing values are filled in by simple random sampling with
replacement from the observed values;
Step 2: x1 is regressed on all other variables x2, …, xk, restricted to individuals with the
observed x1;
Step 3: missing values in x1 are replaced by simulated draws from the corresponding
posterior predictive distribution of x1;
Step 4: x2 is regressed on all other variables x1, x3, …, xk, restricted to individuals with
the observed x2;
Step 5: missing values in x2 are replaced by simulated draws from the corresponding
posterior predictive distribution of x2;
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Step 6 and so on: the process is repeated for all other variables with missing values in
turn; this is called a cycle.
To obtain stabilised results, the procedure is usually repeated for several cycles (e.g., 10
or 20) to produce a single imputed dataset. An important advantage of ICE approach is to
impute different types of variables (continuous, binary, ordered and unordered
categorical) using their own imputation model (linear regression for continuous variables,
logistic regression for binary variables, ordered logistic regression for ordered variables,
and multinomial regression for unordered variables).
ii. Construction of the imputation model
The model includes: (1) all diabetes risk factors included in the risk scores (‘partially
observed variables’); (2) outcome variable: frailty (frail/pre-frail versus non-frail); and,
(3) auxiliary variables: they have to be associated with one or more of the partially
observed variables, observed when the partially observed variables are not, and predictive
of missingness. These variables are not included in the model of the association between
the CVD risk scores and frailty. Here, two auxiliary variables met these criteria: socio-
economic position at phase 5 (administrator, executive officer, office support staff), and
self-reported general health (excellent or very good, good, fair or poor) (Appendix 17).
Non-normally distributed continuous variables need to be transformed towards normality
in the imputation model. After imputation, they are re-transformed back to its original
form. Normality of continuous variables was checked in Appendix 18.
iii. Statistical software
A group of researchers in University of Michigan has developed a SAS callable software
application called IVEware (Imputation and Variance Estimation software) using the ICE
approach.246
Percentage of missing data by variable was calculated basing on study members who both
responded to the questionnaire and attended screening examination at baseline (n=7,412)
(Appendix 19). Variables with the highest number of missing data were the outcome
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variable (frailty) at phase 9 and HDL-cholesterol at phase 5 with percentage > 25%. As
this number is relatively high, I decided to run 20 cycles.
Three steps were carried out after obtaining 20 datasets with imputed values: (1)
calculating diabetes risk scores from imputed risk factors’ values and standardising these
probabilities into z-scores to study their 1-SD increment in association with frailty; (2)
performing logistic regression model on each of the imputed dataset; and (3) combining
the parameter estimates (ORs and their 95% CIs) from each imputed dataset to get a final
single set of parameter estimates. Figure 7.2 illustrates the procedure described above.
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Figure 7.2. Three steps-procedure to conduct a sensitivity analysis with multiple
imputationa
a This figure is adapted from that presented by Mr Cody Olsen (University of Utah, department of
pediatrics) during a biostatistics seminar, October 13, 2011.
Permission to reproduce this figure has been granted by Mr Cody Olsen.
7.4 Results
Complete data analysis
Description of the study participants and missing data
Of the 10,308 study members who participated in phase 1 (1985-1988), 862 had died and
1,447 had dropped out from the study before the start of the data collection at phase 9
(2007-2009). Of the 7,870 participants who attended the phase 5, a total of 3,895
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participants (1,037 women) aged 45-69 years at phase 5 constituted the analytic sample
(Figure 7.3).
Compared with participants alive at phase 9 but excluded (owing to non participation at
phases 5 and 9 and missing data on the CVD risk scores or the frailty scale, (n=4,104)),
persons included in the analytic sample (n=3,895) were 0.3 years younger (p=0.01), less
likely to be female (26.6% versus 35.3%, p < 0.0001), and less likely to be from the lower
socioeconomic group (12.4% versus 26.1%, p < 0.0001).
Figure 7.3. Flow of study members featured in the present analysis
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Table 7.1 shows description of the baseline characteristics of participants according to
frailty status at the end of follow-up (on average 10.5 years (SD=0.5) after the
measurement of CVD risk scores). Of the 3,895 participants, 2.8% were classified as frail,
37.1% pre-frail, and 60.1% non-frail. In comparison with non-frail participants, frail
participants were more likely to be older, female, use antihypertensive treatment, smoke,
and have diabetes. Frail participants were also more likely to have experienced a CVD
event during the follow-up relative to their non-frail counterparts (16.7 versus 8.5%,
p=0.01).
Association between the individual CVD risk factors and frailty
Table 7.2 shows the association between the individual CVD risk factors at baseline and
frailty at follow-up. Age, HDL-cholesterol, and smoking status were independently
associated with future frailty. Thus, a 1-SD increment in age (5.9 years for men and
women) increased the odds of being frail/pre-frail by 12% (OR=1.12; 95% CI: 1.05,
1.20). A 1-SD increment in HDL-cholesterol decreased the odds by 12% (95% CI: 0.83,
0.94), and being a current smoker increased the odds by 40% (95% CI: 1.10, 1.78).
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Table 7.1. Characteristics of participants in the analytical sample (n=3,895)
Frailty status at follow-up
All Not frail Pre-frail Frail P-valuea
Numbers 3895 2342 1445 108
Age, years, mean (SD) 55.2 (5.9) 54.9 (5.7) 55.5 (6.1) 57.9 (6.5) <0.0001
Sex, n (%)
Male 2858 (73.4) 1926 (77.6) 1023 (67.5) 51 (50.5) <0.0001
Female 1037 (26.6) 556 (22.4) 492 (32.5) 50 (49.5)
Total cholesterol, mg/dL 229.23 (40.58) 228.61 (39.50) 230.04 (42.33) 231.63 (40.00) 0.22
HDL cholesterol, mg/dL, mean (SD) 56.65 (15.10) 56.93 (15.23) 56.19 (14.89) 56.77 (15.02) 0.21
Systolic blood pressure, mm Hg 122.7 (16.0) 122.3 (15.7) 123.3 (16.3) 124.5 (16.1) 0.08
Antihypertensive treatment, n (%)
No 3515 (90.2) 2137 (91.3) 1293 (89.5) 85 (78.7) <0.0001
Yes 380 (9.8) 205 (8.7) 152 (10.5) 23 (21.3)
Smoking, n (%)
No 3593 (92.3) 2185 (93.3) 1313 (90.9) 95 (88.0) 0.006
Yes 302 (7.8) 157 (6.7) 132 (9.1) 13 (12.0)
Diabetes, n (%)
No 3755 (96.4) 2273 (97.1) 1381 (95.6) 101 (93.5) 0.01
Yes 140 (3.6) 69 (3.0) 64 (4.4) 7 (6.5)
Atrial fibrillation, n (%)
No 3882 (99.7) 2335 (99.7) 1439 (99.6) 108 (100.0) -
Yes 13 (0.3) 7 (0.3) 6 (0.4) 0
Left ventricular hypertrophy, n (%)
No 3667 (94.2) 2214 (94.5) 1356 (93.8) 97 (89.8) 0.10
Yes 228 (5.8) 128 (5.5) 89 (6.2) 11 (10.2)
Follow-up, years 10.5 (0.5) 10.5 (0.5) 10.5 (0.5) 10.7 (0.5) 0.0003
Incident CVD at follow-up, n (%)
No 3552 (91.2) 2143 (91.5) 1319 (91.3) 90 (83.3) 0.01
Yes 343 (8.8) 199 (8.5) 126 (8.7) 18 (16.7)
Incident CHD at follow-up, n (%)
No 3582 (92.0) 2165 (92.4) 1324 (91.6) 93 (86.1) 0.05
Yes 313 (8.0) 177 (7.6) 121 (8.4) 15 (13.9)
Incident stroke at follow-up, n (%)
No 3856 (99.0) 2316 (98.9) 1436 (99.4) 104 (96.3) 0.01
Yes 39 (1.1) 26 (1.1) 9 (0.6) 4 (3.7)
a P for heterogeneity
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Table 7.2. Association between individual CVD risk factors at baseline and frailty at
10-year follow-up (n=3,895)
Predictors N (%) OR (95% CI) for frailty
Adjusted for sex Fully adjustedb
Age, yearsa 3,895 1.14 (1.07, 1.22) 1.12 (1.05, 1.20)
Total cholesterol, mg/dLa 3,895 1.03 (0.97, 1.10) 1.01 (0.95, 1.08)
HDL cholesterol, mg/dLa 3,895 0.88 (0.82, 0.94) 0.88 (0.83, 0.94)
Systolic blood pressure, mm Hga 3,895 1.09 (1.02, 1.16) 1.04 (0.98, 1.12)
Antihypertensive treatment
No 3,515 (90.2) 1 (ref) 1 (ref)
Yes 380 (9.8) 1.28 (1.03, 1.58) 1.10 (0.88, 1.37)
Smoking
No 3,593 (92.2) 1 (ref) 1 (ref)
Yes 302 (7.8) 1.37 (1.08, 1.74) 1.40 (1.10, 1.78)
Diabetes
No 3,755 (96.4) 1 (ref) 1 (ref)
Yes 140 (3.6) 1.55 (1.10, 2.17) 1.36 (0.96, 1.93)
Atrial fibrillation
No 3,882 (99.7) 1 (ref) 1 (ref)
Yes 13 (0.3) 1.51 (0.51, 4.50) 1.37 (0.46, 4.13)
Left ventricular hypertrophy
No 3,667 (94.1) 1 (ref) 1 (ref)
Yes 228 (5.9) 1.25 (0.95, 1.64) 1.17 (0.88, 1.54)
a Odds ratio per standard deviation increase.
b Model includes all predictors in addition to sex.
Association between CVD risk scores and frailty
Table 7.3 shows the results of analyses of the association of a 1-SD increment in the CVD
risk scores with future frailty and cardiovascular events. All risk scores had a similar
strength of association with frailty with the ORs ranging from 1.17 (95% CI: 1.10, 1.25)
for the Framingham CHD risk score to 1.20 (95% CI: 1.13, 1.28) for the Framingham
CVD risk score. As expected, the association of the CVD risk scores was stronger in
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relation to predicting CVD events, with ORs ranging from 1.36 (95% CI: 1.15, 1.61) for
the Framingham stroke risk score to 1.64 (95% CI: 1.50, 1.80) for the Framingham CVD
risk score. The strength of the associations for frailty was not diminished after exclusion
of incident CVD cases (Table 7.4).
Table 7.3. ORs (95% CIs) per one sex-specific SD increment in score using four
CVD risk algorithms for prediction of frailty and CVD (n=3,895)
Frail and pre-frail CVD
Number of
cases
OR (95% CI) Outcome Number of
cases
OR (95% CI)
Framingham CVD risk score 1553 1.20 (1.13, 1.28) Any CVD 343 1.64 (1.50, 1.80)
Framingham CHD risk score 1553 1.17 (1.10, 1.25) CHD 313 1.53 (1.40, 1.68)
Framingham stroke risk score 1553 1.19 (1.12, 1.27) Stroke 39 1.36 (1.15, 1.61)
SCORE (CVD risk score) 1553 1.18 (1.10, 1.25) Any CVD 343 1.57 (1.44, 1.71)
Table 7.4. ORs (95% CIs) per one sex-specific SD increment in score using four
CVD risk algorithms for prediction of future frailty after excluding incident CVD
CVD risk scores OR (95% CI)
Framingham CVD risk score 1.23 (1.15, 1.32)
Framingham CHD risk score 1.19 (1.11, 1.28)
Framingham stroke risk score 1.22 (1.14, 1.32)
SCORE 1.18 (1.10, 1.27)
CVD risk factors in the association between CVD risk scores and frailty
Table 7.5 shows results of analyses in which the four CVD risk scores as a whole were
adjusted for each of their risk factors. The association between risk scores and frailty
remained statistically significant after successive adjustments for risk factors suggesting
that this association was not driven by any specific risk factor.
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Table 7.5. Association between CVD risk scores and frailty
CVD risk scores OR for frailty
(95% CI)
Framingham CVD score
Unadjusted 1.20 (1.13, 1.28)
Adjusted fora
Age 1.18 (1.09, 1.28)
Total cholesterol 1.22 (1.14, 1.31)
HDL cholesterol 1.21 (1.13, 1.29)
Systolic blood pressure 1.24 (1.15, 1.35)
Antihypertensive treatment 1.20 (1.12, 1.28)
Smoking 1.19 (1.11, 1.27)
Diabetes 1.20 (1.12, 1.28)
Framingham CHD score
Unadjusted 1.17 (1.10, 1.25)
Adjusted fora
Age 1.13 (1.05, 1.22)
Total cholesterol 1.19 (1.11, 1.27)
HDL cholesterol 1.18 (1.10, 1.27)
Systolic blood pressure 1.18 (1.10, 1.27)
Smoking 1.16 (1.08, 1.24)
Diabetes 1.16 (1.08, 1.24)
Framingham stroke score
Unadjusted 1.19 (1.12, 1.27)
Adjusted fora
Age 1.15 (1.07, 1.24)
Systolic blood pressure 1.22 (1.13, 1.33)
Antihypertensive treatment 1.18 (1.10, 1.26)
Smoking 1.18 (1.10, 1.26)
Diabetes 1.18 (1.10, 1.26)
Atrial fibrillation 1.19 (1.12, 1.27)
Left ventricular hypertrophy 1.25 (1.15, 1.35)
SCORE
Unadjusted 1.18 (1.10, 1.25)
Adjusted fora
Age 1.15 (1.05, 1.27)
Total cholesterol 1.19 (1.11, 1.28)
Systolic blood pressure 1.20 (1.11, 1.30)
Smoking 1.16 (1.09, 1.24)
a Each CVD risk score was adjusted for individual CVD risk factors.
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Missing data analysis
After multiple imputation, ORs for the association between risk factors of CVD and
frailty were broadly similar to those with the complete data (Table 7.6). This was also the
case for the Framingham CVD, CHD and stroke risk scores, and the SCORE (Table 7.7).
Table 7.6. ORs (95% CIs) for the association between individual components of the
CVD risk scores and frailty: complete data versus multiple imputation analysis
Complete data analysis
(n=3,895)
Multiple imputation
(n=7,412)
Age, years 1.02 (1.01, 1.03) 1.03 (1.02, 1.04)
Sex
Male 1 (ref) 1 (ref)
Female 1.74 (1.51, 2.01) 1.78 (1.57, 2.01)
Total cholesterol, mg/dL 1.04 (0.98, 1.10) 1.05 (0.99, 1.11)
HDL cholesterol, mg/dL 0.89 (0.75, 1.05) 0.92 (0.79, 1.07)
Systolic blood pressure, mm Hg 1.00 (1.00, 1.01) 1.00 (1.00, 1.01)
Diastolic blood pressure, mm Hg 1.00 (1.00, 1.01) 1.00 (1.00, 1.01)
Antihypertensive treatment
No 1 (ref) 1 (ref)
Yes 1.32 (1.07, 1.64) 1.42 (1.21, 1.67)
Smoking
No 1 (ref) 1 (ref)
Yes 1.43 (1.13, 1.81) 1.41 (1.17, 1.70)
Diabetes
No 1 (ref) 1 (ref)
Yes 1.58 (1.13, 2.21) 1.86 (1.35, 2.55)
Atrial fibrillation
No 1 (ref) 1 (ref)
Yes 1.30 (0.43, 3.86) 1.35 (0.58, 3.11)
Left ventricular hypertrophy
No 1 (ref) 1 (ref)
Yes 1.19 (0.91, 1.56) 1.12 (0.89, 1.41)
Chapter 7
- 112 -
Table 7.7. ORs (95% CIs) of the association between a 1-SD increment in the CVD
risk scores with frailty: complete data versus multiple imputation analysis
Complete data analysis
(n=3,895)
Multiple imputation
(n=7,412)
Framingham CVD risk score 1.20 (1.13, 1.28) 1.26 (1.18, 1.33)
Framingham CHD risk score 1.17 (1.10, 1.25) 1.21 (1.15, 1.29)
Framingham stroke risk score 1.19 (1.12, 1.27) 1.22 (1.14, 1.30)
SCORE (CVD risk score) 1.18 (1.10, 1.25) 1.20 (1.14, 1.27)
7.5 Discussion
Main findings
Main findings from this cohort of middle aged individuals were that four different CVD
risk scores were associated with an elevated risk of frailty. Thus, one sex-specific SD
increment in the risk scores increased the odds of being classified as frail or pre-frail at
the end of the 10-year follow-up by 17% to 20%. The strength of this association was not
diminished after exclusion of cases of CVD during the follow-up, suggesting that the
predictive risk score-frailty associations were not driven by co-morbid CVD (reverse
causality). Furthermore, this association was not attributable to any single risk factor
included in the risk scores. As far as I am aware, this is the first study to examine the link
between scores from CVD risk factor engines and future frailty.
Limitations of the study
This study has some limitations. First, CVD risk at mean age of 55 years was assessed. It
remains unclear whether these findings are generalisable to other age groups because at
older ages low rather than high levels of some cardiovascular risk factors (total
cholesterol, LDL-cholesterol, and systolic blood pressure) are associated with poor health
outcome, as assessed by ADL disability, hospitalisation, functional performance, and
mortality.247-249 Second, in relation to CVD prediction, the risk scores are not
recommended to be used at older ages (> 75 years); the validity of these scores as risk
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markers of frailty should be examined in that age in the future studies. Finally, the study
sample consisted of middle-aged civil servants, limiting the generalisability of the present
findings. However, these limitations can be compared to the main strength of the study,
which resides in the use of prospectively collected data given that previous studies that
have examined the association between CVD or its individual risk factors and frailty used
cross-sectional data.60,75,77,232
Conclusions
Besides the clinical utility of CVD risk scores – Framingham CVD, CHD, stroke, or
SCORE – in predicting risk of cardiovascular death and disease, it may be possible that
they also help to identify middle-aged persons at risk of frailty. As such, the use of CVD
risk scores in clinical practice may also have utility for frailty prediction, although
additional predictive markers still need to be identified to improve predictive association
and performance.
Chapter 7
- 114 -
Chapter 8
- 115 -
8 Predictive validity of diabetes risk algorithms for frailty in the
Whitehall II study
8.1 Introduction
There is some evidence of a relationship between diabetes and its two mediators – obesity
and insulin resistance – and incident frailty247 and some individual components that
denote frailty, such as low grip strength250,251 and low gait speed.252
8.2 Objectives
The specific objectives addressed in this Chapter were:
i. to examine the association between individual diabetes risk factors with frailty.
ii. to examine the predictive capacity of a series of validated diabetes risk algorithms
for frailty and compared it to the one for diabetes
In this Chapter, three diabetes risk algorithms were investigated: the Framingham
Offspring,253 the Cambridge,254 and the Finnish255 diabetes risk scores.
8.3 Materials and methods
Study population
As for the study of the association between CVD risk scores and frailty in Chapter 7,
study members attending phase 5 were included in this Chapter.
Outcome of interest
Outcome was the phenotype of frailty as described in Section 4.4.1.
Diabetes risk factors
Diabetes risk factors necessary to construct three diabetes risk scores included in this
Chapter were those included in the CVD risk scores described in Chapter 7 (age, sex,
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HDL-cholesterol, systolic/diastolic blood pressure, antihypertensive therapy, smoking
status, history of high blood glucose) and other risk factors measured as follows:
Serum triglycerides were determined by enzymatic colorimetric method; BMI calculated
and categorised as in Section 4.4.1; waist was taken to be the smallest circumference at/or
below the costal margin and measured using a fiberglass tape measure at 600 g tension
with the subject in the standing position and still in underwear. Waist circumference
categories used were small (< 94 cm in men and 80 cm in women), intermediate (94 to <
102 cm in men and 80 to < 88 cm in women), and high (≥ 102 cm in men and 88 cm in
women);208 self-reported corticosteroid and antidiabetic medications were coded using the
British National Formulary codes;239 parent or sibling history of diabetes and daily
consumption of fruit and vegetables were reported by the participants; and physical
activity was described as in Section 4.4.1.
Diabetes risk scores
Equations to estimate the 10-year probability of developing diabetes according to the
following algorithms were calculated for this thesis: the Framingham Offspring,253 the
Cambridge,254 and the Finnish255 diabetes risk scores. The table in Appendix 20
summarises the components of these models. The distribution of the probability of
diabetes estimated by these algorithms is shown in Appendix 21.
Type 2 diabetes mellitus
Type 2 diabetes was defined as fasting glucose ≥ 7.0 mmol/L or a 2-hour postload
glucose ≥ 11.1 mmol/L, and/or as physician-diagnosed diabetes, and/or use of diabetes
medication for those with diagnosed diabetes.240
Statistical analyses
Complete data analysis
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Each diabetes risk factors at baseline was described according to the frailty status (frail,
pre-frail, and non-frail) at 10-year of follow-up using appropriate statistics described in
Section 7.3.
As in Chapter 7, owing to the low number of frail participants (n=108, 2.8%), frail and
pre-frail categories were combined in further analyses.
Following analyses were performed to reach the objective of this Chapter.
Associations between individual risk factors for diabetes and subsequent frailty were
examined using logistic regression adjusted for sex. ORs of being frail or pre-frail were
estimated per 1-SD increase (higher score greater diabetes risk) in the risk scores over the
10-year follow-up. Sex modified the relation of the standardised risk score with frailty
only for the Cambridge risk score (p-values for sex interaction = 0.03). Therefore, results
were presented for men and women combined first, and then stratified by sex for the
Cambridge risk score only. To examine the robustness of the association between
frailty/pre-frailty and the diabetes risk scores, we conducted several sensitivity analyses:
in a study sample excluding incident diabetes cases (sensitivity analysis 1) and in a study
sample including prevalent diabetes cases (sensitivity analysis 2). As the variable
assessing physical activity is included in both the Finnish score and the Fried’s scale, one
may expect to observe a strong relationship between this score and frailty. To study the
use of the diabetes scores in the prediction of frailty independent of physical activity, I
conducted a further sensitivity analysis (3) using the Fried’s scale without the physical
activity component.
In order to place these effect estimates into context, I also related diabetes risk scores with
incident diabetes.
To compare the magnitude of the association between the risk scores with future frailty,
95% CI were calculated around the difference between ORs of the scores 2 by 2 using a
‘bias-corrected and accelerated (BCa) bootstrap’ method with 2,000 resamplings.256 This
method consists in repeating random sampling with replacement from the original data, to
produce random samples of the same size of the original sample, and each provides an
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estimate of the difference in ORs. Here, as this process is repeated 2,000 times, 2,000
differences in ORs can be estimated. If these differences in ORs are ordered in increasing
value, a bootstrap 95% CI for the differences in ORs would be from the 50th (2.5*20) to
the 1950th (97.5*20) largest values. This is known as the ‘percentile method’. However,
this method can have biases, which can be estimated and corrected for. This corrected
method is called BCa bootstrap method.257
To evaluate the predictive power for each risk score and to estimate its clinical validity,
area under the receiver operating characteristic (ROC) curve (AUC) was calculated.258
Finally, to explore the extent to which the relationship between the risk scores and frailty
was driven by specific diabetes risk factors included in the scores, analyses on the risk
scores–frailty associations were adjusted successively for the individual risk factors one
at a time. All analyses were performed using SAS version 9.1.
Missing data analysis
Analyses above were based on complete data (n=2,707). This cohort represents 36.5% of
study members for participants eligible at phase 5 and alive at the end of follow-up
(n=7,412). Because the association between the risk scores and frailty could be biased by
missing data, I imputed data for missing frailty/pre-frailty status and individual diabetes
risk factors included in the risk scores using the same procedure described in Section 7.3.
The missing data pattern of the components included in the diabetes risk scores was
arbitrary as shown in Appendix 22.
The auxiliary variables associated with the outcome and the response indicator (for the
outcome) were socio-economic position at phase 5 and self-reported general health as in
Section 7.3 (Appendix 23).
Non-normally distributed continuous variables need to be transformed towards normality
in the imputation model. After imputation, they are re-transformed back to its original
form. Normality of continuous variables was checked in Appendix 24. Of them, two
variables did not have a normal distribution: variable for triglycerides was transformed
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into log-scale and variable for the number hours of moderate/vigorous physical activity
per week was declared as ‘mixed’ (categorical and continuous) variable. For a mixed
variable, a logistic regression model is used to impute zero versus non-zero status and
conditional on imputing a non-zero status, a normal linear regression model is used to
impute non-zero values.
Percentage of missing data by variable was calculated basing on study members who both
responded to the questionnaire and attended screening examination at baseline (n=7,412)
(Appendix 25). Variables with the highest number of missing data were the outcome
variable (frailty) at phase 9 and waist circumference at phase 5 with percentage around
25%. As this number is relatively high, I decided to run 20 cycles.
Three steps were carried out after obtaining 20 datasets with imputed values: (1)
calculating diabetes risk scores from imputed risk factors’ values and standardising these
probabilities into z-scores to study their 1-SD increment in association with frailty; (2)
performing logistic regression model on each of the imputed dataset; and (3) combining
the parameter estimates (ORs and their 95% CIs) from each imputed dataset to get a final
single set of parameter estimates (see Figure 7.2).
8.4 Results
Complete data analysis
Description of the study participants and missing data
Of the 10,308 study members who participated in phase 1 (1985-1988), 862 had died and
1,447 had dropped out from the study before the start of the data collection at phase 9
(2007-2009). Of the 7,870 participants who attended the phase 5, a total of 2,707
participants (755 women) aged 45-69 years at phase 5 constituted the analytic sample
(Figure 8.1).
Compared with participants alive at phase 9 but excluded (owing to non participation at
phases 5 and 9, and missing data on the diabetes risk scores, plasma glucose, or the frailty
scale, (n=5,292)), persons included in the analytic sample (n=2,707) were 0.3 years
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younger (p=0.005), less likely to be female (27.9% versus 32.7%, p < 0.0001), and less
likely to be from the lower socioeconomic group (13.0% versus 22.7%, p < 0.0001).
Of the 2,707 participants, 2.8% were classified as frail, 37.5% pre-frail, and 59.7% non-
frail. Baseline characteristics of participants as a function of frailty status at the end of
follow-up (on average 10.5 years, SD=0.5) are detailed in Table 8.1. In comparison with
non-frail participants, frail participants were more likely to be older, female, have higher
BMI, use antihypertensive treatment, be a current or non-smoker, and less likely to be
physically active and consume fruit and vegetables on a daily basis. Frail participants
were also more likely to have experienced a diabetes event during the follow-up relative
to their non-frail counterparts (13.0% versus 7.4%, p=0.002).
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Figure 8.1. Flow of study members featured in the present analysis
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Table 8.1. Characteristics of study participants (n=2,707)
Frailty status at follow-up
All Not frail Pre-frail Frail P-valueb
Numbers 2707 1616 1014 77
Age, yearsa 55.0 (5.9) 54.6 (5.6) 55.4 (6.2) 57.6 (6.2) <0.0001
Sex, n (%)
Male 1952 (72.1) 1228 (76.0) 689 (68.0) 35 (45.5) <0.0001
Female 755 (27.9) 388 (24.0) 325 (32.0) 42 (54.5)
Parental or siblings history of
diabetes, n (%)
No 2419 (89.4) 1443 (89.3) 907 (89.5) 69 (89.6) 0.99
Yes 288 (10.6) 173 (10.7) 107 (10.5) 8 (10.4)
Body mass index, kg/m2a 25.97 (3.80) 25.81 (3.57) 26.11 (4.01) 27.34 (5.14) 0.001
Waist circumference, cma 90.6 (11.4) 90.3 (11.0) 90.8 (11.6) 92.8 (14.1) 0.07
Systolic blood pressure, mm Hga 121.5 (15.7) 121.3 (15.6) 121.7 (16.0) 124.2 (15.1) 0.24
Diastolic blood pressure, mm Hga 77.1 (10.1) 77.0 (10.0) 77.1 (10.3) 77.1 (11.3) 0.99
Antihypertensive treatment, n (%)
No 2408 (89.0) 1458 (90.2) 889 (87.7) 61 (79.2) <0.0001
Yes 299 (11.0) 158 (9.8) 125 (12.3) 16 (20.8)
Fasting glucose level 100-126 mg/dL,
n (%)
No 2292 (84.7) 1370 (84.8) 856 (84.4) 66 (85.7) 0.94
Yes 415 (15.3) 246 (15.2) 158 (15.6) 11 (14.3)
HDL cholesterol, mg/dLa 56.73 (15.11) 56.89 (15.22) 56.46 (14.99) 56.69 (14.56) 0.53
Triglycerides, geometric mean
(geometric SD), mg/dLa
100.00 (0.52) 98.28 (63.51) 102.62 (63.71) 101.08 (67.05) 0.11
Corticosteroid treatment, n (%)
No 2608 (96.3) 1562 (96.7) 972 (95.9) 74 (96.1) 0.56
Yes 99 (3.7) 54 (3.3) 42 (4.1) 3 (3.9)
Smoking status, n (%)
Non-smoker 1514 (55.9) 891 (55.1) 575 (56.7) 48 (62.3) 0.005
Ex-smoker 967 (35.7) 610 (37.8) 338 (33.3) 19 (24.7)
Current smoker 226 (13.0) 115 (7.1) 101 (10.0) 10 (13.0)
Physical activity ≥ 4 h/week, n (%)
No 1739 (64.2) 905 (56.0) 764 (75.3) 70 (90.9) <0.0001
Yes 968 (35.8) 711 (44.0) 250 (24.7) 7 (9.1)
Daily consumption of fruit and
vegetables, n (%)
No 709 (26.2) 373 (23.1) 307 (30.3) 29 (37.7) <0.0001
Yes 1998 (73.8) 1243 (76.9) 707 (69.7) 48 (62.3)
Follow-up, years 10.5 (0.5) 10.5 (0.5) 10.5 (0.5) 10.7 (0.5) 0.03
Incident diabetes at follow-up, n (%)
No 2466 (91.1) 1497 (92.6) 902 (89.0) 67 (87.0) 0.002
Yes 241 (8.9) 119 (7.4) 112 (11.0) 10 (13.0)
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a Figures are means (SD) unless otherwise stated.
b P for heterogeneity based on Chi-square test, analysis of variance or Fisher’s exact test.
Association between the individual diabetes risk factors and frailty
Table 8.2 presents the association between the risk factors for diabetes and frailty. Older
age, abdominal obesity, physical inactivity, and no daily consumption of fruit and
vegetables were independently associated with future frailty. Thus, a 1-SD increment in
age (5.9 years) increased the odds of being frail/pre-frail by 27% (OR=1.27, 95% CI:
1.17, 1.38); a 1-SD increment in waist circumference (11.4 cm) increased the odds by
24% (95% CI: 1.02, 1.49); participants having a moderate or vigorous physical activity <
4 h/week had 2.5 times (95% CI: 2.08, 2.98) higher odds of frailty than those with ≥ 4
h/week of physical activity; and not having a daily consumption of fruit and vegetables
increased the risk of frailty by 50% (95% CI: 1.25, 1.80).
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Table 8.2. ORs (95% CIs) for the association between individual components of the
diabetes risk scores and frailty (n=2,707)
N (%) Adjusted for sex Fully adjusted
Age, yearsa 2707 1.17 (1.08, 1.27) 1.27 (1.17, 1.38)
Parental/sibling history of diabetes
No 2419 (89.4) 1 (ref) 1 (ref)
Yes 288 (10.6) 0.95 (0.74, 1.22) 0.83 (0.64, 1.08)
BMI, kg/m2a 2707 1.10 (1.01, 1.18) 0.89 (0.75, 1.06)
Waist circumference, cma 2707 1.17 (1.08, 1.27) 1.24 (1.02, 1.49)
Systolic blood pressure, mm Hga 2707 1.05 (0.97, 1.14) 0.98 (0.87, 1.10)
Diastolic blood pressure, mm Hga 2707 1.04 (0.96, 1.12) 1.00 (0.89, 1.13)
Corticoid treatment
No 2608 (96.3) 1 (ref) 1 (ref)
Yes 99 (3.7) 1.27 (0.85, 1.91) 1.20 (0.79, 1.82)
Current smoking
No 2481 (91.7) 1 (ref) 1 (ref)
Yes 226 (8.3) 1.42 (1.08, 1.87) 1.25 (0.94, 1.67)
Low physical activity (< 4 h/week)
No 968 (35.8) 1 (ref) 1 (ref)
Yes 1739 (64.2) 2.41 (2.02, 2.87) 2.49 (2.08, 2.98)
Daily consumption of fruit and vegetables
No 709 (26.2) 1.57 (1.32, 1.87) 1.50 (1.25, 1.80)
Yes 1998 (73.8) 1 (ref) 1 (ref)
HDL cholesterol, mg/dLa 2707 0.89 (0.82, 0.97) 0.94 (0.86, 1.03)
Triglycerides, mg/dLa 2707 1.08 (1.00, 1.17) 0.98 (0.90, 1.08)
Fasting glucose, mg/dLa 2707 1.04 (0.96, 1.12) 1.03 (0.95, 1.12)
a Change per one standard deviation increase.
b Model includes all predictors in addition to sex.
Association between diabetes risk scores and frailty
Table 8.3 shows results of the association of a 1-SD increment in the diabetes risk scores
and subsequent frailty/pre-frailty and incident diabetes. ORs ranged from 1.05 (95% CI:
0.98, 1.14) for the Framingham Offspring score to 1.27 (95% CI: 1.17, 1.37) for the
Finnish score. OR for the Cambridge score was 1.18 (95% CI: 1.09, 1.27).
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After stratification by sex, the odds of becoming frail/pre-frail was higher among women
(OR=1.30; 95% CI: 1.14, 1.47) than men (OR=1.19; 95% CI: 1.08, 1.32) with the
Cambridge risk score.
Table 8.3. ORs (95% CIs) per 1-SD increment in score using three diabetes risk
algorithms for frailty and diabetes (n=2,707)
Frail and pre-frail Diabetes
Framingham Offspring risk scorea 1.05 (0.98, 1.14) 1.72 (1.56, 1.90)
Cambridge risk scorea 1.18 (1.09, 1.27) 1.69 (1.52, 1.88)
Finnish risk scorea 1.27 (1.17, 1.37) 1.52 (1.38, 1.68)
a A 1-SD increase (disadvantage) in the Framingham and Finnish scores was associated with a 4% increase
in the probability of developing diabetes. For the Cambridge score, it represented 18%.
The associations between the diabetes scores and frailty/pre-frailty changed slightly after
exclusion of incident diabetes cases over the follow-up, inclusion of prevalent diabetes,
and modification of the Fried’s scale (original scale without physical activity component),
but the ranking of their associations with frailty/pre-frailty was maintained (Table 8.4).
Table 8.4. Sensitivity analyses: ORs (95% CIs) per 1-SD increment in score using
three diabetes risk algorithms for future frailty
Main analysis Sensitivity analysis 1 Sensitivity analysis 2 Sensitivity analysis 3Diabetes risk scores
Study sample
(n=2,707)
Study sample excluding
incident diabetes cases
(n=2,466)
Study sample including
prevalent diabetes cases
(n=2,824)
Fried’s frailty scale
excluding physical
activity component
(n=2,697)
Framingham Offspring 1.05 (0.98, 1.14) 1.07 (0.97, 1.18) 1.09 (1.01, 1.17) 1.06 (0.97, 1.15)
Cambridge 1.18 (1.09, 1.27) 1.14 (1.04, 1.23) 1.18 (1.09, 1.27) 1.23 (1.13, 1.33)
Finnish 1.27 (1.17, 1.37) 1.25 (1.14, 1.36) 1.26 (1.16, 1.37) 1.28 (1.18, 1.39)
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Comparison of the strength of the association
a. Differences in ORs
The Finnish score had a significantly stronger association with frailty than the other
scores; the differences in ORs were significant in favour for that score, ranging between
0.09 and 0.22 (Table 8.5).
As anticipated, all risk scores were statistically associated with incident diabetes in the
study population, with the highest OR for the Framingham risk score [1.72 (95% CI: 1.56,
1.90)] (Tables 8.3 and 8.5).
Table 8.5. Comparison of performances of diabetes risk scores in the prediction of
future frailty and diabetes onset
∆ in OR (95% CI)a for frailty comparing the upper and
lower tertiles for different diabetes scores
Framingham risk score
OR=1.05 (0.98, 1.14)
Cambridge risk score
OR=1.18 (1.09, 1.27)
Framingham risk score
OR=1.05 (0.98, 1.14)
— —
Cambridge risk score
OR=1.18 (1.09, 1.27) ∆ = 0.12 (0.02, 0.22)
—
Finnish risk score
OR=1.27 (1.17, 1.37) ∆ = 0.22 (0.11, 0.33) ∆ = 0.09 (0.02, 0.17)
∆ in OR (95% CI)a for diabetes comparing the upper and
lower tertiles for different diabetes scores
Framingham risk score
OR=1.72 (1.56, 1.90)
Cambridge risk score
1.69 (1.52, 1.88)
Framingham risk score
OR=1.72 (1.56, 1.90) — —
Cambridge risk score
OR=1.69 (1.52, 1.88) ∆ = -0.03 (-0.28, 0.21) —
Finnish risk score
OR=1.52 (1.38, 1.68) ∆ = -0.20 (-0.46, 0.01) ∆ = -0.17 (-0.32, -0.05)
a Bias-corrected and accelerated bootstrap (BCa) 95% confidence interval.
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b. Comparison of the predictive accuracy
Table 8.6 shows the areas under the curves (AUC) for each diabetes score in the
prediction of frailty. The Finnish score had the highest AUC compared with the other
scores (0.58 versus 0.53).
In the prediction of diabetes, the Framingham score had the highest AUC [0.76 (0.73,
0.79)].
Table 8.6. Comparisons of the areas under the ROC curves (AUC) and their 95%
CIs in the prediction of frailty and diabetes
Frail and pre-frail Diabetes
AUC (95% CI) ∆ (95% CI)a AUC (95% CI) ∆ (95% CI)a
Framingham risk score 0.531 (0.509, 0.553) 0.044 (0.022, 0.066) 0.760 (0.727, 0.792) Ref
Cambridge risk score 0.535 (0.513, 0.557) 0.040 (0.023, 0.057) 0.699 (0.666, 0.732) 0.061 (0.025, 0.097)
Finnish risk score 0.575 (0.553, 0.597) Ref 0.684 (0.649, 0.718) 0.076 (0.040, 0.112)
Diabetes risk factors in the association between diabetes risk scores and frailty
Table 8.7 presents results of analyses in which the three diabetes risk scores as a whole
were adjusted for each of their risk factors. The association between risk scores and
frailty remained statistically significant after successive adjustments for risk factors
suggesting that this association was not driven by any specific risk factor.
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Table 8.7. Association between diabetes risk scores and frailty
a Each diabetes risk score was adjusted for individual diabetes risk factors.
Diabetes risk scores OR (95% CI)
Framingham diabetes score
Unadjusted 1.05 (0.98, 1.14)
Adjusted fora
Age 1.05 (0.97, 1.13)
Sex 1.06 (0.98, 1.14)
Parental history of diabetes 1.05 (0.97, 1.14)
BMI 1.02 (0.94, 1.11)
Blood pressure > 130/85 mmHg or receiving therapy 1.03 (0.95, 1.11)
HDL-cholesterol 1.03 (0.95, 1.12)
Triglycerides 1.05 (0.97, 1.13)
Fasting glucose 1.09 (0.98, 1.21)
Cambridge diabetes score
Unadjusted 1.18 (1.09, 1.27)
Adjusted fora
Age 1.14 (1.05, 1.23)
Sex 1.22 (1.13, 1.31)
Parental/sibling history of diabetes 1.19 (1.10, 1.28)
BMI 1.18 (1.07, 1.30)
Antihypertensive therapy 1.16 (1.06, 1.26)
Corticosteroid therapy 1.18 (1.09, 1.28)
Smoking 1.16 (1.07, 1.25)
Finnish diabetes score
Unadjusted 1.27 (1.17, 1.37)
Adjusted fora
Age 1.25 (1.15, 1.35)
BMI 1.45 (1.28, 1.63)
Waist circumference 1.40 (1.26, 1.54)
Antihypertensive therapy 1.27 (1.17, 1.38)
Physical activity < 4h/week 1.20 (1.11, 1.30)
Daily consumption of fruit and vegetables 1.26 (1.16, 1.36)
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Missing data analysis
After multiple imputation, ORs for the association between risk factors of diabetes and
frailty were broadly similar to those in the complete data analysis (Table 8.8). This was
also the case for the Framingham Offspring, Cambridge, and Finnish risk scores (Table
8.9).
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Table 8.8. ORs (95% CIs) for the association between individual components of the
diabetes risk scores and frailty: complete data versus multiple imputation analysis
Complete data analysis
(n=2,707)
Multiple imputation
(n=7,412)
Age, years 1.03 (1.01, 1.04) 1.03 (1.02, 1.04)
Parental history of diabetes
No 1 (ref) 1 (ref)
Yes 0.96 (0.73, 1.25) 0.85 (0.71, 1.02)
Sibling history of diabetes at phase 1
No 1 (ref) 1 (ref)
Yes 0.81 (0.45, 1.45) 0.69 (0.45, 1.05)
Sibling history of diabetes at phase 2
No 1 (ref) 1 (ref)
Yes 1.57 (1.10, 2.23) 1.25 (0.95, 1.65)
BMI, kg/m2a 1.03 (1.01, 1.05) 1.03 (1.01, 1.04)
Waist circumference, cm 1.01 (1.00, 1.01) 1.00 (1.00, 1.01)
Systolic blood pressure, mm Hg 1.00 (1.00, 1.01) 1.00 (1.00, 1.01)
Diastolic blood pressure, mm Hg 1.00 (0.99, 1.01) 1.00 (1.00, 1.01)
Antihypertensive therapy
No 1 (ref) 1 (ref)
Yes 1.37 (1.08, 1.74) 1.42 (1.22, 1.65)
Corticoid treatment
No 1 (ref) 1 (ref)
Yes 1.24 (0.83, 1.86) 1.21 (0.91, 1.62)
Current smoking
No 1 (ref) 1 (ref)
Yes 1.48 (1.12, 1.94) 1.20 (1.10, 1.31)
Past smoking history
No 1 (ref) 1 (ref)
Yes 0.82 (0.69, 0.96) 0.95 (0.89, 1.00)
Physical activity, h/week 0.83 (0.81, 0.86) 0.81 (0.77, 0.86)
Daily consumption of fruit and vegetables 0.86 (0.81, 0.91) 0.85 (0.81, 0.88)
HDL cholesterol, mg/dL 0.93 (0.77, 1.14) 0.94 (0.82, 1.07)
Triglycerides, mg/dL 1.05 (0.96, 1.15) 1.10 (1.04, 1.17)
Fasting glucose, mg/dL 1.00 (0.85, 1.16) 1.05 (1.00, 1.10)
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Table 8.9. ORs (95% CIs) of the association between a 1-SD increment in the
diabetes risk scores with frailty: complete data versus multiple imputation analysis
Complete data analysis
(n=2,707)
Multiple imputation
(n=7,412)
Framingham risk score 1.05 (0.98, 1.14) 1.11 (1.05, 1.17)
Cambridge risk score 1.18 (1.09, 1.27) 1.17 (1.10, 1.23)
Finnish risk score 1.27 (1.17, 1.37) 1.25 (1.17, 1.33)
8.5 Discussion
Main findings
In this middle aged cohort, several diabetes risk factors that were associated with frailty
were identified. In addition, elevated multifactorial diabetes risk scores were found to be
associated with an increased risk of subsequent frailty and the Finnish risk score was the
strongest predictor.
Results of multiple imputation analysis support the findings from the complete data
analysis.
Limitations of the study
This study has some limitations. First, there is no gold standard measure for diabetes
prediction and although there are numerous diabetes risk scores,259-261 they are less known
and utilised than the CVD risk scores. The three risk scores tested in this Chapter are
widely validated and well known, but several other diabetes prediction algorithms not
included in this study exist. Third, as this study sample consisted of middle-aged civil
servants, this limits the generalisability of these findings.
Conclusion
In conclusion, all diabetes risk scores were associated with future frailty, in particular the
Finnish score. These findings may help to construct an original prediction model to
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identify middle-aged persons at risk of frailty as some diabetes risk factors were found to
be highly associated with frailty. However, additional predictive markers are still needed
to improve predictive association and performance based on diabetes risk factors for
clinical practice.
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9 Overall discussion
In order to improve the understanding of frailty in elderly population, the present work
attempted to answer the following questions: (1) how is frailty currently defined and
measured? (2) based on an overview, are there valid and reliable frailty measures which
can be used in clinical and research settings? (3) If so, can the validity and reliability be
replicated in the Whitehall II study? and (4) to which extent conventional CVD and
diabetes risk scores predict frailty 10-years later?
In this Chapter, the principal findings of the present work are first summarised and
discussed in light of that from other studies, and then, the limitations of the present study
are highlighted. Finally, the directions for future research are outlined.
9.1 Concept of frailty
As highlighted in Chapter 1, there are numerous overlapping definitions of frailty, a
recognised geriatric syndrome characterized by age-related declines in functional reserves
across an array of physiologic systems leading to a state of high vulnerability to adverse
outcomes. However, there is a debate regarding its measurement. Comorbidity and
disability are often used as synonyms for frailty and many researchers included
comorbidity and disability items in their instruments (Mitnitski and colleagues).92 For
other investigators, frailty can also exist in the absence of comorbidity and disability
(Fried and colleagues).16 Frailty may also reflect the existence of underlying or
undiagnosed diseases. However, the concept of frailty is still useful for clinicians and
researchers in the context where, among elderly persons, it is difficult to diagnose a
disease262 because the corresponding symptoms can be masked by existing diseases or it
becomes difficult distinguishing between new diseases and secondary effects due to
frequent polymedication at old age. In addition, atypical presentation of diseases among
older elderly can lead to missing diagnosis. If the frailty concept can contribute to capture
pre-clinical disease or missed diagnosis then it may have some use.
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9.2 Comparison of existing frailty measures
This review provides a comprehensive overview of existing frailty measurements. Two
measures developed by Fried and Mitniski/Rockwood groups are remarkable as they have
been widely used and tested for validation against adverse health outcomes.
Most general reviews or editorials on frailty have implicitly presented the measure
‘phenotype of frailty’ developed by Fried group as reference,10,47,81-90 and a few others91,93
that of Mitnitski/Rockwood group.92 Recommendations from other researchers are more
nuanced. According to Sternberg and colleagues,95 the choice depends on the definition
and outcomes that best suit the needs of those doing the screening: a researcher in biology
may prefer using the phenotype of frailty (Fried group), an administrator the frailty index
(Mitnitski/Rockwood group) as its items can derive from an administrative database, and
a clinician may prefer a tool developed by Saliba and colleagues133 as it can help to
identify complicated patients. The European, Canadian and American Geriatric Advisory
Panel61 recommends to use a hybrid measure composed of components from both the
phenotype of frailty and the frailty index called ‘FRAIL’ scale. Difficulties in accepting
one measure as a gold standard relate to the fact that it is difficult to create a composite
measure that would meet all criteria.
One of the aims of this thesis was to examine potential predictors of frailty. To do so, I
decided not to create a new frailty instrument but rather to use an existing one. In the
context of the absence of a gold standard measure, ideally, the selected instrument must
have the highest reliability and validity. As reported in Chapter 2, the phenotype of frailty
was selected in this thesis as it has a highest number of external validation, although this
instrument has missing information on its reliability. Included components intend to
reflect a sensible theoretical framework of frailty by attempting to capture its key
characteristics: decline in lean body mass (weight loss), weakness (grip strength), poor
endurance (exhaustion and slow walking time), and low activity. Therefore, the
operational definition of frailty by Fried and colleagues seems to correspond to the
criteria required to be a syndrome, defined as an arbitrary score including multiple and
heterogeneous items, reflecting the complexity of clinical phenonemon that cannot be
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measured with traditional biometric data.263 In a different context, this measure has been
operationalised as the well-known ‘metabolic syndrome’, a cluster of 5 risk factors for
cardiovascular disease and diabetes; the presence of any 3 of 5 risk factors constitute a
diagnosis of metabolic syndrome.264
9.3 Phenotype of frailty
The common characteristic captured by all the components included in the phenotype of
frailty is sarcopenia. Exhaustion and low physical activity, expression of either muscle
weakness or diseases (depression, cancer, infection, sleep disorders, etc), by leading to a
prolonged immobility, can cause or deteriorate lean muscle mass loss.265 Slow walking
speed was found to be highly correlated with lower extremity muscle strength (correlation
coefficients ranging from 0.19 to 0.50).266 Both slow walking speed267 and low grip
strength268 are considered to be useful markers of sarcopenia. Two mechanisms may
explain how weight loss leads to sarcopenia, whether the weight loss is intentional or not:
(1) the relationship between unintentional weight loss and sacopenia is well known, often
caused by an underlying disease;265 and (2) weight loss seems to be a marker of obesity
when weight loss is intentional. Indeed, in our study, among those who lost weight
intentionally, 35% of them were obese (7.9% for the unintentional weight loss group and
18.9% for the reference group). Obesity, a well known predictor for type 2 diabetes,269,270
is recently identified as a risk factor of frailty.140,154 The underlying mechanism
explaining the association between obesity and frailty may be the insulin resistance.271 It
has been suggested that insulin resistance occurring among older persons is due to
accumulation of lipid within muscle272 leading to sarcopenia,273,274 a core characteristic of
frailty. This phenomenon is called ‘sarcopenic obesity’.275
The overview presented in this thesis and analyses based on the Whitehall II data
supported the validity and reliability of the phenotype of frailty developed by Fried group.
Main strengths of this review include its extended evaluation of reliability and validity of
each instrument with data extracted from other studies, reflecting its level of their external
validation. Furthermore, to date, no article has been published on the extent to which
frailty measures have been used by other researchers. This finding might reflect the level
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of preference of researchers for a given frailty measurement in the absence of a
consensually recognised tool.
The main limitation of this review is probably the use of a unique keyword ‘frailty’ to
identify relevant publications on frailty measurements. One may find such a strategy
restrictive, leading to miss some screening tools helping to identify frail elderly.
However, all frailty instruments included in previous reviews were also identified in my
review, which additionally identified 18 studies20,109-113,115,117-121,123,124,126-128,131 not
included in a previous review;93 five of them created in 2010 or after.
9.4 Validity of the phenotype of frailty in the Whitehall II study
The phenotype of frailty was found to predict hospitalisation and the strength of
prediction was broadly similar to those of basic ADL disability and comorbidity in a
mutually adjusted model, indicating an independent role of frailty in the prediction.
However, if a more comprehensive measure of comorbidity including many co-occurring
comorbid conditions,276 is used, this could result in frailty not being any longer
independently related to subsequent health outcomes. Furthermore, I cannot rule out the
possibility that this independent association is explained by early and undiagnosed
conditions.
These all three conditions are related to an approximately 1.3-fold increased risk of
hospitalisation. The strength of the prediction was also similar to those found in several
other studies including the CHS16 and Three-City96 studies. However, in the MOBILIZE
Boston study, a stronger association between frailty and hospitalisation was reported
(RR=3.54)98 whereas in the Women’s Health and Aging Studies no association between
frailty and hospital admissions was observed (RR=0.67).75 Heterogeneity in the
measurement of frailty and population characteristics may have contributed to these
inconsistencies.
Several findings supported the concept of frailty as a multifactorial syndrome. Consistent
with the literature, I found that all five frailty components included in the phenotype of
frailty – exhaustion, low physical activity, slow walking speed, low grip strength, and
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weight loss – were independently associated with hospitalisation. However, applying
statistical tests developed for the assessment of the predictive performance of risk score
for clinical practice suggested that the benefit of multi-factorial measurement may be
limited. Indeed, Harrell’s C concordance statistic varied between 0.57 and 0.58 (0.50
indicates that the prediction does not differ from chance) suggesting that neither the
components nor the full scale were adequate prediction tools for hospitalisation. This
probably indicates that frailty and its components capture only a very limited range of the
conditions leading to hospitalisation.
However, other findings in this thesis supported that the frailty measure seems to stratify
risk even within the group of individuals with an individual frailty component. Results
from the predictive association (hazard ratio and its 95% CI) and predictive performance
(concordance statistic and its 95% CI) seemed contradictory; the first showing that the
composite measure was better associated with subsequent hospitalisation than individual
components and the second that the composite measure was not sufficiently
discriminatory to allow differentiating between frail and not frail elderly at individual
level. It has been demonstrated that strong statistical associations between a marker (here
frailty) and outcome (here hospitalisation) do not necessarily mean that the marker can
discriminate between persons likely to have the outcome and those who do not.277
Although, the examination of the predictive performance of an instrument is crucial for
individual-level prediction and classification for ‘personalised medicine’, traditional
statistical methods such as hazard ratio or odds ratio used by epidemiologists are valuable
for characterising population variations in risk and using to target prevention or screening
strategies.
A main limitation of this work, shared with many studies in this field of research, is a
departure from the original frailty scale. This was particularly the case with weight loss
because weight in the previous year was not available in the Whitehall II study. As many
studies on frailty, including the Whitehall II, are analyses of existing cohorts primarily set
up for other purposes, assessment of frailty components tends to differ between them.
Nonetheless, effort should be made to use a standardised definition in the future in order
to allow direct comparisons of results between different populations.
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Furthermore, as the phenotype of frailty measure was not available at baseline, I could not
exclude pre-frail/frail participants. It is likely, however, considering that this was a group
of middle-aged participants (mean age: 55.4 years) and the cohort is occupational, the
prevalence of frailty/pre-frailty would have been very low. Unavailability of the
phenotype of frailty at baseline did not allow estimating the reliability of the frailty
change score, a measure estimating the ability of the measure to discriminate between the
participants who change a lot and those who change little.
Additionally, because the analytic sample consisted predominantly of white collar
workers, this may limit the generalisability of the present findings.
Taken together, these results indicate that a composite measure of frailty proposed by
Fried is related to future risk of hospitalisation but shows poor performance as a
predictive tool. Much previous work in this domain is based on elderly individuals. That
the frailty scale and its individual components were prospectively associated with
hospitalisation among the Whitehall II participants aged 55-79 years at baseline, suggests
that the measure has appropriate predictive validity in middle and early old age.
9.5 Reliability of the phenotype of frailty in the Whitehall II study
Reliability of the phenotype of frailty was assessed using the internal consistency and
test-retest reliability. Because the completion of a health survey questionnaire was not
requested during the second visit, it was not possible to assess fully the reliability of the
phenotype of frailty. Thus, its reliability has been approximately evaluated with the
following three components – walking speed, grip strength, and weight – measured
during the repeated examination.
Internal consistency was low (r=0.3) which may be ascribed to the fact that the phenotype
of frailty includes multiple components which are heterogeneous. The test-retest
reliability of 3 out of 5 components of the phenotype of frailty assessed by the Bland-
Altman plot was good.
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9.6 Prediction of frailty using CVD risk scores
The main finding from this study was that different CVD risk scores were associated with
the risk of frailty: one sex-specific SD increment in the CVD risk scores increased the
odds of being classified as frail or pre-frail at the end of the 10-year follow-up by 17% to
20%. This is the first study in its kind.
Although initially designed to predict CVD, the present results suggest that the CVD risk
scores also appear to be a predictive marker of general health such as frailty status. Our
finding in relation to frailty is in agreement with other studies with other ageing
outcomes. All individual risk factors – age, total cholesterol, HDL-cholesterol, systolic
blood pressure, smoking, and diabetes – included in CVD scores have also been shown to
be associated with cancer,228-231 which, after CVD, is the second leading cause of death in
economically developed countries.203 In addition, The Framingham CVD risk score was
found to be associated with cognitive decline in the Whitehall II study.222 One plausible
mechanism linking risk scores to both CVD and frailty is the presence of atherosclerosis
in arteries and related chronic systemic inflammation.38,278 Atherosclerotic processes can
prevent blood flow through the coronary artery causing CVD278 and through the muscles
causing sarcopenia, a clinical feature of frailty.279
The proportion of frailty and pre-frailty was higher in women than men (49.8% versus
36.3%, respectively). This is in agreement with previous findings,104 but opposite to what
one might expect for CVD, which is more common in men in late middle-age. In this
study, the incidence of CVD was 9.9% in men versus 5.7% in women. A potential
explanation for the higher incidence of frailty in women pertain to difference in biology
between sexes, with men having greater bone mineral density and muscle mass at old
ages.280,281
9.7 Prediction of frailty using diabetes risk scores
In this middle aged cohort, several diabetes risk factors were associated with frailty. In
addition, elevated multifactorial diabetes risk scores were found to be associated with an
increased risk of subsequent frailty: a 1-SD increment in the risk scores increased the
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odds of becoming frail or pre-frail by 5% to 27% at the end of the 10-year follow-up. This
is also the first study in its kind.
The specific risk factors associated with frailty were waist circumference (a strong
correlate of insulin resistance) and two markers of unhealthy behaviours (physical activity
less than 4 hours per week and no daily consumption of fruit and vegetables). All these
associations are plausible.
First, the link between abdominal obesity and frailty is plausible because increased
intramuscular adipose tissue is responsible for insulin resistance,272 which is a potential
contributor to declining muscle strength and quality.282-286 Moreover, the increase in
intramuscular fat in addition to visceral fat has been shown to lead to systemic
inflammation with increase in the adipokines such as IL-6, TNF-a, and CRP, that are
implicated in the aetiology of insulin resistance,287-290 frailty,38 and sarcopenia.291
Second, the strong relationship between physical inactivity and subsequent frailty is not
surprising either given that it is also one of the five components of Fried’s frailty
measurement.16 Inactivity is related to an accelerated loss of lean mass due to a decrease
in muscle fibres leading to a low physical capability.265,292-294
Third, a plausible mechanism linking fruit and vegetable consumption to frailty may be
the antioxidant effect of nutrients included in fruit and vegetables such as carotenoids,
vitamins (C, E), and phenolics. These antioxidants have been shown to inhibit lipid
peroxidation in vitro particularly that of low-density lipoproteins (LDL)295-297 responsible
for the development of atherosclerosis,298 the primary cause of cardiovascular diseases
which have been shown to be related to frailty in several cross-sectional studies.60,75,77
Although several prospective studies demonstrated that fruit and vegetables consumption
is protective against non-communicable diseases particularly cardiovascular diseases,299-
307 the beneficial effect may not be due to isolated individual antioxidant compounds
included in fruit and vegetables, as important meta-analyses of randomised controlled
trials failed to show a beneficial effect of vitamins E, C, or b-carotene,308,309 rather joint
effects of known or unknown antioxidants. In addition, one cannot rule out other
mechanisms besides the antioxidant effect which explain such associations. Several
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researchers support the notion that fruit and vegetables intake is a marker of healthy
lifestyle behaviour rather than an aetiological factor of non-communicable diseases as it is
highly correlated with other disease risk factors.310,311
The strongest prediction of frailty was observed with the Finnish diabetes risk score; this
may be due to score composition as the Finnish score included the risk factors listed
above that were particularly strongly associated with frailty when analysed separately.
Importantly, the association between the Finnish diabetes score and frailty was not driven
by a specific risk factor included in this score. Because physical activity is included in
both Finnish score and the phenotype of frailty, it might be possible that this association
is mediated by this component. However, a supplementary analysis studying the
association with the phenotype of frailty without physical activity showed that this was
not the case as the strength of the association remained stable.
The lower predictive preformance of the Cambridge and Framingham risk scores in
relation to frailty may be explained by the effect of sex, as the direction of this association
was unexpected: old women were more likely to become frail than old men104 whereas in
the prediction of diabetes, sex has a non-significant effect in the Framingham score (β for
men= -0.01) and women are at lower risk in the Cambridge score (β for women= -0.88).
In addition, three strong predictors (waist circumference, physical activity, and
consumption of fruit and vegetables) of frailty were not included in the Cambridge and
Framingham risk scores.
Taken together, all diabetes risk scores were associated with future frailty, in particular
the Finnish score. Although these findings may help to construct a prediction model to
identify middle-aged persons at risk of frailty, additional predictive markers are still
needed to substantially improve predictive association and performance based on diabetes
risk factors for clinical practice.
The strength of the association between the diabetes risk scores (Cambridge and Finnish,
with ORs 1.18 and 1.27) and frailty was quite similar to that with CVD risk scores (OR:
1.18 to 1.20), except the Framingham Offspring diabetes risk score (OR=1.05). As
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discussed above, the weaker association of the Framingham Offspring risk score
compared to all other CVD or diabetes risk scores in relation to frailty may be explained
by the small effect of sex in that score and the absence of strong predictors such as waist
circumference, physical activity, and consumption of fruit and vegetables.
9.8 Implications and future research
The literature review included in this thesis highlighted the difficulty in agreeing a
consensus on the conceptual definition of frailty in the scientific community. Because the
construction of each frailty measure directly depends on the conceptual definition, it is
not surprising that to date there is still no gold standard in its measurement. This
highlights the importance of future attempts to harmonise and standardise in particular the
definition of each component included in frailty instruments, the cut-offs to identify frail,
pre-frail, and non-frail individuals (e.g., the phenotype of frailty by Fried group), and the
number of deficits and symptoms included in a scale (e.g., the frailty index by
Mitnitski/Rockwood group).
Although the CVD and diabetes risk scores were associated with subsequent frailty,
further development is needed to improve early identification of individuals at increased
risk of frailty. There is clearly room for such development. This is illustrated by two
observations. First, in CVD and diabetes risk scores, the direction and the level of some
individual risk factors were not in supportive of the prediction of frailty. Second,
individual predictors not included in all risk algorithms, such as daily consumption of
fruit and vegetables, were strongly associated with frailty. Thus, the frailty risk score
should comprise these items.
After identifying pre-frail/frail individuals, it is important first to investigate potential
morbidities associated with frailty and to treat them accordingly. Where no disease is
diagnosed, then other non-specific interventions may be useful. Evidence from
randomized controlled trials suggest that exercise programmes65 and selected drugs (e.g.,
dehydroepiandrosterone66 and testosterone)67,68 can reverse frailty. High-dose vitamin D
has been shown to be also an interesting intervention to prevent frailty as it reduces the
risk of fall72 and fractures.48 Physical exercises and vitamin D are particularly interesting
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interventions at population level due to their positive pleiotropic effects, few adverse
health effects, and low costs. These interventions used in the secondary frailty can also be
used in the primary frailty as well after identifying individuals at an increased risk of
frailty using the CVD and diabetes risk scores examined in this thesis.
9.9 Conclusions
This work suggests that the phenotype of frailty has a reasonable predictive validity in the
Whitehall II study and its utility is also supported by previous studies identified in a
systematic literature review. Both frailty and pre-frailty mark increased near-term risk of
hospitalisation. Existing diseases risk algorithms, in particular that of CVD and diabetes
scores, appear to predict subsequent onset of frailty although the clinical utility of these
algorithms in identifying those at risk of frailty may be limited. These findings imply that
better prevention of cardiovascular and diabetes risk factors in midlife will reduce frailty
at older ages.
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Appendix 1. Characteristics of frailty instruments utilised in individual studies
Reference/Frailty
instrument name
Study name,
setting, country
Characteristics of population:
N, age (mean (SD); range),
% female
Components Classification Comment
Subjective frailty instruments
Strawbridge et al, 1998
15: 1994 Frailty
Measure
The Alameda
County Study,
Prospective cohort,
USA
Community-dwelling population
N=574
74.0 years; 65+
57.0%
4 domains:
Physical functioning:
Sudden loss of balance
Weakness in arms
Weakness in legs
Dizziness when standing up quickly
Nutritive functioning:
Loss of appetite
Unexplained weight loss
Cognitive functioning:
Difficulty paying attention
Trouble finding the right word
Difficulty remembering things
Forgetting where put something
Sensory problems:
Difficulty reading a newspaper
Difficulty in recognising a friend across the
street
Difficulty reading signs at night
Hearing over the phone
Hearing a normal conversation
Hearing a conversation in a noisy room
Score for the 6 sensory
items:
1: have no difficulty
2: have a little difficulty
3: have some difficulty
4: have a great deal of
difficulty.
Scores on the other 10
items:
1: rarely or never had
the problem in the last
12 months
2: sometimes had the
problem
3: often had the
problem
4: very often had the
problem
Participant was
considered to have a
problem or difficulty
for one domain when
he/she had a score ≥3 at
least 1 of the items.
Frail if ≥ 2 domains
were considered to have
a problem or difficulty.
Dayhoff et al, 1998 115 Subsample of a Community-dwelling Performance of ADLs/IADLs using the World Score range: Frailty defined as
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larger study
examining effects of
two exercise
interventions,
Cross-sectional
analysis,
USA
participants
N=84
Non-frail: 73.2 years (6.0)
Frail: 73.5 years (7.9)
Age range : 60 to 88 years
85.7%
Health Organisation Assessment of Functional
Capacity (14 items, each scored from 1 to 5
(5=unable to perform))
Self-report of perceived health.
14 (self-sufficiency) to
70 (total dependency)
Non-frail if score ≤20
& excellent/good
health.
Frail if score ≥21 &
fair/poor health
disability.
Rockwood et al, 1999
20:
CSHA rules based
definition
The Canadian Study
of Health and Aging
(CSHA),
Prospective cohort,
Canada
Random sample of community
residents
N=not reported
65+
%=not available
0: Those who walk without help, perform basic
ADL, are continent of bowel and bladder, and
are not cognitively impaired
1: Bladder incontinence only
2: One (two if incontinent) or more of needing
assistance with mobility or ADL, has cognitive
impairment with no dementia, or has bowel or
bladder incontinence
3: Two (or three if incontinent) or more of
totally dependent for transfers or one or more
ADL, incontinent of bowel and bladder, and
diagnosis of dementia.
-- Frailty defined as
disability or
comorbidity.
Steverink et al, 2001
129:
Groningen frailty
indicator (GFI)
(manual search)
Cross-sectional
study,
Netherlands
Hospital inpatients, nursing
home residents and community-
dwelling elderly
N=275
78.0 years (7.0), range=64-99
72.9%
15 items scored 0 or 1:
Mobility (4 items)
Comorbidity
Malnutrition
Cognition
Vision
Hearing
Physical energy
Loneliness (3 items)
Depressed mood
Anxiety feelings
Frail if score ≥ 5 out of
15.
Frailty defined as
disability or
comorbidity.
Need further
explanation in the
GFI construction.
Mitnitski et al, 2002 92:
Frailty index (FI)
The Canadian Study
of Health and Aging
(CSHA),
Prospective cohort,
Canada
Random sample of community
residents
N=2914
82.0 years (7.4); 65+
64.4%
20 ‘deficits’ (symptoms, signs, impairments
and disabilities)
Impairment index: 0 to
1
No clear cut-off
between frail vs non-
frail.
No standardised
number and type of
deficits.
Frailty defined as
disability or
Appendices
- 176 -
comorbidity.
Gerdhem et al, 2003
118:
Subjective Frailty
Score
Cross-sectional
analysis
Sweden
Participants randomly selected
from the city files of Malmo
N=993
75 years
100%
To make a general assessment of health and
appearance within 15 sec from first sight, and
transfer this into an arbitrary scale.
Score ranging from 1
(low frailty) to 100
(very frail).
No clear cut-off
between frail vs non-
frail.
Rockwood et al, 2005
126:
Canadian Study of
Health and Aging
Clinical Frailty Scale
(CSHA-CFS)
The Canadian Study
of Health and Aging
(CSHA),
Prospective cohort,
Canada
Random sample of community
residents
N=2305
7-point:
1: Very fit
2: Well
3: Well, with treated comorbid disease
4: Apparently vulnerable
5: Mildly frail
6: Moderately frail
7: Severely frail (complete functional
dependence on others)
Moderately frail: 6
Severely frail: 7
Frailty defined as
disability or
comorbidity.
Needs a clinical
interview.
Cacciatore et al, 2005
113:
Frailty Staging System
Based from Lachs et
al, 1990, USA 132
Osservatorio
Geriatrico Regione
Campania,
Prospective cohort,
Italy
Random sample of subjects
with/without chronic heart
failure, community-dwelling or
institutionalised elderly
N=1332
75.9 years (6.7)
60%
7 core domains of functioning scored 0
(function is preserved) or 1 (function is lost):
BADL disability
Mobility (ability to do heavy housework, to
walk up and down stairs to the second floor and
to walk half a mile)
Cognitive function
Visual function
Hearing function
Urinary continence
Social support
Class 1: 0 or 1
Class 2: 2 or 3
Class 3: ≥4
Frailty defined as
disability.
Amici et al, 2008 109:
Marigliano-
Cacciafesta
Polypathological Scale
(MCPS)
Cross-sectional
design,
Italy
N=180
79.5 years; 70+
63.9%
Neurological disorders (5 items)
Cardiopathy (4 items)
Respiratory disorders (5 items)
Renal disorders (4 items)
Locomotive apparatus disorders (5 items)
Sensory deprivation (5 items)
Metabolism and nutritional state (5 items)
Cognitive state and mood (5 items)
Peripheral vascular system ( 5 items)
Malignant cancerous disorders (5 items)
Gastroenteritic disorders (5 items)
Score range: 0 to 245.
Polypathology:
Slight: <15
Medium: 15-24
Medium-severe: 25-49
Severe: 50-74
Very severe: 75+
Missing information
about population
characteristics
Rationale for
weighting scores not
explained.
Frailty defined as
comorbidity.
Dose-response effect
not shown.
Kanauchi et al, 2008
122:
Cross-sectional
study,
Hospital inpatients with
cardiometabolic risk factors
HRCA Vulnerability Index (2 components):
A component includes self-reported
HRCA Vulnerability
Index::
Frailty defined as
disability.
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Based on Morris et al,
1984, USA 137:
Hebrew Rehabilitation
Center for Aged
(HRCA) Vunerability
Index and Saliba et al,
2001, USA 133:
Vulnerable Elders
Survey-13 (VES-13)
Japan N=101
72.9 years (5.1); range 65-85
43.6%
requirements for help in:
Preparing meals (score 0 or 1)
Taking out the garbage (score 0 or 1)
Doing ordinary work around the house (score 0
or 1)
Walking up and down stairs (score 0 or 1)
Needing to use a cane (score 0 or 1)
Needing to use a walker (score 0 or 1)
Identifying the current year (score 0 or 1)
B component includes self-reported answers
for:
Leaving their residence (score 0 or 1)
Needing help in dressing (score 0 or 1)
Having health impediments (score 0 or 1)
VES-13 (13 items):
Age (score 0 to 3; 3 if ≥85)
Self-reported health (score 0 or 1)
Difficulties in physical activities (6 items)
(score 0 to 2)
ADLs/IADLs (5 items) (score 0 or 4)
Vulnerable if A
component score>1 or
A component score=1
and B component>0
VES-13 :
Score range: 0 to 10
Frail if score >3
Participants were frail if
they were considered as
vulnerable according to
the HRCA Vulnerability
Index or frail according
to the VES-13
Gobbens et al, 2010
120:
Tilburg Frailty
Indicator (TFI)
Cross-sectional
design,
Netherlands
2 random samples of
community-dwelling participants
Sample 1: n=245, 80.3 years
(3.9), 54.7%
Sample 2: n=234, 80.2 years
(3.7), 59.0%
15 items scored 0 or 1:
8 physical domains:
Feeling physically healthy
Unexpected weight loss
Difficulty in walking
Difficulty in maintaining balance
Hearing problems
Vision problems
Lack of strength in hands
Physical tiredness
4 psychological domains:
Cognition
Depressive symptoms
Anxiety
Coping
3 social domains:
Living alone
Social relations
Social support
Score range: 0 to 15
(15=highest score for
frailty)
No clear cut-off
between frail vs non-
frail.
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Objective frailty instruments
Brown et al, 2000 112:
Modified Physical
Performance Test
(PPT)
Based on Reuben &
Siu, 1990, USA 136:
PPT and Guralnik et
al, 1995, USA 135
Cross-sectional
analysis,
USA
Community-dwelling elderly
N=107
83 years (4); 77+
%=not available
9 items scored 0 to 4:
Lift a 7-pound book to a shelf
Put on and remove a jacket
Pick up penny from floor
Performance of a 360 degrees turn
50-foot walk test
Climb one flight of stairs
Climb up and down 4 flights of stairs
Stand up 5 times from a 16-inch chair
Progressive Romberg test
Score range: 0-36
Not frail: 32-36
Mild frailty: 25-32
Moderate frailty: 17-24
Dependent: <17
Gill et al, 2002 119
Based on Gill et al,
1995, USA 134
Primary care
practices,
Randomised
controlled trial,
USA
Community-dwelling elderly
N=188
Intervention group:
n=94, 82.8 years (5.0); 75+, 80%
Control group:
n=94, 83.5 years (5.2); 75+, 70%
Rapid gait (walking back and forth over a 10-
foot (3-m) course as quickly as possible)
Single chair stand
Moderately frail if rapid
gait>10 s or could not
stand from the chair.
Severely frail if meet
both criteria.
Klein et al, 2003 123:
Frailty index
Beaver Dam Eye
Study,
Prospective cohort,
USA
Sample from a private census of
the population of Beaver Dam
43+ years
Timed 10-ft walk (score=1 if in the highest
quartile, stratified by sex)
Handgrip strength (score=1 if in the lowest
quartile, stratified by sex)
Peak expiratory flow rate (score=1 if in the
lowest quartile, stratified by sex)
Ability to stand from a sitting position without
using arms in one try (score=1 if unable)
Score range: 0 (better)
to 4 (worse)
Bandinelli, 2006 110:
Short Physical
Performance Battery
(SPPB)
Based on Guralnik et
al, 1995, USA 135
The FRAilty
Screening and
Intervention trial,
Italy
Community-dwelling elderly
visiting their primary care
physicians
N=251
Treatment group:
n=126, 76.4 years (3.6), 66%
Control group:
n=125, 76.4 years (3.4), 60%
3 items scored 0 (unable to perform complete
the test) to 4 (highest level of performance):
Walking speed over 4 metres
5 timed repeated chair rises
Standing balance
Score range: 0 to 12
Frail if ≤9
Opasich et al, 2010 124 Hospital based,
study of effect of
personalised versus
usual physiotherapy,
Italy
Patients after receiving a cardiac
surgery procedure
N=224
Intervention group:
n=150, 74.6 years (3.6); 70+,
Balance Performance Oriented Mobility
Assessment (BPOMA): assessment of static
and dynamic balance
Get-Up-and-Go (GUG) test
Non-frail:
BPOMA>19 and GUG
≤10s
Moderately frail:
BPOMA≤19 or GUG
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40%
Control group:
n=74, 75 years (3.9); 70+, 45%
>10s
Severely frail:
BPOMA≤19 and GUG
>10s
Mixed (subjective and objective) frailty instruments
Speechley & Tinetti,
1991 128
Subsample of the
Yale Health and
Aging Project
(YHAP) of the
Established
Populations for
Epidemiologic
Study of the Elderly
(EPESE) program
Prospective cohort,
USA
Community dwelling elderly
N=336
75+ years
Frail attributes (each item scored 0 or 1):
Age ≥80 years
Gait/balance abnormalities
Infrequent walking for exercise
Depressed
Taking sedatives
Decreased strength in shoulder
Decreased strength in knee
Lower extremity disability
Near vision loss
Vigorous attributes (each item scored 0 or 1):
Age <80 years
Cognitively intact
Frequent physical exercise other than walking
Good near vision
Score:
0-9 frail attributes
0-4 vigorous attributes
Frail: ≤1 vigorous and
≥4 frail attributes.
Vigorous: ≥3 vigorous
and ≤2 frail attributes.
Transitional: neither
frail nor vigorous.
Fried et al, 2001 16:
Phenotype of Frailty
Cardiovascular
Health Study (CHS),
Prospective cohort,
USA
Community dwelling elderly
from 4 US communities
N=5317
65+ years
57.9%
5 items, each scored 0 or 1:
Unintentional weight loss
Self-reported exhaustion
Weakness (grip strength) (1 if in the lowest
quintile)
Slow walking speed (1 if in the highest
quintile)
Low physical activity (1 if in the lowest
quintile)
Score range: 0 to 5
0: frail
1-2: pre-frail
≥3: frail
Binder et al, 2002 111:
Physical frailty
Randomised
controlled trial,
USA
Community-dwelling elderly
N=444
83 years (4); 78+
65.8%
Modified Physical Performance Test score (see
Brown et al, 2000) of 18-32
Peak oxygen consumption: 11-18 ml/kg
Self-reported difficulty or need for assistance in
2 instrumental ADL or 1 basic ADL
Mild to moderate frailty
if ≥2
Instrument contained
disability component.
Instrument used
exclusively to select
mild to moderate
frailty elderly in
randomised
controlled trials.
Studenski et al, 2004 Qualitative and N=not available Appearance (3 indicators) Change evaluated after Needs a clinical
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130:
Clinical Global
Impression of Change
in Physical Frailty
(CGIC-PF)
quantitative
instrument
development,
USA
80.7 years (6.4)
80%
Healthcare utilisation (3 indicators);
Medical complexity (3 indicators)
Strength (3 objective measures)
Balance (3 self-reported+objective measures)
Nutrition (3 objective measures)
Stamina (2 indicators)
Neuromotor (3 objective measures)
Mobility (4 objective measures)
Perceived health (1 indicator)
ADL (4 indicators)
Emotional status (2 indicators)
Social status (4 indicators)
6 months of follow-up,
scored from 1 (worse)
to 7 (better).
interview.
No clear cut-off
between frail vs non-
frail.
Frailty defined as
disability /
comorbidity.
Puts et al, 2005 125:
Static/Dynamic frailty
index
Longitudinal Aging
Study Amsterdam
(LASA),
Prospective cohort,
Netherlands
Random sample drawn from
registers
N=1152
Range: 55-85 years
52.3 to 60.0%
Body mass index
Peak expiratory flow
Cognition
Vision and hearing problems (self-reported)
Incontinence (self-reported)
Sense of mastery (Pearlin & Schooler Mastery
scale)
Depressive symptoms (CES-D)
Physical activity
Static frail if ≥3
components.
Dynamic frail if decline
or loss ≥3.
Inclusion of one item
of disability.
Inspired from Fried
et al’s instrument.
Carriere et al, 2005 114:
Score-Risk
Correspondence for
dependency
Epidemiologie de
l’Osteoporose
(EPIDOS) study,
Prospective cohort,
France
Random sample drawn from
vote-registration or health-
insurance membership rolls
N=545
Median age (interquartile range):
79 years (76-81); 75+
100%
Time (years) since baseline evaluation
Age (>=74 years) X Time since baseline
evaluation
Mobility
Gait speed<0.78 m/s
Time (s) to complete 5 chair stands
Perceived health
Fear of falling
Time (s) to stand in tandem position
Body mass index
Grip strength
Physical activity
Education
Score: 25-169
Risk: 0.02-0.99
No clear cut-off
between frail vs non-
frail.
Rolfson et al, 2006 127:
Edmonton Frail Scale
(EFS)
(manual research)
Hospital based,
Cross-sectional
analysis,
Canada
Sample of patients referred for a
comprehensive geriatric
assessment (CGA)
N=158
80.4 years (6.8); 65+
Cognition (drawing a clock) (score 0 to 2)
General health status (2 questions each scored
0 to 2)
Functional independence (score 0 to 2)
Social support (score 0 to 2)
Score 0-17 (17=highest
level of frailty)
No clear cut-off
between frail vs non-
frail.
Frailty defined as
disability.
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53% Medication use (2 questions each scored 0 to 1)
Nutrition (score 0 to 1)
Mood (score 0 to 1)
Continence (score 0 to 1)
Functional performance (score 0 to 2)
Ensrud et al, 2008 116:
Study of Osteoporotic
Fractures (SOF) index
Study of
Osteoporotic
Fractures,
Prospective cohort,
USA
Community-dwelling elderly
from population-based listings in
4 areas of USA
N=6701
76.7 years (4.8); 69+
100%
3 items each scored 0 to 1:
Unintentional weight loss (≥5% in 2 years)
Inability to rise from a chair 5 times without
using arms
Reduced energy level (Geriatric Depression
Scale)
Robust: 0
Pre-frail:1
Frail: >=2
Inspired from Fried
et al’s instrument.
Hyde et al, 2010 121:
FRAIL scale
Health in Men
Study,
Prospective cohort,
Australia
Random sample of community-
dwelling elderly from the
electoral roll
N=3616
76.9 years (3.6); 71+
0%
5 items each scored 0 to 1:
Fatigue (SF-36)
Resistance - ability to climb a single flight of
stairs (SF-36)
Ambulation - ability to walk one block (SF-36)
Illnesses - more than 5 (list of 14 diseases)
Loss of weight - more than 5% (between 4 to 5
years)
Frail if ≥3 Frailty defined as
comorbidity.
Inspired from Fried
et al’s and
Mitnitski’s
instruments.
Freiheit et al, 2010 117:
Brief Frailty Index
Substudy of the
Calgary Cardiac and
Cognition (3C)
Study
Prospective cohort
study, hospital-
based,
Canada
Patients with coronary artery
disease
337
70.8 years (5.9); 60+
27%
5 items each scored 0 to 1:
Balance assessment
Body mass index
Trail-Making Test Part B
Geriatric Depression Scale
Living alone
Index score range: 0-5
(high score=high risk)
4 categories:
0; 1; 2; ≥3
Sundermann et al,
2011 131:
Comprehensive
Assessment of Frailty
(CAF)
Hospital-based,
Prospective study,
USA
Patients undergoing cardiac
surgery
N=400
80.1 years (4.0); 74+
51.5%
Modified Fried et al’s phenotype of frailty
criteria, each scored 0 or 1:
BMI score
Exhaustion score
Physical activity score
Slowness score (walking 4 mm in usual gait
speed)
Weakness score (grip strength)
Physical performance tests, each scored 0 to 4:
Standing static Balance
Chair rise
Put on and remove a jacket
Score range: 1-35
Not frail: 1-10
Moderately frail: 11-25
Severely frail: 25+
Based on Fried et al’s
and Rockwood et al’s
instruments.
Appendices
- 182 -
Pick up a pen from floor
Turn 360 degrees
Laboratory tests, each scored 0 to 1:
Serum albumin score
Forced expiratory volume in 1 second
Creatinine score
Rockwood et al’s CSHA-CFS scored 1 to 7
‘Manual search’ characterises an article not referenced by Medline but found in the reference section of selected articles.
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Appendix 2. Reliability and validity results for frailty instruments utilised in individual studies
Frailty instrument Population Reliability Validity
Type: statistical
analysis Type: outcome/statistical analysis
Strength of the association between frailty measure
and mortality (estimate with its 95% CI)d
Subjective
Strawbridge et al, 1998
15:
1994 Frailty Measure
The Alameda County Study
15; sample of outpatients from
a geriatric practice 312; the
Health Retirement Study 192
None Concurrent validity: quality of life 15;
cognitive impairment, ADL & IADL
192/logistic regression
Construct validity: physical performance
measures 312/Pearson’s correlation
coefficient
NA
Dayhoff et al, 1998 115 Not reported 115 None Construct validity: balance test & muscle
strength 115/discriminant analysis
NA
Rockwood et al, 1999
20:
CSHA rules based
definition
The CSHA 20 None Predictive validity: Institutionalisation and
mortality 20/Cox’s proportional hazards
modelling
Rockwood:20 FU=5 y, RR=3.1 (2.7; 3.6)a
Steverink et al, 2001 129:
Groningen frailty
indicator
Hospital inpatients, nursing
home residents, and
community-dwelling elderly
129; sample of community
dwelling elderly 313
Internal consistency:
Cronbach’s alpha=0.76
129; 0.73 313
Concurrent validity: MOS SF20 & GHQ
129/t-test; disability (GARS)/Spearman’s
rank correlation coefficient
Internal construct validity: principal
component analysis 129
Construct validity: TFI & SPQ
313/Spearman’s rank correlation coefficient
NA
Mitnitski et al, 2002 92:
Frailty index
The CSHA 92,126; the
Cardiovascular Health Study
193; the Health Retirement
Study 192; a Chinese health
survey 314; the US National
Long Term Care Survey 315;
the US Medicare Current
Beneficiary Survey 316; the
Chinese longitudinal healthy
longevity survey 317,318; the
Mexican Health and Aging
None Predictive validity: mortality 92,126,193,314-
316,319-321,321,323,324, hospitalisation 316,
institutionalisation 316,320 /Cox’s
proportional hazards modelling; mortality
317/multinomial logistic regression;
mortality 318/Weibull hazard regression;
mortality, institutionalisation 322/Kaplan-
Meier method
Concurrent validity: cognitive
impairment, ADL & IADL 192/logistic
regression
Kulminski:193 FU range=4 y, RR=1.05 (1.04; 1.06)b
Mitnitski:92 median FU (death)=2.8 y, RR=1.008
(1.005; 1.011)b
Rockwood:126 FU range=5.8 y, HR=1.26 (1.24; 1.29)b
Goggins:314 FU range=10 y, RR=1.28 (1.23; 1.33)c
Hastings:316 FU range=30 d, RR=1.98 (1.29; 3.05)a
Garcia-Gonzalez:319 FU range=2 y, HR=6.45 (4.10;
10.14)a
Armstrong:320 FU range=1 y, HR=1.93 (1.79; 2.08)a
Mitnitski:321 FU range=12 y, HR=1.03 (1.03; 1.04)b
Lucicesare:323 FU range=4 y, HR=5.26 (1.05; 26.42)b
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Study 319; home care clients of
8 community Care Access
Centres 320; 7 population-
based and 4
clinical/institutional surveys
in 4 developed countries 321;
the Gothenburg H-70 cohort
study 322; the Conselice Study
of Brain Ageing 323; the
National Population Health
Survey of Canada 324
Construct validity: age 92,314 Song:324 FU range=10 y, RR=1.57 (1.41; 1.74)a
Dupre:317 FU range=over 3 y; RRR(men)=7.75 (5.54;
10.83)a; RRR(women)=10.53 (7.06; 15.70)a
Gu:318 FU range=3 y; RR(men)=4.56 (2.68; 6.44)a;
RR(women)=3.84 (1.86; 5.72)a
Gerdhem et al, 2003 118:
Subjective Frailty Score
Sample of participants living
in Malmo, Sweden 118
Inter-rater reliability:
Spearman rank
correlation=0.51 to 0.59
118
Construct validity: gait, balance, muscle
strength, fall 118/Spearman rank correlation
NA
Rockwood et al, 2005
126:
CSHA Clinical Frailty
Scale
The CSHA 126; sample of
geriatric outpatients 325
Inter-rater reliability:
intraclass correlation
coefficient=0.97 126;
weighted kappa=0.68 325
Predictive validity: mortality 126,
institutionalisation 126/Cox’s proportional
hazards modelling
Construct validity: modified MMSE,
Cumulative Illness Rating Scale, history of
falls, delirium, cognitive impairment or
dementia, CSHA rules-based definition of
frailty, CSHA Frailty Index, CSHA
Function Scale 126/Pearson or Spearman
correlation coefficient; physician version &
Phenotype of Frailty 325/weighted kappa &
Kendall’s tau correlation
Rockwood:126 FU range=5.8 y, HR=1.30 (1.27; 1.33)b
Cacciatore et al, 2005
113:
Frailty Staging System
Osservatorio Geriatrico
Regione Campana 113
None Predictive validity: mortality 113/Cox’s
proportional hazards modelling
Cacciatore:113 FU range=12 y, HR=1.62 (1.08; 2.45)a;
HR=1.48 (1.04; 2.11)b
Amici et al, 2008 109:
Marigliano-Cacciafesta
Polypathological Scale
Sample of patients 109 None Concurrent validity: Mini nutritional
assessment, Tinetti test, Barthel index,
global evaluation functional index, geriatric
depression scale 109/ Pearson’s correlation
coefficient
NA
Kanauchi et al, 2008 122:
Vulnerable Elderly
Survey-13
Patients in nephrology 122;
geriatric outpatients 326; the
Medicare Current Beneficiary
Survey 327
None Predictive validity: mortality 326, fracture
326, cancer diagnosis 327/logistic regression
Concurrent validity: WHO quality of life
122/multi-way ANCOVA
Ma:326 FU range=6 y, OR=1.16 (0.98; 1.37)b
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Gobbens et al, 2010 120:
Tilburg Frailty Indicator
Samples of community
dwelling elderly 120,313
Internal consistency:
Cronbach’s alpha=0.73
120; 0.79 313
Test-retest reliability:
Pearson correlation
coefficient=0.79 120
Predictive validity: disability 120, health
care utilisation 120/linear regression & ROC
analyses
Concurrent validity: disability (GARS)
313/Spearman’s rank correlation coefficient;
WHO quality of life 120/multiple regression
analyses
Construct validity: GFI & SPQ
313/Spearman’s rank correlation coefficient;
15 single TFI components 120/Pearson’s
correlation
NA
Objective
Brown et al, 2000 112:
Modified Physical
Performance Test
Community-dwelling elderly
112
None Construct validity: obstacle course,
Romberg full tandem, Berg balance test,
fast gait 112/ANOVA
NA
Gill et al, 2002 119:
Physical Frailty Score
Participants living in the
municipality of Treviso 328;
the Precipitating Events
Project longitudinal study
324,329
None Predictive validity: mortality 328, ADL
324,329/Cox’s proportional hazards modelling
Concurrent validity: ADL & IADL
328/Chi-square test
Gallucci:328 HR and its CI not reported.
Klein et al, 2003 123:
Frailty index
Sample from a private census
of the population of Beaver
Dam 123
Inter-item consistency:
Spearman and Pearson
correlation
coefficients=0.31 to 0.52
123
Concurrent validity: distance visual acuity
and contrast sensitivity 123
NA
Bandinelli, 2006 110:
Short Physical
Performance Battery
Patients recruited by primary
care physicians 110
None None NA
Opasich et al, 2010 124 Medically stable patients after
a cardiac surgery procedure
124
None Concurrent validity: functional
impairment, disability, postsurgery course
124/2-factor analysis of variance
NA
Mixed
Speechley & Tinetti,
1991 128
The Yale Health and Aging
Project cohort 128
None Predictive validity: falls 128/Chi-2 test for
trend in proportion
Internal construct validity: principal
component analysis 128
NA
Fried et al, 2001 16: The Cardiovascular Health None Predictive validity: mortality Woods:215 mean FU=5.9 y, HR=1.71 (1.48; 1.97)a
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Phenotype of Frailty Study 16,147,193; the MacArthur
Study 330; the Health
Retirement Study 192; Toufen,
Taiwan 331; Sample of women
116; the Maintenance of
Balance, Independent Living,
Intellect, and Zest in the
Elderly Boston Study 98; the
Osteoporotic Fractures in Men
study 219; the Study of
Osteoporotic Fractures 97; the
Three-City Study 96; the
Hispanic Established
Population for the
Epidemiological Study of the
Elderly 332-335; the Concord
Health and Ageing in Men
Project 336; the Montreal
Unmet Needs Study 337; the
Women’s Health and Aging
Studies I & II 75; the Women’s
Health Initiative
Observational Study 215; a
nationwide Survey of Health
and Living Status of the
Elderly in Taiwan 338; the
Canadian Study of Health and
Aging 194; sample of surgical
patients 146
16,75,96,97,116,193,194,215,219,333,335, fractures
97,116,215, falls 16,98, ADL & IADL 16,75,332,
hospitalisation 16, institutionalisation 75,194,
idiopathic venous thromboembolism 147/
Cox’s proportional hazards modelling;
mortality 330, falls 97,116, ADL & IADL
16,96,116,215, hospitalisation 96,98,215,
emergency department visits 98/logistic
regression; MMSE 150/ general linear mixed
model; postoperative complications
146/logistic regression model
Concurrent validity: ADL & IADL 98,192;
Bartel index score & depression 331, use of
specific health and community services
336/logistic regression; chronic medical
conditions 98, SPPB 98, MMSE 98, Hopkins
Verbal Learning Test 98; Trail Making Test
part A & part B 98, Clock-in-a-Box 98,
CESD scale 98/analyse of variance; ADL &
IADL, comorbidity 337/the Cochran-Mantel-
Haenszel test; ADL & IADL, comorbidities
338/one-way ANOVA; health-related quality
of life using SF-36 334/logistic regression
model
Internal construct validity: latent class
analysis 75
Convergent validity: Mitnitski’s Frailty
Index score 194/Pearson’s correlation
coefficient
Bandeen-Roche:75 FU range =3 y, HR=6.03 (3.00;
12.08)a
Cawthon:219 mean FU=4.7 y, HR=2.05 (1.55; 2.72)a
Ensrud:97 mean FU=9 y, HR=1.82 (1.56; 2.13)a
Avila-Funes:96 FU range=4 y, HR=1.21 (0.78; 1.87)a
Kulminski:193 FU range=4 y, RR=1.02 (1.02; 1.03)b
Sarkisian:330 FU range=9 y, OR=2.1 (1.2; 3.8)a
Graham:333 FU range=10 y, HR=1.81 (1.41; 2.31)a
Fried:16 FU range=7 y, HR=1.63 (1.27; 2.08)a
Ensrud:116 FU range=9 y, HR=2.75 (2.46; 3.07)a
Berges:335 FU range=10 y, HR(men)=3.04 (2.16;
4.28)a; HR(women)=1.92 (1.39; 2.65)a
Binder et al, 2002 111:
Physical frailty
Community-dwelling elderly
111
Test-retest reliability
for modified physical
performance test=0.96
111
None NA
Studenski et al, 2004 130:
Clinical Global
Impression of Change in
Physical Frailty
Sample of 24 patients 130 Interrater reliability:
Kendall’s multiple-rater
concordance
coefficient=0.97 130
Face validity: 6 experts & 46 clinicians 130 NA
Puts et al, 2005 125:
Static/Dynamic frailty
The Longitudinal Aging
Study Amsterdam 125
None Predictive validity: performance tests
(walking speed, rising from a chair, putting
NA
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index on and taking off a cardigan, and
maintaining balance in a tandem stand) &
ADL 125/logistic regression
Carriere et al, 2005 114:
Score-Risk
Correspondence for
dependency
The EPIDOS study 114 None Predictive validity: 7-year disability
114/logistic regression
NA
Rolfson et al, 2006 127:
Edmonton Frail Scale
Sample of patients 65+ years
127; home care clients of 8
community Care Access
Centres 320; Toufen, Taiwan
331; Brazilian elderly 339
Internal consistency:
Crohnbach’s
coefficient=0.62 127
Inter-rater reliability:
Kappa coefficient=0.77
127
Predictive validity: mortality 320,
institutionalisation 320/Cox’s proportional
hazards model; postoperative
complications/logistic regression model
Concurrent validity: comorbidity 331,
MMSE 331, incontinence 331, depression
331/logistic regression
Construct validity: Barthel Index 127,
Rolfson and colleagues’ GCIF 127/Pearson
correlation; MMSE score & the Functional
independence measure 339/Spearman’s
correlation coefficient
Armstrong:320 FU range=1 y, HR=2.49 (2.32; 2.68)a
Ensrud et al, 2008 116:
Study of Osteoporotic
Fractures index
Sample of women 116; the
Maintenance of Balance,
Independent Living, Intellect,
and Zest in the Elderly Boston
Study 98; community-dwelling
outpatients 340
None Predictive validity: fractures 116, mortality
116, falls 98/Cox’s proportional hazards; falls
116, disability 116, overnight hospitalisation
98, emergency department visits 98/logistic
regression;
Concurrent validity: ADL & IADL
98/logistic regression; chronic medical
conditions 98, SPPB 98, MMSE 98, Hopkins
Verbal Learning Test 98; Trail Making Test
part A & part B 98, Clock-in-a-Box 98,
CESD scale 98/analyses of variance; Older
People’s quality of life 340/linear regression
analysis
Ensrud:116 FU range=9 y, HR=2.37 (2.14; 2.61)a
Hyde et al, 2010 121:
FRAIL scale
The Health in Men Study 121 None Predictive validity: Mortality 121/Cox’s
proportional hazards model; ADL & IADL
121/logistic regression model
Hyde:121 FU range=7 y, HR=3.97 (2.89; 5.45)a
Freiheit et al, 2010 117:
Brief Frailty Index
Patients undergoing cardiac
catheterisation for coronary
artery disease 117
None Predictive validity: ADL 117, health-related
quality of life 117/Poisson regression model
NA
Sundermann et al, 2011 Patients undergoing elective None Predictive validity: Mortality NA
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131:
Comprehensive
Assessment of Frailty
cardiac surgery 131 131/Armitage’s Trend Test for proportions
Construct validity: Society of Thoracic
Surgeons score & European system for
cardiac operative risk evaluation
131/Spearman’s rank correlation
Abbreviations: (I)ADL: (instrumental)activity of daily living; CI: confidence interval; CSHA: Canadian Study of Health and Aging; FU: follow-up; GARS: Groningen activity
restriction scale; GHQ: general health questionnaire; HR: hazard rate; RR: relative risk; MMSE: mini-mental state examination; MOS-SF20: medical outcomes study 20-item short-
form; NA: not available; OR: odds ratio; RRR: relative risk ratio; SPQ: Sherbrooke postal questionnaire.
a RR calculated for the highest versus lowest category of the frailty score.
b RR calculated based on 1-unit increment in the frailty score.
c RR calculated based on 10-year increment in the frailty score.
d Given that the computation of hazard ratios and odds ratios involves the use of different units and scales of measurement of frailty, they cannot be directly used to make conclusions
about which instrument better predicts a given outcome. Nonetheless, they do provide some insights into the value of each scale.
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Appendix 3. Frailty-defining criteria: Whitehall II and CHS
Whitehall II (n=5,366) CHS (n=5,317)
original validation cohort
Definition % Definition %
Age (range) 55-79 65-101
Age class <65 50.6 <65 0
65-74 41.0 65-74 67.3
75-84 8.4 75-84 29.1
≥85 0 ≥85 3.6
Exhaustion Self-report of either of:
1) felt that everything I did was an effort
in the last week, or
2) could not get going in the last week
10.7 Self-report of either of:
1) felt that everything I did was an effort
in the last week, or
2) could not get going in the last week
21.3
Low energy
expenditure
Whitehall II Time Activity questionnaire:
Men: Those with Kcal of PA/week<383
Women: Those with Kcal of
PA/week<270
22.8 Short version of the Minnesota Leisure
Time Activity questionnaire:
Men: Those with Kcal of PA/week<383
Women: Those with Kcal of
PA/week<270
24.1
Slowness Walking 8 feet (2.44 m):
Men: Height ≤ 173 cm: ≥ 3.73 sec or
height > 173 cm: ≥ 3.20 sec
Women: Height ≤ 159 cm: ≥ 3.73 sec or
height > 159 cm: ≥ 3.20sec
9.7 Walking 15 feet (4.57 m):
Men: Height ≤ 173 cm: ≥ 7sec or
height > 173 cm: ≥ 6 sec
Women: Height ≤ 159 cm: ≥ 7sec or
height > 159 cm: ≥ 6 sec
38.0
Weakness Grip strength (kg):
Men: BMI ≤ 24: ≤ 29 or
BMI ≤ 24.1-26: ≤ 30 or
BMI ≤ 26.1-28: ≤ 30 or
BMI > 28: ≤ 32
Women: BMI ≤ 23: ≤ 17 or
BMI ≤ 23.1-26: ≤ 17.3 or
BMI ≤ 26.1-29: ≤ 18 or
BMI > 29: ≤ 21
9.9 Grip strength (kg):
Men: BMI ≤ 24: ≤ 29 or
BMI ≤ 24.1-26: ≤ 30 or
BMI ≤ 26.1-28: ≤ 30 or
BMI > 28: ≤ 32
Women: BMI ≤ 23: ≤ 17 or
BMI ≤ 23.1-26: ≤ 17.3 or
BMI ≤ 26.1-29: ≤ 18 or
BMI > 29: ≤ 21
26.2
Weight loss Lost ≥10% of previous 5 years’ body
weight
3.7 Either of:
1) Lost >10 pounds unintentionally in
the last year
2) Lost ≥5% of previous year’s body
weight
7.3
Frailty status Non-frail 58.6 Non-frail 46.4
Pre-frail 38.6 Pre-frail 46.7
Frail 2.8 Frail 6.9
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Appendix 4. Basic and instrumental activities of daily living (BADL and IADL)
scales
A. BADL scale
Katz BADL
(score 0 to 6)
BADL in the Whitehall II study
(‘modified’ Katz BADL), score 0 to 6
Bathing (sponge bath, tub bath, or shower) - Receives
either no assistance or assistance in bathing only one part
of body
Bathing or showering
Dressing - Gets clothes and dresses without any
assistance except for tying shoes.
Dressing, including putting on shoes and socks
Toileting - Goes to toilet room, uses toilet, arranges
clothes, and returns without any assistance (may use cane
or walker for support and may use bedpan/urinal at nights
Using the toilet, including getting up or down
Transferring - Moves in and out of bed and chair without
assistance (may use can or walker)
Getting in or out of bed
Continence - Controls bowel and bladder completely by
self (without occasional ‘accidents’)a
--
Feeding - Feeds self without assistance (except for help
with cutting meat or buttering bread).
Eating, such as cutting up your food
-- Walking across a roomb
a Question on bowel and bladder continence was not present in the Whitehall II study.
b Question on ‘walking across a room’ was not present in original Katz questionnaire.
B. IADL scale
Lawton and Brody IADL
Score 0 to 8
IADL in the Whitehall II study
(‘modified’ Lawton IADL), score 0 to 7
Ability to use telephone Making telephone calls
Shopping Shopping for groceries
Food preparation Preparing a hot meal
Housekeeping Doing work around the house or garden
Laundrya --
Mode of transportationa --
Responsibility for own medications Taking medication
Ability to handle finances Managing money, such as paying bills and keeping track of
expenses
-- Using a map to figure out how to get around in a strange placeb
a Questions on laundry and mode of transportation were not present in the Whitehall II study.
b Question on ‘using a map…’ was not present in the original Lawton and Brody questionnaire.
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Appendix 5. Characteristics of the 5,169 study participants according to frailty
status
Frailty status
Frail
(n=147, 2.8%)
Pre-frail/non-frail
(n=5022, 97.2%)
P-value
N
% / Mean (SD) or
Median (IQR)
N
% / Mean (SD) or
Median (IQR)
Sex
Men 79 53.7 3671 73.1 <0.00011
Women 68 46.3 1351 26.9
Age (years) in median (IQR) 147 69.9 (62.7; 74.3) 5022 64.8 (60.8; 70.7) <0.00012
Ethnicity
White 116 78.9 4663 92.9 <0.00011
Non-White 31 21.1 359 7.1
Education
No or lower secondary 78 55.7 2055 42.5 0.053
A levels 21 15.0 1313 27.2
University or higher 41 29.3 1468 30.3
Missing 7 - 186 -
Socio-economic position
Low 38 25.8 477 9.5 <0.00013
Intermediate 67 45.6 2147 42.8
High 42 28.6 2398 47.8
Income ₤/year
<15,000 42 29.8 520 10.6 <0.00013
15,000-<25,000 42 29.8 1055 21.6
25,000-<50,000 43 30.5 2065 42.2
≥50,000 17 10.4 1251 25.6
Missing 6 - 131 -
Marital status
Married/Cohabiting 82 58.2 3788 76.5 <0.00011
Other 59 41.8 1164 23.5
Missing 6 - 70 -
Number of relatives and
friends in median (IQR)
142 6 (3; 10) 4937 6 (4; 10) 0.262
Smoking status
Never 83 57.2 2605 52.3 0.061
Stopped before phase 1 30 20.7 1513 30.4
Stopped during follow-up 21 14.5 515 10.4
Current 11 7.6 345 6.9
Missing 2 - 44 -
Daily consumption of fruit
and vegetables
No 57 38.8 1070 21.3 <0.00011
Yes 90 61.2 3948 78.7
Missing
Daily alcohol consumption
level (WHO)
None 60 41.4 873 17.6 <0.00013
Not risky 62 42.7 3190 64.2
Risky 23 15.9 907 18.2
Missing 2 - 52 -
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Alcohol consumption
(units/week) in median (IQR)
145 2 (0; 12) 4970 7 (2; 15) <0.00012
Physical activity
(hours/week) in categories
<2.5 140 95.2 2068 41.4 <0.00011
≥2.5 7 4.8 2933 58.6
Missing 0 - 21 -
Physical activity
(hours/week) in median
(IQR)
147 0.3 (0; 0.8) 5001 3.1 (1.3; 5.7) <0.00012
BMI (kg/m2) in categories
Normal (<25) 54 36.7 1930 38.4 0.0053
Overweight ([25-30[) 43 29.3 2171 43.2
Obese (≥30) 50 34.0 921 18.4
BMI (kg/m2) in mean (SD) 147 28.1 (6.3) 5022 26.6 (4.3) 0.0054
Systolic blood pressure status
Hypotension/normal 60 41.4 1949 38.9 0.643
Prehypertension 53 36.6 2228 44.4
Hypertension 32 22.0 838 16.7
Missing 2 - 7 -
Systolic blood pressure
(mmHg) in mean (SD)
145 125.7 (16.5) 5015 125.2 (16.1) 0.734
Diastolic blood pressure
status
Hypotension/normal 118 81.4 4102 81.8 0.673
Prehypertension 20 13.8 738 14.7
Hypertension 7 4.8 175 3.5
Missing 2 - 7 -
Diastolic blood pressure
(mmHg) in mean (SD)
145 69.5 (11.5) 5015 71.0 (10.0) 0.124
MMSE score <24
No 142 97.3 4946 99.5 0.015
Yes 4 2.7 26 0.5
Missing 1 - 50 -
MMSE score in median
(IQR)
146 28 (27; 29) 4972 29 (28; 29) 0.0052
Diabetes status
No 90 61.2 3542 70.5 0.021
Yes 57 38.8 1480 29.5
Previous history of
hospitalisation
No 32 21.8 2041 40.6 <0.00011
Yes 115 78.2 2981 59.4
Number of medications in
median (IQR)
147 4 (2; 7) 5022 2 (1; 4) <0.00012
Modified basic ADL≥1
No 86 58.9 4627 92.4 <0.00011
Yes 60 41.1 382 7.6
Missing 1 - 13 -
Modified instrumental
ADL≥1
No 65 44.5 4425 88.3 <0.00011
Yes 81 55.5 584 11.7
Missing 1 - 13 -
Presence of comorbidity
No 57 38.8 3325 66.2 <0.00011
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Yes 90 61.2 1697 33.8
Hospitalisation after phase 9
No 87 59.2 3932 78.3 <0.00011
Yes 60 40.8 1090 21.7
SD: standard deviation; IQR: interquartile range; WHO: World Health Organisation; BMI: body mass
index; MMSE: mini mental state examination; ADL: activity daily living.
1 Chi-square test; 2 Wilcoxon-Mann-Whitney test; 3 Cochrane-Armitage trend test; 4 Student’s t-test; 5
Fisher’s exact test.
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Appendix 6. Characteristics of the 5,169 study participants according to comorbidity
status
Comorbidity
Yes
(n=1787, 34.6%)
No
(n=3382, 65.4%)
P-value
N
% / Mean (SD) or
Median (IQR)
N
% / Mean (SD) or
Median (IQR)
Sex
Men 1269 71.0 2481 73.4 0.071
Women 518 29.0 901 26.6
Age (years) in median (IQR) 1787 66.3 (61.7; 72,2) 3382 64.2 (60.5; 69.9) <0.00012
Ethnicity
White 1590 89.0 3189 94.3 <0.00011
Non-White 197 11.0 193 5.7
Education
No or lower secondary 716 41.7 1417 43.5 0.32
A levels 473 27.5 861 26.4
University or higher 529 30.8 980 30.1
Missing 69 - 124 -
Socio-economic position
Low 179 10.0 336 9.9 0.713
Intermediate 772 43.2 1442 42.7
High 836 46.8 1604 47.4
Income ₤/year
<15,000 228 13.1 334 10.2 <0.00013
15,000-<25,000 413 23.7 684 20.8
25,000-<50,000 729 41.9 1379 41.9
≥50,000 372 21.3 893 27.1
Missing 45 - 92 -
Marital status
Married/Cohabiting 1312 74.4 2558 76.8 0.061
Other 451 25.6 772 23.2
Missing 24 - 52 -
Number of relatives and friends
in median (IQR)/mean
1756 6 (4; 10)/7.7 3323 6 (4; 10)/8.3 0.0032
Smoking status
Never 875 49.5 1813 54.0 <0.00011
Stopped before phase 1 560 31.7 983 29.3
Stopped during follow-up 225 12.7 311 9.3
Current 107 6.1 249 7.4
Missing 20 - 26 -
Daily consumption of fruit and
vegetables
No 383 21.5 744 22.0 0.651
Yes 1402 78.5 2636 78.0
Missing 2 - 2 -
Daily alcohol consumption level
(WHO)
None 366 20.7 567 17.0 0.243
Not risky 1062 60.0 2190 65.4
Risky 341 19.3 589 17.6
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Missing 18 - 36 -
Alcohol consumption
(units/week) in median
(IQR)/mean
1769 7 (2; 16)/10.9 3346 7 (2; 15)/10.6 0.092
Physical activity (hours/week) in
categories
<2.5 834 46.9 1374 40.8 <0.00011
≥2.5 946 53.1 1994 59.2
Missing 7 - 14 -
Physical activity (hours/week) in
median (IQR)
1780 2.8 (0.9; 5.2) 3368 3.3 (1.3; 5.9) <0.00012
BMI (kg/m2) in categories
Normal (<25) 566 31.7 1418 41.9 <0.00013
Overweight ([25-30[) 788 44.1 1426 42.2
Obese (≥30) 433 24.2 538 15.9
BMI (kg/m2) in mean (SD) 1787 27.5 (4.7) 3382 26.2 (4.1) <0.00014
Systolic blood pressure status
Hypotension/normal 687 38.6 1322 39.1 0.703
Prehypertension 792 44.4 1489 44.1
Hypertension 303 17.0 567 16.8
Missing 5 - 4 -
Systolic blood pressure (mmHg)
in mean (SD)
1782 125.3 (16.0) 3378 125.2 (16.1) 0.744
Diastolic blood pressure status
Hypotension/normal 1476 82.8 2744 81.2 0.203
Prehypertension 246 13.8 512 15.2
Hypertension 60 3.4 122 3.6
Missing 5 - 4 -
Diastolic blood pressure (mmHg)
in mean (SD)
1782 70.5 (10.0) 3378 71.1 (10.1) 0.034
MMSE score <24
No 1760 99.3 3328 99.5 0.531
Yes 12 0.7 18 0.5
Missing 15 - 36 -
MMSE score in median
(IQR)/mean
1772 29 (28; 29)/28.4 3346 29 (28; 29)/28.5 0.032
Diabetes status
No 1140 63.8 2492 73.7 <0.00011
Yes 647 36.2 890 26.3
Previous history of hospitalisation
No 505 28.3 1568 46.4 <0.00011
Yes 1282 71.7 1814 53.6
Number of medications in median
(IQR)
1787 4 (2; 6) 3382 1 (0; 3) <0.00012
Phenotype of frailty
Non-frail 918 51.4 2111 62.4 <0.00013
Pre-frail 779 43.6 1214 35.9
Frail 90 5.0 57 1.7
Modified basic ADL≥1
No 1524 85.5 3189 94.5 <0.00011
Yes 258 14.5 184 5.5
Missing 5 - 9 -
Modified instrumental ADL≥1
No 1420 79.7 3070 91.0 <0.00011
Yes 362 20.3 303 9.0
Missing 5 - 9 -
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Hospitalisation after phase 9
No 1256 70.3 2763 81.7 <0.00011
Yes 531 29.7 619 18.3
SD: standard deviation; IQR: interquartile range; WHO: World Health Organisation; BMI: body mass
index; MMSE: mini mental state examination; ADL: activity daily living.
1 Chi-square test; 2 Mann-Whitney test; 3 Cochrane-Armitage trend test; 4 Student’s t-test.
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Appendix 7. Characteristics of the 5,155 study participants according to BADL
disability status
Disability (≥ 1 BADL)
Yes
(n=442, 8.6%)
No
(n=4713, 91.4%)
P-value
N
% / Mean (SD) or
Median (IQR)
N
% / Mean (SD) or
Median (IQR)
Sex
Men 287 64.9 3456 73.3 0.00021
Women 155 35.1 1257 26.7
Age (years) in median (IQR) 442 66.6 (61.6, 72.6) 4713 64.7 (60.8, 70.6) <0.00012
Ethnicity
White 397 89.8 4372 92.8 0.021
Non-White 45 10.2 341 7.2
Education
No or lower secondary 208 49.0 1919 42.3 0.00053
A levels 119 28.1 1211 26.7
University or higher 97 22.9 1409 31.0
Missing 18 - 174 -
Socio-economic position
Low 70 15.8 441 9.4 <0.00013
Intermediate 206 46.6 2003 42.5
High 166 37.6 2269 48.1
Income ₤/year
<15,000 78 18.4 479 10.4 <0.00013
15,000-<25,000 123 29.0 971 21.2
25,000-<50,000 138 32.6 1967 42.8
≥50,000 85 20.0 1177 25.6
Missing 18 - 119 -
Marital status
Married/Cohabiting 299 68.7 3566 76.8 0.00021
Other 136 31.3 1078 23.2
Missing 7 - 69 -
Number of relatives and friends in median
(IQR)/mean
433 6 (4; 10)/7.6 4633 6 (4; 10)/7.9 0.572
Smoking status
Never 217 49.5 2466 52.8 0.00041
Stopped before phase 1 119 27.2 1421 30.4
Stopped during follow-up 72 16.4 464 9.9
Current 30 6.9 324 6.9
Missing 4 - 38 -
Daily consumption of fruit and vegetables
No 129 29.2 992 21.1 <0.00011
Yes 313 70.8 3717 78.9
Missing 0 - 4 -
Daily alcohol consumption level (WHO)
None 104 24.1 827 17.7 0.043
Not risky 249 57.6 2993 64.1
Risky 79 18.3 849 18.2
Missing 10 - 44 -
Alcohol consumption (units/week) in 432 6 (1; 14) 4669 7 (2; 15) 0.0022
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median (IQR)
Physical activity (hours/week) in
categories
<2.5 250 56.6 1950 41.6 <0.00011
≥2.5 192 43.4 2742 58.4
Missing 0 - 21 -
Physical activity (hours/week) in median
(IQR)
442 1.9 (0.6; 3.9) 4692 3.2 (1.3; 5.8) <0.00012
BMI (kg/m2) in categories
Normal (<25) 106 24.0 1875 39.8 <0.00013
Overweight ([25-30[) 170 38.5 2039 43.3
Obese (≥30) 166 37.5 799 16.9
BMI (kg/m2) in mean (SD) 442 29.0 (5.4) 4713 26.5 (4.2) <0.00014
Systolic blood pressure status
Hypotension/normal 164 37.3 1842 39.1 0.233
Prehypertension 192 43.6 2080 44.2
Hypertension 84 19.1 785 16.7
Missing 2 - 6 -
Systolic blood pressure (mmHg) in mean
(SD)
440 126.0 (16.3) 4707 125.2 (16.1) 0.324
Diastolic blood pressure status
Hypotension/normal 352 80.0 3856 81.9 0.413
Prehypertension 72 16.4 685 14.6
Hypertension 16 3.6 166 3.5
Missing 2 - 6 -
Diastolic blood pressure (mmHg) in mean
(SD)
440 71.0 (10.2) 4707 70.9 (10.1) 0.854
MMSE score <24
No 434 99.1 4641 99.5 0.315
Yes 4 0.9 25 0.5
Missing 4 - 47 -
MMSE score in median (IQR)/mean 438 29 (28; 29)/28.3 4666 29 (28; 29)/28.5 0.0042
Diabetes status
No 302 68.3 3322 70.5 0.341
Yes 140 31.7 1391 29.5
Previous history of hospitalisation
No 125 28.3 1945 41.3 <0.00011
Yes 317 71.7 2768 58.7
Number of medications in median (IQR) 442 4 (2; 6) 4713 2 (1; 4) <0.00012
Phenotype of frailty
Non-frail 157 35.5 2867 60.8 <0.00013
Pre-frail 225 50.9 1760 37.4
Frail 60 13.6 86 1.8
Modified instrumental ADL≥1
No 193 43.7 4297 91.2 <0.00011
Yes 249 56.3 416 8.8
Presence of comorbidity
No 184 41.6 3189 67.7 <0.00011
Yes 258 58.4 1524 32.3
Hospitalisation after phase 9
No 290 65.6 3720 78.9 <0.00011
Yes 152 34.4 993 21.1
SD: standard deviation; IQR: interquartile range; WHO: World Health Organisation; BMI: body mass
index; MMSE: mini mental state examination; ADL: activity daily living.
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1 Chi-square test; 2 Mann-Whitney test; 3 Cochrane-Armitage trend test; 4 Student’s t-test; 5 Fisher’s exact
test.
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Appendix 8. Factors significantly associated with frailty, comorbidity, and disability
Frailty Comorbidity
Disability
(BADL ≥1)
Sex √ -- √
Age (years) √ √ √
Ethnicity √ √ √
Education √ -- √
Socio-economic position √ -- √
Income ₤/year √ √ √
Marital status √ -- √
Number of relatives and friends -- √ --
Smoking status -- √b √b
Daily consumption of fruit and vegetables √ -- √
Alcohol consumption (units/week) √a -- √a
Physical activity (hours/week) √ √ √
BMI (kg/m2) √ √ √
Systolic blood pressure (mmHg) -- -- --
Diastolic blood pressure (mmHg) -- -- --
MMSE score √ -- --
Diabetes status √ √ √
Previous history of hospitalisation √ √ √
Number of medications √ √ √
Frailty status √ √
Modified basic ADL≥1 √ √
Modified instrumental ADL≥1 √ √ √
Comorbidity √ √
Hospitalisation after phase 9 √ √ √
Directions of the associations:
a Participants who had comorbidity and/or were disabled were less likely to consume alcohol.
b Participants who had comorbidity and/or were disabled were more likely to be a never-smoker or to stop
smoking.
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Appendix 9. Cross-sectional association between frailty and modified BADL/IADL disability, and comorbidity
Modified Basic ADL
N(Yes)=442
Modified Instrumental ADL
N(Yes)=665
Comorbidity
N(Yes)=1787
Odds ratio 95% CI p-value Odds ratio 95% CI p-value Odds ratio 95% CI p-value
Unadjusted
Frailty
Non-frail
(n=3029)
1 -- -- 1 -- -- 1 -- --
Pre-frail
(n=1993)
2.34 1.89-2.89 <0.0001 3.03 2.54-3.63 <0.0001 1.48 1.31-1.66 <0.0001
Frail
(n=147)
12.74 8.83-18.39 <0.0001 16.45 11.53-23.45 <0.0001 3.63 2.58-5.10 <0.0001
Sex and age adjusted
Frailty
Non-frail
(n=3029)
1 -- -- 1 -- -- 1 -- --
Pre-frail
(n=1993)
2.24 1.81-2.78 <0.0001 2.83 2.36-3.39 <0.0001 1.43 1.26-1.61 <0.0001
Frail
(n=147)
11.31 7.78-16.42 <0.0001 13.86 9.65-19.89 <0.0001 3.20 2.27-4.52 <0.0001
ADL: activity daily living; CI: confidence interval.
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Appendix 10. Verification of proportionality assumption: log(-log(hospitalisation))
on function of log of duration of follow-up
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Appendix 11. Characteristics of the 5,169 study participants according to
hospitalisation status
Incident hospitalisation
Yes
(n=1150, 22.2%)
No
(n=4019, 77.8%)
P-value
N
% / Mean (SD) or
median (IQR)
N
% / Mean (SD) or
median (IQR)
Sex
Men 835 72.6 2915 72.5 0.961
Women 315 27.4 1104 27.5
Age (years) in median (IQR) 1150 66.8 (62.1; 72.7) 4019 64.4 (60.6; 70.2) <0.00012
Ethnicity
White 1025 89.1 3754 93.4 <0.00011
Non-White 113 10.0 265 6.6
Education
No or lower secondary 518 46.9 1615 41.7 0.00043
A levels 295 26.7 1039 26.8
University or higher 291 26.4 1218 31.5
Missing 46 - 147 -
Socio-economic position
Low 130 11.3 385 9.6 0.0033
Intermediate 521 45.3 1693 42.1
High 499 43.4 1941 48.3
Income ₤/year
<15,000 134 12.0 428 10.9 <0.00013
15,000-<25,000 288 25.8 809 20.7
25,000-<50,000 460 41.3 1648 42.1
≥50,000 233 20.9 1032 26.3
Missing 35 - 102 -
Marital status
Married/Cohabiting 851 75.1 3019 76.2 0.431
Other 282 24.9 941 23.8
Missing 17 - 59 -
Number of relatives and friends in
median (IQR)
1128 6 (4; 10) 3951 6 (4; 10) 0.172
Smoking status
Never 579 50.8 2109 52.9 0.651
Stopped before phase 1 357 31.3 1186 29.8
Stopped during follow-up 123 10.8 413 10.4
Current 80 7.0 276 6.9
Missing 11 - 35 -
Daily consumption of fruit and
vegetables
No 272 23.7 855 21.3 0.081
Yes 877 76.3 3161 78.7
Missing 1 - 3 -
Daily alcohol consumption level
(WHO)
None 242 21.3 691 17.4 0.023
Not risky 695 61.1 2557 64.3
Risky 200 17.6 730 18.3
Missing 13 - 41 -
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Alcohol consumption (units/week)
in median (IQR)/mean
1137 7 (1; 14)/10.3 3978 7 (2; 16)/10.8 0.012
Physical activity (hours/week) in
categories
<2.5 537 46.9 1671 41.7 0.0021
≥2.5 608 53.1 2332 58.3
Missing 5 - 16 -
Physical activity (hours/week) in
median (IQR)
1145 2.7 (0.9; 5.3) 4003 3.1 (1.3; 5.7) 0.0012
BMI (kg/m2) in categories
Normal (<25) 424 36.9 1560 38.8 0.263
Overweight ([25-30[) 503 43.7 1711 42.6
Obese (≥30) 223 19.4 748 18.6
BMI (kg/m2) in mean (SD) 1150 26.8 (4.3) 4019 26.6 (4.4) 0.134
Systolic blood pressure status
Hypotension/normal 460 40.0 1549 38.6 0.103
Prehypertension 518 45.1 1763 44.0
Hypertension 171 14.9 699 17.4
Missing 1 - 8 -
Systolic blood pressure (mmHg)
in mean (SD)
1149 124.6 (15.4) 4011 125.4 (16.3) 0.114
Diastolic blood pressure status
Hypotension/normal 963 83.8 3257 81.2 0.073
Prehypertension 149 13.0 609 15.2
Hypertension 37 3.2 145 3.6
Missing 1 - 8 -
Diastolic blood pressure (mmHg)
in mean (SD)
1149 69.9 (10.0) 4011 71.2 (10.1) 0.00024
MMSE score <24
No 1121 98.8 3967 99.6 0.0051
Yes 13 1.2 17 0.4
Missing 16 - 35 -
MMSE score in median
(IQR)/mean
1134 29 (28; 29)/28.3 3984 29 (28; 29)/28.5 <0.00012
Diabetes status
No 783 68.1 2849 70.9 0.071
Yes 367 31.9 1170 29.1
Previous history of hospitalisation
No 278 24.2 1795 44.7 <0.00011
Yes 872 75.8 2224 55.3
Number of medications in median
(IQR) 1150
3 (1; 5) 4019 2 (1; 4) <0.00012
Phenotype of frailty
Non-frail 614 53.4 2415 60.1 <0.00013
Pre-frail 476 41.4 1517 37.8
Frail 60 5.2 87 2.1
Modified basic ADL≥1
No 993 86.7 3720 92.8 <0.00011
Yes 152 13.3 290 7.2
Missing 5 - 9 -
Modified instrumental ADL≥1
No 940 82.1 3550 88.5 <0.00011
Yes 205 17.9 460 11.5
Missing 5 - 9 -
Presence of comorbidity
No 619 53.8 2763 68.8 <0.00011
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Yes 531 46.2 1256 31.2
SD: standard deviation; IQR: interquartile range; WHO: World Health Organisation; BMI: body mass
index: MMSE: mini mental state examination; ADL: activity daily living.
1 Chi-square test; 2 Mann-Whitney test; 3 Cochrane-Armitage trend test; 4 Student’s t-test.
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Appendix 12. HRs (95% CI) for hospitalisation according to frailty, comorbidity,
and disability status, with a maximum follow-up time of 30 months
Hazard ratios (95% CI)
n1/n2 Model 11 Model 22 Model 32
Frailty status (yes vs no) 147/5022 2.21 (1.70; 2.88) 1.56 (1.15; 2.11) 1.38 (1.01; 1.89)
Comorbidity (yes vs no) 1787/3382 1.65 (1.47; 1.85) 1.32 (1.15; 1.52) 1.30 (1.13; 1.49)
Disability (yes vs no) 442/4713 1.81 (1.52; 2.14) 1.52 (1.25; 1.84) 1.42 (1.17; 1.73)
1 Model 1: Adjusted for sex and age.
2 Model 2: Adjusted for the predictors (frailty, comorbidity, or disability) and the covariates (sex, age,
ethnicity, educational level, socio-economic position, income/year, number of relatives and friends, daily
consumption of fruit and vegetables, alcohol consumption, physical activity, body mass index, systolic
blood pressure, diastolic blood pressure, mini-mental state examination, diabetes status, previous history of
hospitalisation, and number of medications).
3 Model 3: As model 2 with frailty, comorbidity, and disability mutually adjusted.
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Appendix 13. Distribution of walking speed (A), grip strength (B), and weight (C)
measured at phase 9 (test) and within 30 days after (retest)
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Appendix 14. Composition of the SCORE and Framingham CVD, CHD, and stroke risk algorithms
Score Country Sex Age Total C HDL-C SBP DBP AHTD Smoking Diabetes CVD AF LVH
Framingham
CVD
USA + + + + + + + +
Framingham
CHD
USA + + + + + + + +
Framingham
stroke
USA + + + + + + + + +
SCORE Europe + + + + +
Abbreviations: CVD: cardiovascular disease; CHD: coronary heart disease; C: cholesterol; S/DBP: systolic/diastolic blood pressure; AHTD: anti-hypertensive drug; AF: atrial
fibrillation; LVH: left ventricular hypertrophy
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Appendix 15. Distribution of the probability of developing CVD estimated by 4 CVD
risk scores
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Appendix 16. Missing data pattern of components included in the CVD risk scores
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Appendix 17. Construction of the imputation model to study the association between
the CVD risk scores and frailty
1) Probability modeled is frailcb22f='Yes'
Point 95% Wald
Effect Estimate Confidence Limits
TAGE_C 1.036 1.023 1.049
SEX 1.308 1.086 1.574
TANTIHYP 0.898 0.713 1.131
TSMOKE 0.773 0.600 0.995
TSBP 0.999 0.993 1.005
TDBP 1.002 0.992 1.011
TBLCHOL 1.010 0.945 1.079
THDL 0.877 0.724 1.062
tdiab 1.277 0.901 1.811
AFS5 1.298 0.432 3.898
LVHS5 1.192 0.893 1.590
BT123Y 1.241 0.914 1.683
TUNITWK0 1.002 0.997 1.007
tsumill 1.057 0.981 1.138
TSES 1.371 1.221 1.540
ETHNIC51 1.116 0.936 1.331
TNETW 0.944 0.922 0.966
TGENHLT3 1.616 1.447 1.805
TREGDIS2 2.155 1.128 4.119
2) Probability modeled is resp='Yes'
Point 95% Wald
Effect Estimate Confidence Limits
TAGE_C 0.970 0.957 0.983
SEX 0.915 0.761 1.102
TANTIHYP 0.959 0.769 1.197
TSMOKE 1.617 1.286 2.032
TSBP 0.998 0.992 1.004
TDBP 0.997 0.987 1.007
TBLCHOL 0.934 0.872 1.001
THDL 0.933 0.767 1.135
tdiab 0.532 0.400 0.708
AFS5 0.573 0.224 1.462
LVHS5 1.054 0.776 1.430
BT123Y 1.071 0.784 1.464
TSES 0.688 0.612 0.773 (auxiliary variable)
TNETW 1.016 0.991 1.041
TGENHLT3 0.794 0.713 0.884 (auxiliary variable)
TREGDIS2 0.706 0.404 1.236
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Appendix 18. Distribution of continuous variables included in the imputation model
in the study of the association between the CVD risk scores and frailty
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Appendix 19. Proportion of missing values for each variable included in the CVD
risk scores
Obs _NAME_ nmiss1 pmiss
1 STNO_NMiss 0 0.0000
2 TSMOKE_NMiss 580 7.8251
3 TUNITWK0_NMiss 719 9.7005
4 TGENHLT3_NMiss 671 9.0529
5 TANTIHYP_NMiss 66 0.8904
6 TAGE_C_NMiss 0 0.0000
7 TNETW_NMiss 991 13.3702
8 SEX_NMiss 0 0.0000
9 ETHNIC51_NMiss 8 0.1079
10 TBLCHOL_NMiss 1272 17.1614
11 THDL_NMiss 1953 26.3492
12 TDBP_NMiss 1211 16.3384
13 TSBP_NMiss 1211 16.3384
14 AFS5_NMiss 1251 16.8780
15 LVHS5_NMiss 1251 16.8780
16 BT123Y_NMiss 0 0.0000
17 frailcb22f_NMiss 2133 28.7777
18 tsumill_NMiss 41 0.5532
19 TDMWHOTO_NMiss 0 0.0000
20 tdiab_NMiss 1367 18.4431
21 TSES_NMiss 89 1.2008
22 TREGDIS2_NMiss 675 9.1069
Appendices
- 214 -
Appendix 20. Composition of the Framingham Offspring, Cambridge, and Finnish diabetes risk algorithms
Study Year Country Age Sex PSHD BMI WC SBP AHT Steroid HDL TG FG HHG Smoking PA FV
Framingham 2007 USA X X X X X X X X X
Cambridge 2000 UK X X X X X X X
Finnish 2003 Finland X X X X X X X
Abbreviations: PSHD: parent/sibling history of diabetes; BMI: body mass index; WC: waist circumference; SBP: systolic blood pressure; AHT: antihypertensive treatment; HDL-C:
HDL-cholesterol; TG: triglycerides; FG: fasting glucose; HHG: history of high blood glucose; PA: physical activity < 4h/wks; FV: daily consumption of fruit and vegetables
Appendices
- 215 -
Appendix 21. Distribution of the probability of developing diabetes estimated by 3
diabetes risk scores
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Appendix 22. Missing data pattern of components included in the diabetes risk
scores
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Appendix 23. Construction of the imputation model to study the association between
the diabetes risk scores and frailty
1) Probability modeled is frailcb22f='Yes'
Point 95% Wald
Effect Estimate Confidence Limits
TAGE_C 1.059 1.040 1.078
SEX 1.157 0.832 1.609
DIABPAR 1.122 0.806 1.563
TBMI 0.977 0.926 1.032
TSBP 0.999 0.992 1.005
TANTIHYP 1.065 0.777 1.460
THDL 0.876 0.649 1.181
TTRIG 0.910 0.797 1.038
TGLUC_F 1.004 0.889 1.134
TCRTSDRG 1.082 0.647 1.810
TSMOKE 1.460 0.385 5.528
TSMKPAST 1.216 0.994 1.488
DIABSIB 1.327 0.702 2.509
TWAIST2 1.009 0.989 1.030
tpdiab 1.238 0.696 2.203
TSPORT 0.840 0.808 0.873
TFRUITVG 0.875 0.806 0.948
TUNITWK0 1.002 0.994 1.010
tsumill 1.039 0.935 1.155
TSES 1.280 1.085 1.508
ETHNIC51 1.048 0.832 1.321
TNETW 0.976 0.945 1.008
TGENHLT3 1.454 1.241 1.704
TREGDIS 0.476 0.180 1.262
2) Probability modeled is resp='Yes'
Point 95% Wald
Effect Estimate Confidence Limits
TAGE_C 1.055 1.038 1.074
SEX 1.240 0.905 1.699
DIABPAR 1.113 0.808 1.534
TBMI 0.978 0.928 1.030
TSBP 0.998 0.992 1.004
TANTIHYP 1.029 0.764 1.386
THDL 0.834 0.626 1.109
TTRIG 0.907 0.798 1.031
TGLUC_F 1.024 0.914 1.149
TCRTSDRG 1.218 0.742 1.998
TSMOKE 1.172 0.336 4.094
TSMKPAST 1.238 1.019 1.502
DIABSIB 1.246 0.673 2.307
TWAIST2 1.010 0.991 1.030
tpdiab 1.183 0.677 2.070
TSPORT 0.842 0.811 0.874
TFRUITVG 0.885 0.819 0.957
TSES 1.308 1.118 1.529 (auxiliary variable)
TGENHLT3 1.488 1.287 1.720 (auxiliary variable)
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Appendix 24. Distribution of continuous variables included in the imputation model
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Appendix 25. Proportion of missing values for each variable included in diabetes
risk scores
Obs _NAME_ nmiss1 pmiss
1 STNO_NMiss 0 0.0000
2 frailcb22f_NMiss 1675 25.7296
3 TSBP_NMiss 22 0.3379
4 TWAIST2_NMiss 1583 24.3164
5 TBMI_NMiss 864 13.2719
6 TGLUC_F_NMiss 94 1.4439
7 THDL_NMiss 803 12.3349
8 TTRIG_NMiss 83 1.2750
9 TSMOKE_NMiss 36 0.5530
10 TSMKPAST_NMiss 881 13.5330
11 TCRTSDRG_NMiss 23 0.3533
12 TANTIHYP_NMiss 23 0.3533
13 TAGE_C_NMiss 0 0.0000
14 tpdiab_NMiss 0 0.0000
15 SEX_NMiss 0 0.0000
16 DIABPAR_NMiss 331 5.0845
17 DIABSIB_NMiss 1261 19.3702
18 TSPORT_NMiss 180 2.7650
19 TFRUITVG_NMiss 175 2.6882
